JPH03500543A - Novel transdermal penetration enhancer - Google Patents
Novel transdermal penetration enhancerInfo
- Publication number
- JPH03500543A JPH03500543A JP1505213A JP50521389A JPH03500543A JP H03500543 A JPH03500543 A JP H03500543A JP 1505213 A JP1505213 A JP 1505213A JP 50521389 A JP50521389 A JP 50521389A JP H03500543 A JPH03500543 A JP H03500543A
- Authority
- JP
- Japan
- Prior art keywords
- hydrogen
- alkyl
- oxygen
- ycoor1
- sulfur
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000003961 penetration enhancing agent Substances 0.000 title description 15
- 229910052739 hydrogen Inorganic materials 0.000 claims description 185
- 239000001257 hydrogen Substances 0.000 claims description 184
- 125000000217 alkyl group Chemical group 0.000 claims description 99
- 229910052760 oxygen Inorganic materials 0.000 claims description 78
- 239000000203 mixture Substances 0.000 claims description 77
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 76
- 239000001301 oxygen Substances 0.000 claims description 76
- 229910052717 sulfur Inorganic materials 0.000 claims description 69
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 67
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims description 60
- 239000011593 sulfur Substances 0.000 claims description 60
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 50
- 150000002431 hydrogen Chemical group 0.000 claims description 50
- 239000000126 substance Substances 0.000 claims description 49
- 150000001875 compounds Chemical class 0.000 claims description 48
- 238000000034 method Methods 0.000 claims description 37
- -1 Represents rukylthio Chemical group 0.000 claims description 30
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 29
- 241000607479 Yersinia pestis Species 0.000 claims description 28
- 125000004423 acyloxy group Chemical group 0.000 claims description 25
- 125000003545 alkoxy group Chemical group 0.000 claims description 24
- 150000003839 salts Chemical class 0.000 claims description 24
- 125000004414 alkyl thio group Chemical group 0.000 claims description 22
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 21
- 239000005648 plant growth regulator Substances 0.000 claims description 20
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 18
- 125000004183 alkoxy alkyl group Chemical group 0.000 claims description 17
- 125000006350 alkyl thio alkyl group Chemical group 0.000 claims description 17
- 125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 claims description 17
- 239000013543 active substance Substances 0.000 claims description 15
- 235000015097 nutrients Nutrition 0.000 claims description 15
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 15
- 125000004103 aminoalkyl group Chemical group 0.000 claims description 14
- 239000000575 pesticide Substances 0.000 claims description 13
- 125000000623 heterocyclic group Chemical group 0.000 claims description 12
- 238000009826 distribution Methods 0.000 claims description 11
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 8
- 230000001737 promoting effect Effects 0.000 claims description 6
- YZCKVEUIGOORGS-IGMARMGPSA-N Protium Chemical compound [1H] YZCKVEUIGOORGS-IGMARMGPSA-N 0.000 claims 14
- 125000000547 substituted alkyl group Chemical group 0.000 claims 5
- 239000003513 alkali Substances 0.000 claims 2
- YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical group [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 claims 1
- 241000196324 Embryophyta Species 0.000 description 60
- 239000003623 enhancer Substances 0.000 description 35
- 210000003491 skin Anatomy 0.000 description 31
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 27
- QTBSBXVTEAMEQO-UHFFFAOYSA-N acetic acid Substances CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 27
- 239000000835 fiber Substances 0.000 description 26
- 239000003814 drug Substances 0.000 description 20
- 239000002253 acid Substances 0.000 description 19
- 239000002917 insecticide Substances 0.000 description 19
- 238000004043 dyeing Methods 0.000 description 18
- 229940079593 drug Drugs 0.000 description 17
- 239000003795 chemical substances by application Substances 0.000 description 16
- RWRDLPDLKQPQOW-UHFFFAOYSA-N tetrahydropyrrole Substances C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 description 14
- 241001465754 Metazoa Species 0.000 description 13
- 239000000975 dye Chemical class 0.000 description 13
- 239000000243 solution Substances 0.000 description 13
- 230000000699 topical effect Effects 0.000 description 13
- 210000004027 cell Anatomy 0.000 description 12
- 238000009472 formulation Methods 0.000 description 12
- 239000000417 fungicide Substances 0.000 description 12
- 238000011282 treatment Methods 0.000 description 12
- ZDPHROOEEOARMN-UHFFFAOYSA-N undecanoic acid Chemical compound CCCCCCCCCCC(O)=O ZDPHROOEEOARMN-UHFFFAOYSA-N 0.000 description 12
- 241000233866 Fungi Species 0.000 description 11
- 230000012010 growth Effects 0.000 description 11
- 239000004009 herbicide Substances 0.000 description 11
- 230000001965 increasing effect Effects 0.000 description 11
- 230000035699 permeability Effects 0.000 description 11
- 230000009885 systemic effect Effects 0.000 description 11
- 230000000694 effects Effects 0.000 description 10
- 235000019441 ethanol Nutrition 0.000 description 10
- IIUZTXTZRGLYTI-UHFFFAOYSA-N Dihydrogriseofulvin Natural products COC1CC(=O)CC(C)C11C(=O)C(C(OC)=CC(OC)=C2Cl)=C2O1 IIUZTXTZRGLYTI-UHFFFAOYSA-N 0.000 description 9
- UXWOXTQWVMFRSE-UHFFFAOYSA-N Griseoviridin Natural products O=C1OC(C)CC=C(C(NCC=CC=CC(O)CC(O)C2)=O)SCC1NC(=O)C1=COC2=N1 UXWOXTQWVMFRSE-UHFFFAOYSA-N 0.000 description 9
- DDUHZTYCFQRHIY-UHFFFAOYSA-N Negwer: 6874 Natural products COC1=CC(=O)CC(C)C11C(=O)C(C(OC)=CC(OC)=C2Cl)=C2O1 DDUHZTYCFQRHIY-UHFFFAOYSA-N 0.000 description 9
- 238000010521 absorption reaction Methods 0.000 description 9
- DDUHZTYCFQRHIY-RBHXEPJQSA-N griseofulvin Chemical compound COC1=CC(=O)C[C@@H](C)[C@@]11C(=O)C(C(OC)=CC(OC)=C2Cl)=C2O1 DDUHZTYCFQRHIY-RBHXEPJQSA-N 0.000 description 9
- 229960002867 griseofulvin Drugs 0.000 description 9
- 239000000463 material Substances 0.000 description 9
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 8
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 8
- 230000008569 process Effects 0.000 description 8
- 210000001519 tissue Anatomy 0.000 description 8
- OCKGFTQIICXDQW-ZEQRLZLVSA-N 5-[(1r)-1-hydroxy-2-[4-[(2r)-2-hydroxy-2-(4-methyl-1-oxo-3h-2-benzofuran-5-yl)ethyl]piperazin-1-yl]ethyl]-4-methyl-3h-2-benzofuran-1-one Chemical compound C1=C2C(=O)OCC2=C(C)C([C@@H](O)CN2CCN(CC2)C[C@H](O)C2=CC=C3C(=O)OCC3=C2C)=C1 OCKGFTQIICXDQW-ZEQRLZLVSA-N 0.000 description 7
- 241000894006 Bacteria Species 0.000 description 7
- ULGZDMOVFRHVEP-RWJQBGPGSA-N Erythromycin Natural products O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 ULGZDMOVFRHVEP-RWJQBGPGSA-N 0.000 description 7
- 238000006243 chemical reaction Methods 0.000 description 7
- 230000002538 fungal effect Effects 0.000 description 7
- 230000007062 hydrolysis Effects 0.000 description 7
- 238000006460 hydrolysis reaction Methods 0.000 description 7
- 239000004615 ingredient Substances 0.000 description 7
- 239000011785 micronutrient Substances 0.000 description 7
- 235000013369 micronutrients Nutrition 0.000 description 7
- 239000000546 pharmaceutical excipient Substances 0.000 description 7
- 239000000047 product Substances 0.000 description 7
- 210000000434 stratum corneum Anatomy 0.000 description 7
- 230000017260 vegetative to reproductive phase transition of meristem Effects 0.000 description 7
- 229930191978 Gibberellin Natural products 0.000 description 6
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 6
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 6
- 235000013305 food Nutrition 0.000 description 6
- 239000003448 gibberellin Substances 0.000 description 6
- 208000015181 infectious disease Diseases 0.000 description 6
- 235000021073 macronutrients Nutrition 0.000 description 6
- GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 description 6
- 238000010186 staining Methods 0.000 description 6
- 150000003431 steroids Chemical class 0.000 description 6
- 238000002560 therapeutic procedure Methods 0.000 description 6
- 241000238631 Hexapoda Species 0.000 description 5
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 5
- 230000009471 action Effects 0.000 description 5
- 239000003242 anti bacterial agent Substances 0.000 description 5
- 150000003976 azacycloalkanes Chemical class 0.000 description 5
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 5
- 210000002615 epidermis Anatomy 0.000 description 5
- 239000004744 fabric Substances 0.000 description 5
- 230000000855 fungicidal effect Effects 0.000 description 5
- IXORZMNAPKEEDV-UHFFFAOYSA-N gibberellic acid GA3 Natural products OC(=O)C1C2(C3)CC(=C)C3(O)CCC2C2(C=CC3O)C1C3(C)C(=O)O2 IXORZMNAPKEEDV-UHFFFAOYSA-N 0.000 description 5
- 239000003630 growth substance Substances 0.000 description 5
- 230000006698 induction Effects 0.000 description 5
- 239000007788 liquid Substances 0.000 description 5
- 238000004519 manufacturing process Methods 0.000 description 5
- 210000004379 membrane Anatomy 0.000 description 5
- 239000012528 membrane Substances 0.000 description 5
- 230000004060 metabolic process Effects 0.000 description 5
- 229910052757 nitrogen Inorganic materials 0.000 description 5
- 239000003921 oil Substances 0.000 description 5
- 230000035515 penetration Effects 0.000 description 5
- 229910052698 phosphorus Inorganic materials 0.000 description 5
- 229920000728 polyester Polymers 0.000 description 5
- 230000004044 response Effects 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- 239000004753 textile Substances 0.000 description 5
- 230000001225 therapeutic effect Effects 0.000 description 5
- 239000011701 zinc Substances 0.000 description 5
- UDPGUMQDCGORJQ-UHFFFAOYSA-N (2-chloroethyl)phosphonic acid Chemical compound OP(O)(=O)CCCl UDPGUMQDCGORJQ-UHFFFAOYSA-N 0.000 description 4
- ALYNCZNDIQEVRV-UHFFFAOYSA-N 4-aminobenzoic acid Chemical compound NC1=CC=C(C(O)=O)C=C1 ALYNCZNDIQEVRV-UHFFFAOYSA-N 0.000 description 4
- 229920002972 Acrylic fiber Polymers 0.000 description 4
- 239000005973 Carvone Substances 0.000 description 4
- 229920000742 Cotton Polymers 0.000 description 4
- 239000005976 Ethephon Substances 0.000 description 4
- 206010017533 Fungal infection Diseases 0.000 description 4
- 241000699666 Mus <mouse, genus> Species 0.000 description 4
- 208000031888 Mycoses Diseases 0.000 description 4
- PMDCZENCAXMSOU-UHFFFAOYSA-N N-ethylacetamide Chemical compound CCNC(C)=O PMDCZENCAXMSOU-UHFFFAOYSA-N 0.000 description 4
- 239000004952 Polyamide Substances 0.000 description 4
- 239000013566 allergen Substances 0.000 description 4
- 229940088710 antibiotic agent Drugs 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 239000001913 cellulose Substances 0.000 description 4
- 229920002678 cellulose Polymers 0.000 description 4
- 235000013339 cereals Nutrition 0.000 description 4
- 238000011161 development Methods 0.000 description 4
- 230000018109 developmental process Effects 0.000 description 4
- 235000013399 edible fruits Nutrition 0.000 description 4
- JBKVHLHDHHXQEQ-UHFFFAOYSA-N epsilon-caprolactam Chemical compound O=C1CCCCCN1 JBKVHLHDHHXQEQ-UHFFFAOYSA-N 0.000 description 4
- 239000003205 fragrance Substances 0.000 description 4
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 4
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 4
- 239000000077 insect repellent Substances 0.000 description 4
- 230000008635 plant growth Effects 0.000 description 4
- 229920002647 polyamide Polymers 0.000 description 4
- 235000018102 proteins Nutrition 0.000 description 4
- 108090000623 proteins and genes Proteins 0.000 description 4
- 102000004169 proteins and genes Human genes 0.000 description 4
- 230000002829 reductive effect Effects 0.000 description 4
- 239000011734 sodium Substances 0.000 description 4
- 229910052708 sodium Inorganic materials 0.000 description 4
- 239000011780 sodium chloride Substances 0.000 description 4
- RZCJYMOBWVJQGV-UHFFFAOYSA-N 2-naphthyloxyacetic acid Chemical compound C1=CC=CC2=CC(OCC(=O)O)=CC=C21 RZCJYMOBWVJQGV-UHFFFAOYSA-N 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 3
- 201000004624 Dermatitis Diseases 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- OJMMVQQUTAEWLP-UHFFFAOYSA-N Lincomycin Natural products CN1CC(CCC)CC1C(=O)NC(C(C)O)C1C(O)C(O)C(O)C(SC)O1 OJMMVQQUTAEWLP-UHFFFAOYSA-N 0.000 description 3
- 239000004677 Nylon Substances 0.000 description 3
- 240000005809 Prunus persica Species 0.000 description 3
- 235000006040 Prunus persica var persica Nutrition 0.000 description 3
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 3
- 229910052770 Uranium Inorganic materials 0.000 description 3
- 241000700605 Viruses Species 0.000 description 3
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 3
- NIXOWILDQLNWCW-UHFFFAOYSA-N acrylic acid group Chemical group C(C=C)(=O)O NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 3
- 238000005904 alkaline hydrolysis reaction Methods 0.000 description 3
- 230000000844 anti-bacterial effect Effects 0.000 description 3
- 230000004888 barrier function Effects 0.000 description 3
- 239000011575 calcium Substances 0.000 description 3
- 229910052791 calcium Inorganic materials 0.000 description 3
- 235000005607 chanvre indien Nutrition 0.000 description 3
- 239000013043 chemical agent Substances 0.000 description 3
- 239000007795 chemical reaction product Substances 0.000 description 3
- 235000020971 citrus fruits Nutrition 0.000 description 3
- 238000007796 conventional method Methods 0.000 description 3
- 239000002537 cosmetic Substances 0.000 description 3
- 230000006378 damage Effects 0.000 description 3
- 238000009792 diffusion process Methods 0.000 description 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N dimethyl sulfoxide Natural products CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 230000002708 enhancing effect Effects 0.000 description 3
- 229960003276 erythromycin Drugs 0.000 description 3
- FEBLZLNTKCEFIT-VSXGLTOVSA-N fluocinolone acetonide Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]2(C)C[C@@H]1O FEBLZLNTKCEFIT-VSXGLTOVSA-N 0.000 description 3
- IXORZMNAPKEEDV-OBDJNFEBSA-N gibberellin A3 Chemical compound C([C@@]1(O)C(=C)C[C@@]2(C1)[C@H]1C(O)=O)C[C@H]2[C@]2(C=C[C@@H]3O)[C@H]1[C@]3(C)C(=O)O2 IXORZMNAPKEEDV-OBDJNFEBSA-N 0.000 description 3
- 210000004209 hair Anatomy 0.000 description 3
- 229940088597 hormone Drugs 0.000 description 3
- 239000005556 hormone Substances 0.000 description 3
- 230000003301 hydrolyzing effect Effects 0.000 description 3
- JTEDVYBZBROSJT-UHFFFAOYSA-N indole-3-butyric acid Chemical compound C1=CC=C2C(CCCC(=O)O)=CNC2=C1 JTEDVYBZBROSJT-UHFFFAOYSA-N 0.000 description 3
- 239000006210 lotion Substances 0.000 description 3
- 244000005700 microbiome Species 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 210000004400 mucous membrane Anatomy 0.000 description 3
- GOQYKNQRPGWPLP-UHFFFAOYSA-N n-heptadecyl alcohol Natural products CCCCCCCCCCCCCCCCCO GOQYKNQRPGWPLP-UHFFFAOYSA-N 0.000 description 3
- 235000016709 nutrition Nutrition 0.000 description 3
- 230000035764 nutrition Effects 0.000 description 3
- 229920001778 nylon Polymers 0.000 description 3
- 239000002304 perfume Substances 0.000 description 3
- 239000000376 reactant Substances 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 230000000475 sunscreen effect Effects 0.000 description 3
- 239000000516 sunscreening agent Substances 0.000 description 3
- 230000032258 transport Effects 0.000 description 3
- 229910052725 zinc Inorganic materials 0.000 description 3
- JLIDBLDQVAYHNE-YKALOCIXSA-N (+)-Abscisic acid Chemical compound OC(=O)/C=C(/C)\C=C\[C@@]1(O)C(C)=CC(=O)CC1(C)C JLIDBLDQVAYHNE-YKALOCIXSA-N 0.000 description 2
- ZORQXIQZAOLNGE-UHFFFAOYSA-N 1,1-difluorocyclohexane Chemical compound FC1(F)CCCCC1 ZORQXIQZAOLNGE-UHFFFAOYSA-N 0.000 description 2
- XQLBHPDRLKZRPJ-UHFFFAOYSA-N 1-dodecyl-5-oxopyrrolidine-2-carboxylic acid Chemical compound CCCCCCCCCCCCN1C(C(O)=O)CCC1=O XQLBHPDRLKZRPJ-UHFFFAOYSA-N 0.000 description 2
- AGWPBFFUIGQGJG-UHFFFAOYSA-N 1-ethyl-5-oxopyrrolidine-2-carboxylic acid Chemical compound CCN1C(C(O)=O)CCC1=O AGWPBFFUIGQGJG-UHFFFAOYSA-N 0.000 description 2
- KJCVRFUGPWSIIH-UHFFFAOYSA-N 1-naphthol Chemical compound C1=CC=C2C(O)=CC=CC2=C1 KJCVRFUGPWSIIH-UHFFFAOYSA-N 0.000 description 2
- IZXIZTKNFFYFOF-UHFFFAOYSA-N 2-Oxazolidone Chemical compound O=C1NCCO1 IZXIZTKNFFYFOF-UHFFFAOYSA-N 0.000 description 2
- HIQIXEFWDLTDED-UHFFFAOYSA-N 4-hydroxy-1-piperidin-4-ylpyrrolidin-2-one Chemical compound O=C1CC(O)CN1C1CCNCC1 HIQIXEFWDLTDED-UHFFFAOYSA-N 0.000 description 2
- DLFVBJFMPXGRIB-UHFFFAOYSA-N Acetamide Chemical compound CC(N)=O DLFVBJFMPXGRIB-UHFFFAOYSA-N 0.000 description 2
- 208000002874 Acne Vulgaris Diseases 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- 241001480043 Arthrodermataceae Species 0.000 description 2
- QWOJMRHUQHTCJG-UHFFFAOYSA-N CC([CH2-])=O Chemical compound CC([CH2-])=O QWOJMRHUQHTCJG-UHFFFAOYSA-N 0.000 description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
- 241000222120 Candida <Saccharomycetales> Species 0.000 description 2
- 244000025254 Cannabis sativa Species 0.000 description 2
- 235000012766 Cannabis sativa ssp. sativa var. sativa Nutrition 0.000 description 2
- 235000012765 Cannabis sativa ssp. sativa var. spontanea Nutrition 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 2
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 2
- 241000207199 Citrus Species 0.000 description 2
- 241000195493 Cryptophyta Species 0.000 description 2
- 241000186427 Cutibacterium acnes Species 0.000 description 2
- 239000005975 Daminozide Substances 0.000 description 2
- NOQGZXFMHARMLW-UHFFFAOYSA-N Daminozide Chemical compound CN(C)NC(=O)CCC(O)=O NOQGZXFMHARMLW-UHFFFAOYSA-N 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 2
- WJOHZNCJWYWUJD-IUGZLZTKSA-N Fluocinonide Chemical compound C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@]1(F)[C@@H]2[C@@H]2C[C@H]3OC(C)(C)O[C@@]3(C(=O)COC(=O)C)[C@@]2(C)C[C@@H]1O WJOHZNCJWYWUJD-IUGZLZTKSA-N 0.000 description 2
- 241000237858 Gastropoda Species 0.000 description 2
- 239000005562 Glyphosate Substances 0.000 description 2
- 208000009889 Herpes Simplex Diseases 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- 244000070406 Malus silvestris Species 0.000 description 2
- 241000699660 Mus musculus Species 0.000 description 2
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 2
- 241000244206 Nematoda Species 0.000 description 2
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 2
- 101100014660 Rattus norvegicus Gimap8 gene Proteins 0.000 description 2
- 229920000297 Rayon Polymers 0.000 description 2
- ISRUGXGCCGIOQO-UHFFFAOYSA-N Rhoden Chemical compound CNC(=O)OC1=CC=CC=C1OC(C)C ISRUGXGCCGIOQO-UHFFFAOYSA-N 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 239000004098 Tetracycline Substances 0.000 description 2
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 2
- 241001464837 Viridiplantae Species 0.000 description 2
- 210000001015 abdomen Anatomy 0.000 description 2
- 239000003377 acid catalyst Substances 0.000 description 2
- 238000010306 acid treatment Methods 0.000 description 2
- 206010000496 acne Diseases 0.000 description 2
- 125000002252 acyl group Chemical group 0.000 description 2
- 239000000443 aerosol Substances 0.000 description 2
- QGLZXHRNAYXIBU-WEVVVXLNSA-N aldicarb Chemical compound CNC(=O)O\N=C\C(C)(C)SC QGLZXHRNAYXIBU-WEVVVXLNSA-N 0.000 description 2
- 229940121375 antifungal agent Drugs 0.000 description 2
- 208000010668 atopic eczema Diseases 0.000 description 2
- 239000000987 azo dye Substances 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- RIOXQFHNBCKOKP-UHFFFAOYSA-N benomyl Chemical compound C1=CC=C2N(C(=O)NCCCC)C(NC(=O)OC)=NC2=C1 RIOXQFHNBCKOKP-UHFFFAOYSA-N 0.000 description 2
- MITFXPHMIHQXPI-UHFFFAOYSA-N benzoxaprofen Natural products N=1C2=CC(C(C(O)=O)C)=CC=C2OC=1C1=CC=C(Cl)C=C1 MITFXPHMIHQXPI-UHFFFAOYSA-N 0.000 description 2
- 230000003115 biocidal effect Effects 0.000 description 2
- 230000033228 biological regulation Effects 0.000 description 2
- 230000005540 biological transmission Effects 0.000 description 2
- 229910052796 boron Inorganic materials 0.000 description 2
- 235000009120 camo Nutrition 0.000 description 2
- 229910052799 carbon Inorganic materials 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 229960000541 cetyl alcohol Drugs 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 239000000460 chlorine Substances 0.000 description 2
- 229910052801 chlorine Inorganic materials 0.000 description 2
- 229930002875 chlorophyll Natural products 0.000 description 2
- 235000019804 chlorophyll Nutrition 0.000 description 2
- ATNHDLDRLWWWCB-AENOIHSZSA-M chlorophyll a Chemical compound C1([C@@H](C(=O)OC)C(=O)C2=C3C)=C2N2C3=CC(C(CC)=C3C)=[N+]4C3=CC3=C(C=C)C(C)=C5N3[Mg-2]42[N+]2=C1[C@@H](CCC(=O)OC\C=C(/C)CCC[C@H](C)CCC[C@H](C)CCCC(C)C)[C@H](C)C2=C5 ATNHDLDRLWWWCB-AENOIHSZSA-M 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- KDLRVYVGXIQJDK-AWPVFWJPSA-N clindamycin Chemical compound CN1C[C@H](CCC)C[C@H]1C(=O)N[C@H]([C@H](C)Cl)[C@@H]1[C@H](O)[C@H](O)[C@@H](O)[C@@H](SC)O1 KDLRVYVGXIQJDK-AWPVFWJPSA-N 0.000 description 2
- 238000004040 coloring Methods 0.000 description 2
- 238000010014 continuous dyeing Methods 0.000 description 2
- 239000006071 cream Substances 0.000 description 2
- 238000005520 cutting process Methods 0.000 description 2
- 238000000354 decomposition reaction Methods 0.000 description 2
- 230000037304 dermatophytes Effects 0.000 description 2
- FHIVAFMUCKRCQO-UHFFFAOYSA-N diazinon Chemical compound CCOP(=S)(OCC)OC1=CC(C)=NC(C(C)C)=N1 FHIVAFMUCKRCQO-UHFFFAOYSA-N 0.000 description 2
- RXKJFZQQPQGTFL-UHFFFAOYSA-N dihydroxyacetone Chemical compound OCC(=O)CO RXKJFZQQPQGTFL-UHFFFAOYSA-N 0.000 description 2
- 239000006185 dispersion Substances 0.000 description 2
- POULHZVOKOAJMA-UHFFFAOYSA-N dodecanoic acid Chemical compound CCCCCCCCCCCC(O)=O POULHZVOKOAJMA-UHFFFAOYSA-N 0.000 description 2
- 239000006196 drop Substances 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 150000002148 esters Chemical class 0.000 description 2
- QPNJHVDIRZNKOX-LURJTMIESA-N ethyl (2s)-pyrrolidine-2-carboxylate Chemical compound CCOC(=O)[C@@H]1CCCN1 QPNJHVDIRZNKOX-LURJTMIESA-N 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 229940043075 fluocinolone Drugs 0.000 description 2
- 229960000785 fluocinonide Drugs 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 229940097068 glyphosate Drugs 0.000 description 2
- XDDAORKBJWWYJS-UHFFFAOYSA-N glyphosate Chemical compound OC(=O)CNCP(O)(O)=O XDDAORKBJWWYJS-UHFFFAOYSA-N 0.000 description 2
- 238000003306 harvesting Methods 0.000 description 2
- 239000011487 hemp Substances 0.000 description 2
- 230000002363 herbicidal effect Effects 0.000 description 2
- 229960000890 hydrocortisone Drugs 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 229910052742 iron Inorganic materials 0.000 description 2
- OJMMVQQUTAEWLP-KIDUDLJLSA-N lincomycin Chemical compound CN1C[C@H](CCC)C[C@H]1C(=O)N[C@H]([C@@H](C)O)[C@@H]1[C@H](O)[C@H](O)[C@@H](O)[C@@H](SC)O1 OJMMVQQUTAEWLP-KIDUDLJLSA-N 0.000 description 2
- 229960005287 lincomycin Drugs 0.000 description 2
- 230000033001 locomotion Effects 0.000 description 2
- 239000011777 magnesium Substances 0.000 description 2
- 229910052749 magnesium Inorganic materials 0.000 description 2
- 230000014759 maintenance of location Effects 0.000 description 2
- 229910052751 metal Inorganic materials 0.000 description 2
- 239000002184 metal Substances 0.000 description 2
- 230000001069 nematicidal effect Effects 0.000 description 2
- 239000005645 nematicide Substances 0.000 description 2
- 238000011580 nude mouse model Methods 0.000 description 2
- 239000002674 ointment Substances 0.000 description 2
- 150000002903 organophosphorus compounds Chemical class 0.000 description 2
- 230000003071 parasitic effect Effects 0.000 description 2
- 239000012466 permeate Substances 0.000 description 2
- LCPDWSOZIOUXRV-UHFFFAOYSA-N phenoxyacetic acid Chemical compound OC(=O)COC1=CC=CC=C1 LCPDWSOZIOUXRV-UHFFFAOYSA-N 0.000 description 2
- 230000029553 photosynthesis Effects 0.000 description 2
- 238000010672 photosynthesis Methods 0.000 description 2
- 230000035790 physiological processes and functions Effects 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 239000005020 polyethylene terephthalate Substances 0.000 description 2
- 229920000098 polyolefin Polymers 0.000 description 2
- 229920000136 polysorbate Polymers 0.000 description 2
- 239000011591 potassium Substances 0.000 description 2
- 229910052700 potassium Inorganic materials 0.000 description 2
- 229960004618 prednisone Drugs 0.000 description 2
- XOFYZVNMUHMLCC-ZPOLXVRWSA-N prednisone Chemical compound O=C1C=C[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 XOFYZVNMUHMLCC-ZPOLXVRWSA-N 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 125000004805 propylene group Chemical group [H]C([H])([H])C([H])([*:1])C([H])([H])[*:2] 0.000 description 2
- BBEAQIROQSPTKN-UHFFFAOYSA-N pyrene Chemical compound C1=CC=C2C=CC3=CC=CC4=CC=C1C2=C43 BBEAQIROQSPTKN-UHFFFAOYSA-N 0.000 description 2
- HNJBEVLQSNELDL-UHFFFAOYSA-N pyrrolidin-2-one Chemical compound O=C1CCCN1 HNJBEVLQSNELDL-UHFFFAOYSA-N 0.000 description 2
- 210000003370 receptor cell Anatomy 0.000 description 2
- 239000004627 regenerated cellulose Substances 0.000 description 2
- 230000000717 retained effect Effects 0.000 description 2
- 239000003128 rodenticide Substances 0.000 description 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
- 210000004761 scalp Anatomy 0.000 description 2
- 231100000241 scar Toxicity 0.000 description 2
- 229910052710 silicon Inorganic materials 0.000 description 2
- 230000005808 skin problem Effects 0.000 description 2
- HEMHJVSKTPXQMS-UHFFFAOYSA-M sodium hydroxide Inorganic materials [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 2
- 239000001593 sorbitan monooleate Substances 0.000 description 2
- 229940035049 sorbitan monooleate Drugs 0.000 description 2
- 235000011069 sorbitan monooleate Nutrition 0.000 description 2
- 239000007921 spray Substances 0.000 description 2
- 239000000021 stimulant Substances 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 229920002994 synthetic fiber Polymers 0.000 description 2
- 239000012209 synthetic fiber Substances 0.000 description 2
- 235000019364 tetracycline Nutrition 0.000 description 2
- 150000003522 tetracyclines Chemical class 0.000 description 2
- ZFXYFBGIUFBOJW-UHFFFAOYSA-N theophylline Chemical compound O=C1N(C)C(=O)N(C)C2=C1NC=N2 ZFXYFBGIUFBOJW-UHFFFAOYSA-N 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- 229910052721 tungsten Inorganic materials 0.000 description 2
- 239000003981 vehicle Substances 0.000 description 2
- 239000002023 wood Substances 0.000 description 2
- WRIYPTGFYKBSFU-UHFFFAOYSA-N ()-Conen Chemical compound CCCCOP(=O)(SCC)SCC1=CC=CC=C1 WRIYPTGFYKBSFU-UHFFFAOYSA-N 0.000 description 1
- JWZZKOKVBUJMES-UHFFFAOYSA-N (+-)-Isoprenaline Chemical compound CC(C)NCC(O)C1=CC=C(O)C(O)=C1 JWZZKOKVBUJMES-UHFFFAOYSA-N 0.000 description 1
- SNICXCGAKADSCV-JTQLQIEISA-N (-)-Nicotine Chemical compound CN1CCC[C@H]1C1=CC=CN=C1 SNICXCGAKADSCV-JTQLQIEISA-N 0.000 description 1
- YKSVGLFNJPQDJE-YDMQLZBCSA-N (19E,21E,23E,25E,27E,29E,31E)-33-[(2R,3S,4R,5S,6R)-4-amino-3,5-dihydroxy-6-methyloxan-2-yl]oxy-17-[7-(4-aminophenyl)-5-hydroxy-4-methyl-7-oxoheptan-2-yl]-1,3,5,7,37-pentahydroxy-18-methyl-9,13,15-trioxo-16,39-dioxabicyclo[33.3.1]nonatriaconta-19,21,23,25,27,29,31-heptaene-36-carboxylic acid Chemical compound CC(CC(C)C1OC(=O)CC(=O)CCCC(=O)CC(O)CC(O)CC(O)CC2(O)CC(O)C(C(CC(O[C@@H]3O[C@H](C)[C@@H](O)[C@@H](N)[C@@H]3O)\C=C\C=C\C=C\C=C\C=C\C=C\C=C\C1C)O2)C(O)=O)C(O)CC(=O)C1=CC=C(N)C=C1 YKSVGLFNJPQDJE-YDMQLZBCSA-N 0.000 description 1
- OXJCAZVAEYOCSY-HNNXBMFYSA-N (2s)-2-[acetyl(dodecyl)amino]propanoic acid Chemical compound CCCCCCCCCCCCN(C(C)=O)[C@@H](C)C(O)=O OXJCAZVAEYOCSY-HNNXBMFYSA-N 0.000 description 1
- LJRDOKAZOAKLDU-UDXJMMFXSA-N (2s,3s,4r,5r,6r)-5-amino-2-(aminomethyl)-6-[(2r,3s,4r,5s)-5-[(1r,2r,3s,5r,6s)-3,5-diamino-2-[(2s,3r,4r,5s,6r)-3-amino-4,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-6-hydroxycyclohexyl]oxy-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl]oxyoxane-3,4-diol;sulfuric ac Chemical compound OS(O)(=O)=O.N[C@@H]1[C@@H](O)[C@H](O)[C@H](CN)O[C@@H]1O[C@H]1[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](N)C[C@@H](N)[C@@H]2O)O[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)N)O[C@@H]1CO LJRDOKAZOAKLDU-UDXJMMFXSA-N 0.000 description 1
- LDVVMCZRFWMZSG-OLQVQODUSA-N (3ar,7as)-2-(trichloromethylsulfanyl)-3a,4,7,7a-tetrahydroisoindole-1,3-dione Chemical compound C1C=CC[C@H]2C(=O)N(SC(Cl)(Cl)Cl)C(=O)[C@H]21 LDVVMCZRFWMZSG-OLQVQODUSA-N 0.000 description 1
- ZXBDZLHAHGPXIG-VTXLJDRKSA-N (3r,4s,5s,6r,7r,9r,11r,12r,13s,14r)-6-[(2s,3r,4s,6r)-4-(dimethylamino)-3-hydroxy-6-methyloxan-2-yl]oxy-14-ethyl-7,12,13-trihydroxy-4-[(2r,4r,5s,6s)-5-hydroxy-4-methoxy-4,6-dimethyloxan-2-yl]oxy-3,5,7,9,11,13-hexamethyl-oxacyclotetradecane-2,10-dione;(2r,3 Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)[C@@H](O)C(O)=O.O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 ZXBDZLHAHGPXIG-VTXLJDRKSA-N 0.000 description 1
- SODPIMGUZLOIPE-UHFFFAOYSA-N (4-chlorophenoxy)acetic acid Chemical compound OC(=O)COC1=CC=C(Cl)C=C1 SODPIMGUZLOIPE-UHFFFAOYSA-N 0.000 description 1
- SGKRLCUYIXIAHR-AKNGSSGZSA-N (4s,4ar,5s,5ar,6r,12ar)-4-(dimethylamino)-1,5,10,11,12a-pentahydroxy-6-methyl-3,12-dioxo-4a,5,5a,6-tetrahydro-4h-tetracene-2-carboxamide Chemical compound C1=CC=C2[C@H](C)[C@@H]([C@H](O)[C@@H]3[C@](C(O)=C(C(N)=O)C(=O)[C@H]3N(C)C)(O)C3=O)C3=C(O)C2=C1O SGKRLCUYIXIAHR-AKNGSSGZSA-N 0.000 description 1
- FFTVPQUHLQBXQZ-KVUCHLLUSA-N (4s,4as,5ar,12ar)-4,7-bis(dimethylamino)-1,10,11,12a-tetrahydroxy-3,12-dioxo-4a,5,5a,6-tetrahydro-4h-tetracene-2-carboxamide Chemical compound C1C2=C(N(C)C)C=CC(O)=C2C(O)=C2[C@@H]1C[C@H]1[C@H](N(C)C)C(=O)C(C(N)=O)=C(O)[C@@]1(O)C2=O FFTVPQUHLQBXQZ-KVUCHLLUSA-N 0.000 description 1
- DDMOUSALMHHKOS-UHFFFAOYSA-N 1,2-dichloro-1,1,2,2-tetrafluoroethane Chemical compound FC(F)(Cl)C(F)(F)Cl DDMOUSALMHHKOS-UHFFFAOYSA-N 0.000 description 1
- QKJPOZCEEIAMHV-UHFFFAOYSA-N 1-(2-decylsulfanylethyl)-5-oxopyrrolidine-2-carboxylic acid Chemical compound CCCCCCCCCCSCCN1C(C(O)=O)CCC1=O QKJPOZCEEIAMHV-UHFFFAOYSA-N 0.000 description 1
- PBLNBZIONSLZBU-UHFFFAOYSA-N 1-bromododecane Chemical compound CCCCCCCCCCCCBr PBLNBZIONSLZBU-UHFFFAOYSA-N 0.000 description 1
- YIKWKLYQRFRGPM-UHFFFAOYSA-N 1-dodecylguanidine acetate Chemical compound CC(O)=O.CCCCCCCCCCCCN=C(N)N YIKWKLYQRFRGPM-UHFFFAOYSA-N 0.000 description 1
- XVQFBKZKVCPMOO-UHFFFAOYSA-N 1-hexyl-5-oxopyrrolidine-2-carboxylic acid Chemical compound CCCCCCN1C(C(O)=O)CCC1=O XVQFBKZKVCPMOO-UHFFFAOYSA-N 0.000 description 1
- PRPINYUDVPFIRX-UHFFFAOYSA-N 1-naphthaleneacetic acid Chemical compound C1=CC=C2C(CC(=O)O)=CC=CC2=C1 PRPINYUDVPFIRX-UHFFFAOYSA-N 0.000 description 1
- 239000005971 1-naphthylacetic acid Substances 0.000 description 1
- XTUGSPPMHSEFDO-ZDUSSCGKSA-N 11-[acetyl-[(1s)-1-carboxyethyl]amino]undecanoic acid Chemical compound OC(=O)[C@H](C)N(C(C)=O)CCCCCCCCCCC(O)=O XTUGSPPMHSEFDO-ZDUSSCGKSA-N 0.000 description 1
- FUFLCEKSBBHCMO-UHFFFAOYSA-N 11-dehydrocorticosterone Natural products O=C1CCC2(C)C3C(=O)CC(C)(C(CC4)C(=O)CO)C4C3CCC2=C1 FUFLCEKSBBHCMO-UHFFFAOYSA-N 0.000 description 1
- WHBHBVVOGNECLV-OBQKJFGGSA-N 11-deoxycortisol Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 WHBHBVVOGNECLV-OBQKJFGGSA-N 0.000 description 1
- MHKBMNACOMRIAW-UHFFFAOYSA-N 2,3-dinitrophenol Chemical class OC1=CC=CC([N+]([O-])=O)=C1[N+]([O-])=O MHKBMNACOMRIAW-UHFFFAOYSA-N 0.000 description 1
- 239000005631 2,4-Dichlorophenoxyacetic acid Substances 0.000 description 1
- HXKWSTRRCHTUEC-UHFFFAOYSA-N 2,4-Dichlorophenoxyaceticacid Chemical compound OC(=O)C(Cl)OC1=CC=C(Cl)C=C1 HXKWSTRRCHTUEC-UHFFFAOYSA-N 0.000 description 1
- UFBJCMHMOXMLKC-UHFFFAOYSA-N 2,4-dinitrophenol Chemical compound OC1=CC=C([N+]([O-])=O)C=C1[N+]([O-])=O UFBJCMHMOXMLKC-UHFFFAOYSA-N 0.000 description 1
- YOYAIZYFCNQIRF-UHFFFAOYSA-N 2,6-dichlorobenzonitrile Chemical compound ClC1=CC=CC(Cl)=C1C#N YOYAIZYFCNQIRF-UHFFFAOYSA-N 0.000 description 1
- JVGPVVUTUMQJKL-UHFFFAOYSA-N 2-(2-butoxyethoxy)ethyl thiocyanate Chemical compound CCCCOCCOCCSC#N JVGPVVUTUMQJKL-UHFFFAOYSA-N 0.000 description 1
- FJMFGVFKZCRXQS-UHFFFAOYSA-N 2-(diethylamino)tetradecanoic acid Chemical compound CCCCCCCCCCCCC(C(O)=O)N(CC)CC FJMFGVFKZCRXQS-UHFFFAOYSA-N 0.000 description 1
- YOAXAWWLQAUPHR-UHFFFAOYSA-N 2-[acetyl(ethyl)amino]tetradecanoic acid Chemical compound CCCCCCCCCCCCC(C(O)=O)N(CC)C(C)=O YOAXAWWLQAUPHR-UHFFFAOYSA-N 0.000 description 1
- PEZYALDQLLTBBL-UHFFFAOYSA-N 2-[bis(2-hydroxyethyl)amino]ethanol;3-(4-chlorophenyl)-6-methoxy-1h-1,3,5-triazine-2,4-dione Chemical compound OCCN(CCO)CCO.O=C1NC(OC)=NC(=O)N1C1=CC=C(Cl)C=C1 PEZYALDQLLTBBL-UHFFFAOYSA-N 0.000 description 1
- GBHCABUWWQUMAJ-UHFFFAOYSA-N 2-hydrazinoethanol Chemical compound NNCCO GBHCABUWWQUMAJ-UHFFFAOYSA-N 0.000 description 1
- ZCHRCALASPNJEQ-UHFFFAOYSA-N 3-chloro-5-methyl-4-nitro-1h-pyrazole Chemical compound CC=1NN=C(Cl)C=1[N+]([O-])=O ZCHRCALASPNJEQ-UHFFFAOYSA-N 0.000 description 1
- ZXVONLUNISGICL-UHFFFAOYSA-N 4,6-dinitro-o-cresol Chemical compound CC1=CC([N+]([O-])=O)=CC([N+]([O-])=O)=C1O ZXVONLUNISGICL-UHFFFAOYSA-N 0.000 description 1
- IIDAJRNSZSFFCB-UHFFFAOYSA-N 4-amino-5-methoxy-2-methylbenzenesulfonamide Chemical compound COC1=CC(S(N)(=O)=O)=C(C)C=C1N IIDAJRNSZSFFCB-UHFFFAOYSA-N 0.000 description 1
- UZFMOKQJFYMBGY-UHFFFAOYSA-N 4-hydroxy-TEMPO Chemical compound CC1(C)CC(O)CC(C)(C)N1[O] UZFMOKQJFYMBGY-UHFFFAOYSA-N 0.000 description 1
- GZVBPNSXCWYLJU-UHFFFAOYSA-N 5,6-diphenyl-2,3-dihydro-1,4-oxathiine Chemical compound O1CCSC(C=2C=CC=CC=2)=C1C1=CC=CC=C1 GZVBPNSXCWYLJU-UHFFFAOYSA-N 0.000 description 1
- CTSLUCNDVMMDHG-UHFFFAOYSA-N 5-bromo-3-(butan-2-yl)-6-methylpyrimidine-2,4(1H,3H)-dione Chemical compound CCC(C)N1C(=O)NC(C)=C(Br)C1=O CTSLUCNDVMMDHG-UHFFFAOYSA-N 0.000 description 1
- ODHCTXKNWHHXJC-VKHMYHEASA-N 5-oxo-L-proline Chemical compound OC(=O)[C@@H]1CCC(=O)N1 ODHCTXKNWHHXJC-VKHMYHEASA-N 0.000 description 1
- UPULOMQHYQDNNT-UHFFFAOYSA-N 5h-1,3-oxazol-2-one Chemical compound O=C1OCC=N1 UPULOMQHYQDNNT-UHFFFAOYSA-N 0.000 description 1
- MYYIMZRZXIQBGI-HVIRSNARSA-N 6alpha-Fluoroprednisolone Chemical compound O=C1C=C[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3C[C@H](F)C2=C1 MYYIMZRZXIQBGI-HVIRSNARSA-N 0.000 description 1
- HCKFPALGXKOOBK-NRYMJLQJSA-N 7332-27-6 Chemical compound C1([C@]2(O[C@]3([C@@]4(C)C[C@H](O)[C@]5(F)[C@@]6(C)C=CC(=O)C=C6CC[C@H]5[C@@H]4C[C@H]3O2)C(=O)CO)C)=CC=CC=C1 HCKFPALGXKOOBK-NRYMJLQJSA-N 0.000 description 1
- RSWGJHLUYNHPMX-UHFFFAOYSA-N Abietic-Saeure Natural products C12CCC(C(C)C)=CC2=CCC2C1(C)CCCC2(C)C(O)=O RSWGJHLUYNHPMX-UHFFFAOYSA-N 0.000 description 1
- 241000238876 Acari Species 0.000 description 1
- NLHHRLWOUZZQLW-UHFFFAOYSA-N Acrylonitrile Chemical compound C=CC#N NLHHRLWOUZZQLW-UHFFFAOYSA-N 0.000 description 1
- KLSJWNVTNUYHDU-UHFFFAOYSA-N Amitrole Chemical compound NC1=NC=NN1 KLSJWNVTNUYHDU-UHFFFAOYSA-N 0.000 description 1
- 244000144725 Amygdalus communis Species 0.000 description 1
- 239000004382 Amylase Substances 0.000 description 1
- 102000013142 Amylases Human genes 0.000 description 1
- 108010065511 Amylases Proteins 0.000 description 1
- 244000099147 Ananas comosus Species 0.000 description 1
- 235000007119 Ananas comosus Nutrition 0.000 description 1
- 241000722948 Apocynum cannabinum Species 0.000 description 1
- 241000238421 Arthropoda Species 0.000 description 1
- 229930192334 Auxin Natural products 0.000 description 1
- 241000193830 Bacillus <bacterium> Species 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-N Benzoic acid Natural products OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
- 240000008564 Boehmeria nivea Species 0.000 description 1
- ZOXJGFHDIHLPTG-UHFFFAOYSA-N Boron Chemical compound [B] ZOXJGFHDIHLPTG-UHFFFAOYSA-N 0.000 description 1
- 244000056139 Brassica cretica Species 0.000 description 1
- 235000003351 Brassica cretica Nutrition 0.000 description 1
- 235000003343 Brassica rupestris Nutrition 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 1
- NOSSIEBYKIGOER-UHFFFAOYSA-N C(CCCC)SCCN1C(CCC1C(=O)O)=O.C(CCC)SCCN1C(CCC1C(=O)O)=O.C(CCCCCCCCCCC)SCCN1C(CCC1C(=O)O)=O Chemical compound C(CCCC)SCCN1C(CCC1C(=O)O)=O.C(CCC)SCCN1C(CCC1C(=O)O)=O.C(CCCCCCCCCCC)SCCN1C(CCC1C(=O)O)=O NOSSIEBYKIGOER-UHFFFAOYSA-N 0.000 description 1
- CYFQGYDRAKICTK-UHFFFAOYSA-N C(CCCCCCCC)SCCN1C(CCC1C(=O)O)=O.C(CCCCCCC)SCCN1C(CCC1C(=O)O)=O.C(CCCCC)SCCN1C(CCC1C(=O)O)=O Chemical compound C(CCCCCCCC)SCCN1C(CCC1C(=O)O)=O.C(CCCCCCC)SCCN1C(CCC1C(=O)O)=O.C(CCCCC)SCCN1C(CCC1C(=O)O)=O CYFQGYDRAKICTK-UHFFFAOYSA-N 0.000 description 1
- 239000005745 Captan Substances 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 229920003043 Cellulose fiber Polymers 0.000 description 1
- 229930186147 Cephalosporin Natural products 0.000 description 1
- 241000283153 Cetacea Species 0.000 description 1
- 239000005493 Chloridazon (aka pyrazone) Substances 0.000 description 1
- IVHVNMLJNASKHW-UHFFFAOYSA-M Chlorphonium chloride Chemical compound [Cl-].CCCC[P+](CCCC)(CCCC)CC1=CC=C(Cl)C=C1Cl IVHVNMLJNASKHW-UHFFFAOYSA-M 0.000 description 1
- 239000004099 Chlortetracycline Substances 0.000 description 1
- 241001478240 Coccus Species 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- MFYSYFVPBJMHGN-ZPOLXVRWSA-N Cortisone Chemical compound O=C1CC[C@]2(C)[C@H]3C(=O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 MFYSYFVPBJMHGN-ZPOLXVRWSA-N 0.000 description 1
- MFYSYFVPBJMHGN-UHFFFAOYSA-N Cortisone Natural products O=C1CCC2(C)C3C(=O)CC(C)(C(CC4)(O)C(=O)CO)C4C3CCC2=C1 MFYSYFVPBJMHGN-UHFFFAOYSA-N 0.000 description 1
- 241000186216 Corynebacterium Species 0.000 description 1
- HJIUPFPIEBPYIE-UHFFFAOYSA-N Crimidine Chemical compound CN(C)C1=CC(C)=NC(Cl)=N1 HJIUPFPIEBPYIE-UHFFFAOYSA-N 0.000 description 1
- XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- 229920004934 Dacron® Polymers 0.000 description 1
- 239000005644 Dazomet Substances 0.000 description 1
- 239000005947 Dimethoate Substances 0.000 description 1
- 239000005630 Diquat Substances 0.000 description 1
- 239000005766 Dodine Substances 0.000 description 1
- 208000030453 Drug-Related Side Effects and Adverse reaction Diseases 0.000 description 1
- 206010013786 Dry skin Diseases 0.000 description 1
- 229920002466 Dynel Polymers 0.000 description 1
- OVBJJZOQPCKUOR-UHFFFAOYSA-L EDTA disodium salt dihydrate Chemical compound O.O.[Na+].[Na+].[O-]C(=O)C[NH+](CC([O-])=O)CC[NH+](CC([O-])=O)CC([O-])=O OVBJJZOQPCKUOR-UHFFFAOYSA-L 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical compound C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 description 1
- GLPZEHFBLBYFHN-UHFFFAOYSA-N Ethychlozate Chemical compound C1=CC(Cl)=CC2=C(CC(=O)OCC)NN=C21 GLPZEHFBLBYFHN-UHFFFAOYSA-N 0.000 description 1
- 239000005977 Ethylene Substances 0.000 description 1
- 239000005789 Folpet Substances 0.000 description 1
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 1
- 239000005980 Gibberellic acid Substances 0.000 description 1
- 244000043261 Hevea brasiliensis Species 0.000 description 1
- 235000015928 Hibiscus cannabinus Nutrition 0.000 description 1
- 240000005979 Hordeum vulgare Species 0.000 description 1
- 235000007340 Hordeum vulgare Nutrition 0.000 description 1
- 235000008694 Humulus lupulus Nutrition 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- XQFRJNBWHJMXHO-RRKCRQDMSA-N IDUR Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 XQFRJNBWHJMXHO-RRKCRQDMSA-N 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- XRHGWAGWAHHFLF-UHFFFAOYSA-N Isazofos Chemical compound CCOP(=S)(OCC)OC=1N=C(Cl)N(C(C)C)N=1 XRHGWAGWAHHFLF-UHFFFAOYSA-N 0.000 description 1
- 241001293495 Lactuca virosa Species 0.000 description 1
- 239000004166 Lanolin Substances 0.000 description 1
- NNJVILVZKWQKPM-UHFFFAOYSA-N Lidocaine Chemical compound CCN(CC)CC(=O)NC1=C(C)C=CC=C1C NNJVILVZKWQKPM-UHFFFAOYSA-N 0.000 description 1
- 235000007688 Lycopersicon esculentum Nutrition 0.000 description 1
- 239000005574 MCPA Substances 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 239000005949 Malathion Substances 0.000 description 1
- 239000005983 Maleic hydrazide Substances 0.000 description 1
- BGRDGMRNKXEXQD-UHFFFAOYSA-N Maleic hydrazide Chemical compound OC1=CC=C(O)N=N1 BGRDGMRNKXEXQD-UHFFFAOYSA-N 0.000 description 1
- PWHULOQIROXLJO-UHFFFAOYSA-N Manganese Chemical compound [Mn] PWHULOQIROXLJO-UHFFFAOYSA-N 0.000 description 1
- OKIBNKKYNPBDRS-UHFFFAOYSA-N Mefluidide Chemical compound CC(=O)NC1=CC(NS(=O)(=O)C(F)(F)F)=C(C)C=C1C OKIBNKKYNPBDRS-UHFFFAOYSA-N 0.000 description 1
- ZOKXTWBITQBERF-UHFFFAOYSA-N Molybdenum Chemical compound [Mo] ZOKXTWBITQBERF-UHFFFAOYSA-N 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- MMOXZBCLCQITDF-UHFFFAOYSA-N N,N-diethyl-m-toluamide Chemical compound CCN(CC)C(=O)C1=CC=CC(C)=C1 MMOXZBCLCQITDF-UHFFFAOYSA-N 0.000 description 1
- 229910002651 NO3 Inorganic materials 0.000 description 1
- 229920002302 Nylon 6,6 Polymers 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 208000005141 Otitis Diseases 0.000 description 1
- 208000012868 Overgrowth Diseases 0.000 description 1
- KYGZCKSPAKDVKC-UHFFFAOYSA-N Oxolinic acid Chemical compound C1=C2N(CC)C=C(C(O)=O)C(=O)C2=CC2=C1OCO2 KYGZCKSPAKDVKC-UHFFFAOYSA-N 0.000 description 1
- 239000004100 Oxytetracycline Substances 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- ABLZXFCXXLZCGV-UHFFFAOYSA-N Phosphorous acid Chemical class OP(O)=O ABLZXFCXXLZCGV-UHFFFAOYSA-N 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- 239000005595 Picloram Substances 0.000 description 1
- 239000005923 Pirimicarb Substances 0.000 description 1
- 239000004698 Polyethylene Substances 0.000 description 1
- 208000020584 Polyploidy Diseases 0.000 description 1
- 239000004743 Polypropylene Substances 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
- 206010037083 Prurigo Diseases 0.000 description 1
- 241000220324 Pyrus Species 0.000 description 1
- 244000088415 Raphanus sativus Species 0.000 description 1
- 235000006140 Raphanus sativus var sativus Nutrition 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 241000282806 Rhinoceros Species 0.000 description 1
- KHPCPRHQVVSZAH-HUOMCSJISA-N Rosin Natural products O(C/C=C/c1ccccc1)[C@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 KHPCPRHQVVSZAH-HUOMCSJISA-N 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 240000000111 Saccharum officinarum Species 0.000 description 1
- 235000007201 Saccharum officinarum Nutrition 0.000 description 1
- XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 description 1
- BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical compound [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 description 1
- 208000000453 Skin Neoplasms Diseases 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 239000004902 Softening Agent Substances 0.000 description 1
- 240000003768 Solanum lycopersicum Species 0.000 description 1
- 244000061458 Solanum melongena Species 0.000 description 1
- 235000002597 Solanum melongena Nutrition 0.000 description 1
- 244000061456 Solanum tuberosum Species 0.000 description 1
- 235000002595 Solanum tuberosum Nutrition 0.000 description 1
- 244000062793 Sorghum vulgare Species 0.000 description 1
- 240000004460 Tanacetum coccineum Species 0.000 description 1
- GUGOEEXESWIERI-UHFFFAOYSA-N Terfenadine Chemical compound C1=CC(C(C)(C)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 GUGOEEXESWIERI-UHFFFAOYSA-N 0.000 description 1
- 229920004933 Terylene® Polymers 0.000 description 1
- WHKUVVPPKQRRBV-UHFFFAOYSA-N Trasan Chemical compound CC1=CC(Cl)=CC=C1OCC(O)=O WHKUVVPPKQRRBV-UHFFFAOYSA-N 0.000 description 1
- BABJTMNVJXLAEX-UHFFFAOYSA-N Triamiphos Chemical compound N1=C(N)N(P(=O)(N(C)C)N(C)C)N=C1C1=CC=CC=C1 BABJTMNVJXLAEX-UHFFFAOYSA-N 0.000 description 1
- 241000611866 Tyrophagus putrescentiae Species 0.000 description 1
- 229920002978 Vinylon Polymers 0.000 description 1
- 229920001617 Vinyon Polymers 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 241000219094 Vitaceae Species 0.000 description 1
- 235000009754 Vitis X bourquina Nutrition 0.000 description 1
- 235000012333 Vitis X labruscana Nutrition 0.000 description 1
- 240000006365 Vitis vinifera Species 0.000 description 1
- 235000014787 Vitis vinifera Nutrition 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- IXEVGHXRXDBAOB-BREBYQMCSA-N [(1r,3r,4r)-4,7,7-trimethyl-3-bicyclo[2.2.1]heptanyl] 2-thiocyanatoacetate Chemical compound C1C[C@@]2(C)[C@H](OC(=O)CSC#N)C[C@@H]1C2(C)C IXEVGHXRXDBAOB-BREBYQMCSA-N 0.000 description 1
- UFUVLHLTWXBHGZ-MGZQPHGTSA-N [(2r,3r,4s,5r,6r)-6-[(1s,2s)-2-chloro-1-[[(2s,4r)-1-methyl-4-propylpyrrolidine-2-carbonyl]amino]propyl]-4,5-dihydroxy-2-methylsulfanyloxan-3-yl] dihydrogen phosphate Chemical compound CN1C[C@H](CCC)C[C@H]1C(=O)N[C@H]([C@H](C)Cl)[C@@H]1[C@H](O)[C@H](O)[C@@H](OP(O)(O)=O)[C@@H](SC)O1 UFUVLHLTWXBHGZ-MGZQPHGTSA-N 0.000 description 1
- BSUQCLSFQSUNED-PPPRQHODSA-N [(2s,3r,4s,6r)-4-(dimethylamino)-2-[[(3r,4s,5s,6r,7r,9r,11r,12r,13s,14r)-14-ethyl-7,12,13-trihydroxy-4-[(2r,4r,5s,6s)-5-hydroxy-4-methoxy-4,6-dimethyloxan-2-yl]oxy-3,5,7,9,11,13-hexamethyl-2,10-dioxo-oxacyclotetradec-6-yl]oxy]-6-methyloxan-3-yl] ethyl car Chemical compound O1[C@H](C)C[C@H](N(C)C)[C@@H](OC(=O)OCC)[C@@H]1O[C@H]1[C@@](O)(C)C[C@@H](C)C(=O)[C@H](C)[C@@H](O)[C@](C)(O)[C@@H](CC)OC(=O)[C@H](C)[C@@H](O[C@@H]2O[C@@H](C)[C@H](O)[C@](C)(OC)C2)[C@@H]1C BSUQCLSFQSUNED-PPPRQHODSA-N 0.000 description 1
- ROVGZAWFACYCSP-MQBLHHJJSA-N [2-methyl-4-oxo-3-[(2z)-penta-2,4-dienyl]cyclopent-2-en-1-yl] (1r,3r)-2,2-dimethyl-3-(2-methylprop-1-enyl)cyclopropane-1-carboxylate Chemical compound CC1(C)[C@H](C=C(C)C)[C@H]1C(=O)OC1C(C)=C(C\C=C/C=C)C(=O)C1 ROVGZAWFACYCSP-MQBLHHJJSA-N 0.000 description 1
- RQTYNJRMROVVQJ-UHFFFAOYSA-N [ClH]1OC=CC=C1 Chemical compound [ClH]1OC=CC=C1 RQTYNJRMROVVQJ-UHFFFAOYSA-N 0.000 description 1
- FPWJLQXCGHQXLL-UHFFFAOYSA-N [P].OP(O)(O)=O Chemical compound [P].OP(O)(O)=O FPWJLQXCGHQXLL-UHFFFAOYSA-N 0.000 description 1
- 230000003187 abdominal effect Effects 0.000 description 1
- 230000006578 abscission Effects 0.000 description 1
- 230000000895 acaricidal effect Effects 0.000 description 1
- 239000000642 acaricide Substances 0.000 description 1
- 229920006221 acetate fiber Polymers 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 239000000674 adrenergic antagonist Substances 0.000 description 1
- 239000002386 air freshener Substances 0.000 description 1
- 239000003619 algicide Substances 0.000 description 1
- 230000029936 alkylation Effects 0.000 description 1
- 238000005804 alkylation reaction Methods 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 235000020224 almond Nutrition 0.000 description 1
- 208000004631 alopecia areata Diseases 0.000 description 1
- 229950003408 amcinafide Drugs 0.000 description 1
- 150000001412 amines Chemical group 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 235000019418 amylase Nutrition 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 230000000507 anthelmentic effect Effects 0.000 description 1
- 230000000843 anti-fungal effect Effects 0.000 description 1
- 230000001387 anti-histamine Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000000118 anti-neoplastic effect Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 229940127219 anticoagulant drug Drugs 0.000 description 1
- 239000003429 antifungal agent Substances 0.000 description 1
- 239000000739 antihistaminic agent Substances 0.000 description 1
- 239000004599 antimicrobial Substances 0.000 description 1
- 235000021016 apples Nutrition 0.000 description 1
- 239000012298 atmosphere Substances 0.000 description 1
- MXWJVTOOROXGIU-UHFFFAOYSA-N atrazine Chemical compound CCNC1=NC(Cl)=NC(NC(C)C)=N1 MXWJVTOOROXGIU-UHFFFAOYSA-N 0.000 description 1
- 239000002363 auxin Substances 0.000 description 1
- OTSAMNSACVKIOJ-UHFFFAOYSA-N azane;carbamoyl(ethoxy)phosphinic acid Chemical compound [NH4+].CCOP([O-])(=O)C(N)=O OTSAMNSACVKIOJ-UHFFFAOYSA-N 0.000 description 1
- XYOVOXDWRFGKEX-UHFFFAOYSA-N azepine Chemical compound N1C=CC=CC=C1 XYOVOXDWRFGKEX-UHFFFAOYSA-N 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- 244000052616 bacterial pathogen Species 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 150000001556 benzimidazoles Chemical class 0.000 description 1
- WXBLLCUINBKULX-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1.OC(=O)C1=CC=CC=C1 WXBLLCUINBKULX-UHFFFAOYSA-N 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- 235000019445 benzyl alcohol Nutrition 0.000 description 1
- QKSKPIVNLNLAAV-UHFFFAOYSA-N bis(2-chloroethyl) sulfide Chemical compound ClCCSCCCl QKSKPIVNLNLAAV-UHFFFAOYSA-N 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 125000001246 bromo group Chemical group Br* 0.000 description 1
- HCOMFAYPHBFMKU-UHFFFAOYSA-N butanedihydrazide Chemical compound NNC(=O)CCC(=O)NN HCOMFAYPHBFMKU-UHFFFAOYSA-N 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 229960004348 candicidin Drugs 0.000 description 1
- 229940117949 captan Drugs 0.000 description 1
- DUEPRVBVGDRKAG-UHFFFAOYSA-N carbofuran Chemical compound CNC(=O)OC1=CC=CC2=C1OC(C)(C)C2 DUEPRVBVGDRKAG-UHFFFAOYSA-N 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 125000002091 cationic group Chemical group 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 229940124587 cephalosporin Drugs 0.000 description 1
- 150000001780 cephalosporins Chemical class 0.000 description 1
- 235000013351 cheese Nutrition 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- WYKYKTKDBLFHCY-UHFFFAOYSA-N chloridazon Chemical compound O=C1C(Cl)=C(N)C=NN1C1=CC=CC=C1 WYKYKTKDBLFHCY-UHFFFAOYSA-N 0.000 description 1
- UHZZMRAGKVHANO-UHFFFAOYSA-M chlormequat chloride Chemical compound [Cl-].C[N+](C)(C)CCCl UHZZMRAGKVHANO-UHFFFAOYSA-M 0.000 description 1
- CYDMQBQPVICBEU-UHFFFAOYSA-N chlorotetracycline Natural products C1=CC(Cl)=C2C(O)(C)C3CC4C(N(C)C)C(O)=C(C(N)=O)C(=O)C4(O)C(O)=C3C(=O)C2=C1O CYDMQBQPVICBEU-UHFFFAOYSA-N 0.000 description 1
- CWJSHJJYOPWUGX-UHFFFAOYSA-N chlorpropham Chemical compound CC(C)OC(=O)NC1=CC=CC(Cl)=C1 CWJSHJJYOPWUGX-UHFFFAOYSA-N 0.000 description 1
- 229960004475 chlortetracycline Drugs 0.000 description 1
- CYDMQBQPVICBEU-XRNKAMNCSA-N chlortetracycline Chemical compound C1=CC(Cl)=C2[C@](O)(C)[C@H]3C[C@H]4[C@H](N(C)C)C(O)=C(C(N)=O)C(=O)[C@@]4(O)C(O)=C3C(=O)C2=C1O CYDMQBQPVICBEU-XRNKAMNCSA-N 0.000 description 1
- 235000019365 chlortetracycline Nutrition 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 229960002227 clindamycin Drugs 0.000 description 1
- 229960002291 clindamycin phosphate Drugs 0.000 description 1
- 229960004208 clodantoin Drugs 0.000 description 1
- VOGJJBHRUDVEFM-UHFFFAOYSA-N clodantoin Chemical compound CCCCC(CC)C1NC(=O)N(SC(Cl)(Cl)Cl)C1=O VOGJJBHRUDVEFM-UHFFFAOYSA-N 0.000 description 1
- 229960004022 clotrimazole Drugs 0.000 description 1
- VNFPBHJOKIVQEB-UHFFFAOYSA-N clotrimazole Chemical compound ClC1=CC=CC=C1C(N1C=NC=C1)(C=1C=CC=CC=1)C1=CC=CC=C1 VNFPBHJOKIVQEB-UHFFFAOYSA-N 0.000 description 1
- 239000010941 cobalt Substances 0.000 description 1
- 229910017052 cobalt Inorganic materials 0.000 description 1
- GUTLYIVDDKVIGB-UHFFFAOYSA-N cobalt atom Chemical compound [Co] GUTLYIVDDKVIGB-UHFFFAOYSA-N 0.000 description 1
- 239000008294 cold cream Substances 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 230000021615 conjugation Effects 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- 239000003246 corticosteroid Substances 0.000 description 1
- 229960001334 corticosteroids Drugs 0.000 description 1
- 229960004544 cortisone Drugs 0.000 description 1
- 229950002276 cortodoxone Drugs 0.000 description 1
- 239000010779 crude oil Substances 0.000 description 1
- 239000004062 cytokinin Substances 0.000 description 1
- UQHKFADEQIVWID-UHFFFAOYSA-N cytokinin Natural products C1=NC=2C(NCC=C(CO)C)=NC=NC=2N1C1CC(O)C(CO)O1 UQHKFADEQIVWID-UHFFFAOYSA-N 0.000 description 1
- QAYICIQNSGETAS-UHFFFAOYSA-N dazomet Chemical compound CN1CSC(=S)N(C)C1 QAYICIQNSGETAS-UHFFFAOYSA-N 0.000 description 1
- 230000035613 defoliation Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 238000002716 delivery method Methods 0.000 description 1
- XUWHAWMETYGRKB-UHFFFAOYSA-N delta-valerolactam Natural products O=C1CCCCN1 XUWHAWMETYGRKB-UHFFFAOYSA-N 0.000 description 1
- 210000004207 dermis Anatomy 0.000 description 1
- 229960003662 desonide Drugs 0.000 description 1
- WBGKWQHBNHJJPZ-LECWWXJVSA-N desonide Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@@H]2[C@@H]1[C@@H]1C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]1(C)C[C@@H]2O WBGKWQHBNHJJPZ-LECWWXJVSA-N 0.000 description 1
- FCRACOPGPMPSHN-UHFFFAOYSA-N desoxyabscisic acid Natural products OC(=O)C=C(C)C=CC1C(C)=CC(=O)CC1(C)C FCRACOPGPMPSHN-UHFFFAOYSA-N 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 239000000032 diagnostic agent Substances 0.000 description 1
- 229940039227 diagnostic agent Drugs 0.000 description 1
- PXBRQCKWGAHEHS-UHFFFAOYSA-N dichlorodifluoromethane Chemical compound FC(F)(Cl)Cl PXBRQCKWGAHEHS-UHFFFAOYSA-N 0.000 description 1
- 235000019404 dichlorodifluoromethane Nutrition 0.000 description 1
- XFMJUIKWKVJNDY-UHFFFAOYSA-N diethoxyphosphorylsulfanylmethylbenzene Chemical compound CCOP(=O)(OCC)SCC1=CC=CC=C1 XFMJUIKWKVJNDY-UHFFFAOYSA-N 0.000 description 1
- JXSJBGJIGXNWCI-UHFFFAOYSA-N diethyl 2-[(dimethoxyphosphorothioyl)thio]succinate Chemical compound CCOC(=O)CC(SP(=S)(OC)OC)C(=O)OCC JXSJBGJIGXNWCI-UHFFFAOYSA-N 0.000 description 1
- HPNMFZURTQLUMO-UHFFFAOYSA-N diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 description 1
- 229960001673 diethyltoluamide Drugs 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 229940120503 dihydroxyacetone Drugs 0.000 description 1
- MCWXGJITAZMZEV-UHFFFAOYSA-N dimethoate Chemical compound CNC(=O)CSP(=S)(OC)OC MCWXGJITAZMZEV-UHFFFAOYSA-N 0.000 description 1
- USIUVYZYUHIAEV-UHFFFAOYSA-N diphenyl ether Chemical class C=1C=CC=CC=1OC1=CC=CC=C1 USIUVYZYUHIAEV-UHFFFAOYSA-N 0.000 description 1
- SYJFEGQWDCRVNX-UHFFFAOYSA-N diquat Chemical compound C1=CC=[N+]2CC[N+]3=CC=CC=C3C2=C1 SYJFEGQWDCRVNX-UHFFFAOYSA-N 0.000 description 1
- 239000000982 direct dye Substances 0.000 description 1
- 238000009967 direct dyeing Methods 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 229960003722 doxycycline Drugs 0.000 description 1
- 230000037336 dry skin Effects 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 239000003221 ear drop Substances 0.000 description 1
- 229940047652 ear drops Drugs 0.000 description 1
- 208000019258 ear infection Diseases 0.000 description 1
- 238000011067 equilibration Methods 0.000 description 1
- 229960000741 erythromycin ethylsuccinate Drugs 0.000 description 1
- NSYZCCDSJNWWJL-YXOIYICCSA-N erythromycin ethylsuccinate Chemical compound O1[C@H](C)C[C@H](N(C)C)[C@@H](OC(=O)CCC(=O)OCC)[C@@H]1O[C@H]1[C@@](O)(C)C[C@@H](C)C(=O)[C@H](C)[C@@H](O)[C@](C)(O)[C@@H](CC)OC(=O)[C@H](C)[C@@H](O[C@@H]2O[C@@H](C)[C@H](O)[C@](C)(OC)C2)[C@@H]1C NSYZCCDSJNWWJL-YXOIYICCSA-N 0.000 description 1
- 235000020774 essential nutrients Nutrition 0.000 description 1
- VKPHXAZSBHQZRC-LURJTMIESA-N ethyl (2s)-2-(ethylamino)propanoate Chemical compound CCN[C@@H](C)C(=O)OCC VKPHXAZSBHQZRC-LURJTMIESA-N 0.000 description 1
- BFNYDDPQMKYKKJ-YFKPBYRVSA-N ethyl (2s)-2-acetamidopropanoate Chemical compound CCOC(=O)[C@H](C)NC(C)=O BFNYDDPQMKYKKJ-YFKPBYRVSA-N 0.000 description 1
- SITGEDUCHSPQDQ-UHFFFAOYSA-N ethyl 1-dodecyl-5-oxopyrrolidine-2-carboxylate Chemical compound CCCCCCCCCCCCN1C(C(=O)OCC)CCC1=O SITGEDUCHSPQDQ-UHFFFAOYSA-N 0.000 description 1
- DWTATFFXYVNHEB-UHFFFAOYSA-N ethyl 2-[5-(4-chlorophenyl)tetrazol-2-yl]acetate Chemical compound CCOC(=O)CN1N=NC(C=2C=CC(Cl)=CC=2)=N1 DWTATFFXYVNHEB-UHFFFAOYSA-N 0.000 description 1
- 239000003889 eye drop Substances 0.000 description 1
- 229940012356 eye drops Drugs 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 230000008126 female flower development Effects 0.000 description 1
- 230000004720 fertilization Effects 0.000 description 1
- 239000003337 fertilizer Substances 0.000 description 1
- 230000004992 fission Effects 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 229960001347 fluocinolone acetonide Drugs 0.000 description 1
- GVEPBJHOBDJJJI-UHFFFAOYSA-N fluoranthrene Natural products C1=CC(C2=CC=CC=C22)=C3C2=CC=CC3=C1 GVEPBJHOBDJJJI-UHFFFAOYSA-N 0.000 description 1
- 229960000618 fluprednisolone Drugs 0.000 description 1
- 230000004907 flux Effects 0.000 description 1
- HKIOYBQGHSTUDB-UHFFFAOYSA-N folpet Chemical compound C1=CC=C2C(=O)N(SC(Cl)(Cl)Cl)C(=O)C2=C1 HKIOYBQGHSTUDB-UHFFFAOYSA-N 0.000 description 1
- PGBHMTALBVVCIT-VCIWKGPPSA-N framycetin Chemical compound N[C@@H]1[C@@H](O)[C@H](O)[C@H](CN)O[C@@H]1O[C@H]1[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](N)C[C@@H](N)[C@@H]2O)O[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CN)O2)N)O[C@@H]1CO PGBHMTALBVVCIT-VCIWKGPPSA-N 0.000 description 1
- 230000005078 fruit development Effects 0.000 description 1
- 230000005094 fruit set Effects 0.000 description 1
- 239000002316 fumigant Substances 0.000 description 1
- ZZUFCTLCJUWOSV-UHFFFAOYSA-N furosemide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC(C(O)=O)=C1NCC1=CC=CO1 ZZUFCTLCJUWOSV-UHFFFAOYSA-N 0.000 description 1
- 230000035784 germination Effects 0.000 description 1
- 235000021021 grapes Nutrition 0.000 description 1
- 239000003966 growth inhibitor Substances 0.000 description 1
- 239000000118 hair dye Substances 0.000 description 1
- AEDIXYWIVPYNBI-UHFFFAOYSA-N heptanamide Chemical compound CCCCCCC(N)=O AEDIXYWIVPYNBI-UHFFFAOYSA-N 0.000 description 1
- 241000411851 herbal medicine Species 0.000 description 1
- 150000002391 heterocyclic compounds Chemical class 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- 150000002430 hydrocarbons Chemical class 0.000 description 1
- JXYZHMPRERWTPM-UHFFFAOYSA-N hydron;morpholine;chloride Chemical compound Cl.C1COCCN1 JXYZHMPRERWTPM-UHFFFAOYSA-N 0.000 description 1
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
- 229960004716 idoxuridine Drugs 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 238000007654 immersion Methods 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 239000007943 implant Substances 0.000 description 1
- 230000008676 import Effects 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 208000027866 inflammatory disease Diseases 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 238000004920 integrated pest control Methods 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 229940039009 isoproterenol Drugs 0.000 description 1
- 230000002147 killing effect Effects 0.000 description 1
- 210000003127 knee Anatomy 0.000 description 1
- 238000009940 knitting Methods 0.000 description 1
- 229940039717 lanolin Drugs 0.000 description 1
- 235000019388 lanolin Nutrition 0.000 description 1
- 239000004816 latex Substances 0.000 description 1
- 229920000126 latex Polymers 0.000 description 1
- 229960004194 lidocaine Drugs 0.000 description 1
- 229940059904 light mineral oil Drugs 0.000 description 1
- 244000144972 livestock Species 0.000 description 1
- 230000003050 macronutrient Effects 0.000 description 1
- 229960000453 malathion Drugs 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 238000004890 malting Methods 0.000 description 1
- 229910052748 manganese Inorganic materials 0.000 description 1
- 239000011572 manganese Substances 0.000 description 1
- WPBNNNQJVZRUHP-UHFFFAOYSA-L manganese(2+);methyl n-[[2-(methoxycarbonylcarbamothioylamino)phenyl]carbamothioyl]carbamate;n-[2-(sulfidocarbothioylamino)ethyl]carbamodithioate Chemical compound [Mn+2].[S-]C(=S)NCCNC([S-])=S.COC(=O)NC(=S)NC1=CC=CC=C1NC(=S)NC(=O)OC WPBNNNQJVZRUHP-UHFFFAOYSA-L 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- AFCCDDWKHLHPDF-UHFFFAOYSA-M metam-sodium Chemical compound [Na+].CNC([S-])=S AFCCDDWKHLHPDF-UHFFFAOYSA-M 0.000 description 1
- GEPDYQSQVLXLEU-AATRIKPKSA-N methyl (e)-3-dimethoxyphosphoryloxybut-2-enoate Chemical compound COC(=O)\C=C(/C)OP(=O)(OC)OC GEPDYQSQVLXLEU-AATRIKPKSA-N 0.000 description 1
- 235000019713 millet Nutrition 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 229960004023 minocycline Drugs 0.000 description 1
- 239000003750 molluscacide Substances 0.000 description 1
- 230000002013 molluscicidal effect Effects 0.000 description 1
- 229910052750 molybdenum Inorganic materials 0.000 description 1
- 239000011733 molybdenum Substances 0.000 description 1
- 235000010460 mustard Nutrition 0.000 description 1
- 239000007923 nasal drop Substances 0.000 description 1
- 229940100662 nasal drops Drugs 0.000 description 1
- 239000007922 nasal spray Substances 0.000 description 1
- 229940053050 neomycin sulfate Drugs 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 229960002715 nicotine Drugs 0.000 description 1
- SNICXCGAKADSCV-UHFFFAOYSA-N nicotine Natural products CN1CCCC1C1=CC=CN=C1 SNICXCGAKADSCV-UHFFFAOYSA-N 0.000 description 1
- 235000021231 nutrient uptake Nutrition 0.000 description 1
- 230000009965 odorless effect Effects 0.000 description 1
- 150000005677 organic carbonates Chemical class 0.000 description 1
- 150000002894 organic compounds Chemical group 0.000 description 1
- 239000005416 organic matter Substances 0.000 description 1
- 239000003992 organochlorine insecticide Substances 0.000 description 1
- 239000003986 organophosphate insecticide Substances 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 229960000625 oxytetracycline Drugs 0.000 description 1
- IWVCMVBTMGNXQD-PXOLEDIWSA-N oxytetracycline Chemical compound C1=CC=C2[C@](O)(C)[C@H]3[C@H](O)[C@H]4[C@H](N(C)C)C(O)=C(C(N)=O)C(=O)[C@@]4(O)C(O)=C3C(=O)C2=C1O IWVCMVBTMGNXQD-PXOLEDIWSA-N 0.000 description 1
- 235000019366 oxytetracycline Nutrition 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
- FIKAKWIAUPDISJ-UHFFFAOYSA-L paraquat dichloride Chemical compound [Cl-].[Cl-].C1=C[N+](C)=CC=C1C1=CC=[N+](C)C=C1 FIKAKWIAUPDISJ-UHFFFAOYSA-L 0.000 description 1
- 244000045947 parasite Species 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 235000021017 pears Nutrition 0.000 description 1
- 229960001639 penicillamine Drugs 0.000 description 1
- 150000002960 penicillins Chemical class 0.000 description 1
- 230000000361 pesticidal effect Effects 0.000 description 1
- DCNLOVYDMCVNRZ-UHFFFAOYSA-N phenylmercury(.) Chemical class [Hg]C1=CC=CC=C1 DCNLOVYDMCVNRZ-UHFFFAOYSA-N 0.000 description 1
- 150000008298 phosphoramidates Chemical class 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 230000005097 photorespiration Effects 0.000 description 1
- 230000000243 photosynthetic effect Effects 0.000 description 1
- 230000037074 physically active Effects 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 229930195732 phytohormone Natural products 0.000 description 1
- NQQVFXUMIDALNH-UHFFFAOYSA-N picloram Chemical compound NC1=C(Cl)C(Cl)=NC(C(O)=O)=C1Cl NQQVFXUMIDALNH-UHFFFAOYSA-N 0.000 description 1
- YFGYUFNIOHWBOB-UHFFFAOYSA-N pirimicarb Chemical compound CN(C)C(=O)OC1=NC(N(C)C)=NC(C)=C1C YFGYUFNIOHWBOB-UHFFFAOYSA-N 0.000 description 1
- 239000003375 plant hormone Substances 0.000 description 1
- 238000004161 plant tissue culture Methods 0.000 description 1
- 229920000573 polyethylene Polymers 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 229920001155 polypropylene Polymers 0.000 description 1
- 229940068965 polysorbates Drugs 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 238000012794 pre-harvesting Methods 0.000 description 1
- 229960005205 prednisolone Drugs 0.000 description 1
- OIGNJSKKLXVSLS-VWUMJDOOSA-N prednisolone Chemical compound O=C1C=C[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 OIGNJSKKLXVSLS-VWUMJDOOSA-N 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 229960003857 proglumide Drugs 0.000 description 1
- VXPLXMJHHKHSOA-UHFFFAOYSA-N propham Chemical compound CC(C)OC(=O)NC1=CC=CC=C1 VXPLXMJHHKHSOA-UHFFFAOYSA-N 0.000 description 1
- 229940080818 propionamide Drugs 0.000 description 1
- QQONPFPTGQHPMA-UHFFFAOYSA-N propylene Natural products CC=C QQONPFPTGQHPMA-UHFFFAOYSA-N 0.000 description 1
- 239000003223 protective agent Substances 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 230000001823 pruritic effect Effects 0.000 description 1
- 208000014237 psoriasis 1 Diseases 0.000 description 1
- 239000008213 purified water Substances 0.000 description 1
- 229940015367 pyrethrum Drugs 0.000 description 1
- 150000004053 quinones Chemical class 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 239000002964 rayon Substances 0.000 description 1
- 238000004045 reactive dyeing Methods 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 230000026267 regulation of growth Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 230000000979 retarding effect Effects 0.000 description 1
- 230000021749 root development Effects 0.000 description 1
- 229960004889 salicylic acid Drugs 0.000 description 1
- 239000004576 sand Substances 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 210000001732 sebaceous gland Anatomy 0.000 description 1
- 230000037307 sensitive skin Effects 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 239000010703 silicon Substances 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 229910052709 silver Inorganic materials 0.000 description 1
- 239000004332 silver Substances 0.000 description 1
- 201000000849 skin cancer Diseases 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- DEWVPZYHFVYXMZ-QCILGFJPSA-M sodium;(3ar,4as,8ar,8bs)-2,2,7,7-tetramethyl-4a,5,8a,8b-tetrahydro-[1,3]dioxolo[3,4]furo[1,3-d][1,3]dioxine-3a-carboxylate Chemical compound [Na+].O([C@H]12)C(C)(C)OC[C@@H]1O[C@]1(C([O-])=O)[C@H]2OC(C)(C)O1 DEWVPZYHFVYXMZ-QCILGFJPSA-M 0.000 description 1
- XNRNJIIJLOFJEK-UHFFFAOYSA-N sodium;1-oxidopyridine-2-thione Chemical compound [Na+].[O-]N1C=CC=CC1=S XNRNJIIJLOFJEK-UHFFFAOYSA-N 0.000 description 1
- 239000002689 soil Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 238000000638 solvent extraction Methods 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 239000012177 spermaceti Substances 0.000 description 1
- 229940084106 spermaceti Drugs 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 229940041022 streptomycins Drugs 0.000 description 1
- 229940124530 sulfonamide Drugs 0.000 description 1
- 150000003456 sulfonamides Chemical class 0.000 description 1
- 230000008833 sun damage Effects 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 230000009182 swimming Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- IWVCMVBTMGNXQD-UHFFFAOYSA-N terramycin dehydrate Natural products C1=CC=C2C(O)(C)C3C(O)C4C(N(C)C)C(O)=C(C(N)=O)C(=O)C4(O)C(O)=C3C(=O)C2=C1O IWVCMVBTMGNXQD-UHFFFAOYSA-N 0.000 description 1
- 229960002180 tetracycline Drugs 0.000 description 1
- 229930101283 tetracycline Natural products 0.000 description 1
- 229940040944 tetracyclines Drugs 0.000 description 1
- VPYHKSUKMGPRIN-UHFFFAOYSA-N tetrakis(3-methylbutyl)azanium Chemical compound CC(C)CC[N+](CCC(C)C)(CCC(C)C)CCC(C)C VPYHKSUKMGPRIN-UHFFFAOYSA-N 0.000 description 1
- 229960000278 theophylline Drugs 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 239000004308 thiabendazole Substances 0.000 description 1
- WJCNZQLZVWNLKY-UHFFFAOYSA-N thiabendazole Chemical compound S1C=NC(C=2NC3=CC=CC=C3N=2)=C1 WJCNZQLZVWNLKY-UHFFFAOYSA-N 0.000 description 1
- 235000010296 thiabendazole Nutrition 0.000 description 1
- 229960004546 thiabendazole Drugs 0.000 description 1
- FUSNMLFNXJSCDI-UHFFFAOYSA-N tolnaftate Chemical compound C=1C=C2C=CC=CC2=CC=1OC(=S)N(C)C1=CC=CC(C)=C1 FUSNMLFNXJSCDI-UHFFFAOYSA-N 0.000 description 1
- 229960004880 tolnaftate Drugs 0.000 description 1
- 238000011200 topical administration Methods 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 239000011573 trace mineral Substances 0.000 description 1
- 235000013619 trace mineral Nutrition 0.000 description 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
- KHPCPRHQVVSZAH-UHFFFAOYSA-N trans-cinnamyl beta-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OCC=CC1=CC=CC=C1 KHPCPRHQVVSZAH-UHFFFAOYSA-N 0.000 description 1
- ILJSQTXMGCGYMG-UHFFFAOYSA-N triacetic acid Chemical compound CC(=O)CC(=O)CC(O)=O ILJSQTXMGCGYMG-UHFFFAOYSA-N 0.000 description 1
- 229960002117 triamcinolone acetonide Drugs 0.000 description 1
- YNDXUCZADRHECN-JNQJZLCISA-N triamcinolone acetonide Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]1(C)C[C@@H]2O YNDXUCZADRHECN-JNQJZLCISA-N 0.000 description 1
- XREXPQGDOPQPAH-QKUPJAQQSA-K trisodium;[(z)-18-[1,3-bis[[(z)-12-sulfonatooxyoctadec-9-enoyl]oxy]propan-2-yloxy]-18-oxooctadec-9-en-7-yl] sulfate Chemical compound [Na+].[Na+].[Na+].CCCCCCC(OS([O-])(=O)=O)C\C=C/CCCCCCCC(=O)OCC(OC(=O)CCCCCCC\C=C/CC(CCCCCC)OS([O-])(=O)=O)COC(=O)CCCCCCC\C=C/CC(CCCCCC)OS([O-])(=O)=O XREXPQGDOPQPAH-QKUPJAQQSA-K 0.000 description 1
- LEONUFNNVUYDNQ-UHFFFAOYSA-N vanadium atom Chemical compound [V] LEONUFNNVUYDNQ-UHFFFAOYSA-N 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 229960005080 warfarin Drugs 0.000 description 1
- PJVWKTKQMONHTI-UHFFFAOYSA-N warfarin Chemical compound OC=1C2=CC=CC=C2OC(=O)C=1C(CC(=O)C)C1=CC=CC=C1 PJVWKTKQMONHTI-UHFFFAOYSA-N 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
- 231100000054 whole-body exposure Toxicity 0.000 description 1
- 210000002268 wool Anatomy 0.000 description 1
- 238000010626 work up procedure Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
- C07D207/22—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/24—Oxygen or sulfur atoms
- C07D207/26—2-Pyrrolidones
- C07D207/263—2-Pyrrolidones with only hydrogen atoms or radicals containing only hydrogen and carbon atoms directly attached to other ring carbon atoms
- C07D207/27—2-Pyrrolidones with only hydrogen atoms or radicals containing only hydrogen and carbon atoms directly attached to other ring carbon atoms with substituted hydrocarbon radicals directly attached to the ring nitrogen atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- A01N37/00—Biocides, pest repellants or attractants, or plant growth regulators containing organic compounds containing a carbon atom having three bonds to hetero atoms with at the most two bonds to halogen, e.g. carboxylic acids
- A01N37/44—Biocides, pest repellants or attractants, or plant growth regulators containing organic compounds containing a carbon atom having three bonds to hetero atoms with at the most two bonds to halogen, e.g. carboxylic acids containing at least one carboxylic group or a thio analogue, or a derivative thereof, and a nitrogen atom attached to the same carbon skeleton by a single or double bond, this nitrogen atom not being a member of a derivative or of a thio analogue of a carboxylic group, e.g. amino-carboxylic acids
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- A01N43/00—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds
- A01N43/34—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with one nitrogen atom as the only ring hetero atom
- A01N43/36—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with one nitrogen atom as the only ring hetero atom five-membered rings
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- A01N43/00—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds
- A01N43/34—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with one nitrogen atom as the only ring hetero atom
- A01N43/40—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with one nitrogen atom as the only ring hetero atom six-membered rings
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- A01N43/00—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds
- A01N43/34—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with one nitrogen atom as the only ring hetero atom
- A01N43/46—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with one nitrogen atom as the only ring hetero atom rings with more than six members
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C05—FERTILISERS; MANUFACTURE THEREOF
- C05G—MIXTURES OF FERTILISERS COVERED INDIVIDUALLY BY DIFFERENT SUBCLASSES OF CLASS C05; MIXTURES OF ONE OR MORE FERTILISERS WITH MATERIALS NOT HAVING A SPECIFIC FERTILISING ACTIVITY, e.g. PESTICIDES, SOIL-CONDITIONERS, WETTING AGENTS; FERTILISERS CHARACTERISED BY THEIR FORM
- C05G3/00—Mixtures of one or more fertilisers with additives not having a specially fertilising activity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C233/00—Carboxylic acid amides
- C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
- C07C233/45—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups
- C07C233/46—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom
- C07C233/47—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by carboxyl groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom having the carbon atom of the carboxamide group bound to a hydrogen atom or to a carbon atom of an acyclic saturated carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/16—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
- C07D207/22—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/24—Oxygen or sulfur atoms
- C07D207/26—2-Pyrrolidones
- C07D207/273—2-Pyrrolidones with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to other ring carbon atoms
- C07D207/277—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D207/28—2-Pyrrolidone-5- carboxylic acids; Functional derivatives thereof, e.g. esters, nitriles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D223/00—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom
- C07D223/02—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom not condensed with other rings
- C07D223/06—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom not condensed with other rings with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D223/08—Oxygen atoms
- C07D223/10—Oxygen atoms attached in position 2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
- C07D263/08—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
- C07D263/16—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D263/18—Oxygen atoms
- C07D263/20—Oxygen atoms attached in position 2
- C07D263/22—Oxygen atoms attached in position 2 with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to other ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/14—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D295/145—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with the ring nitrogen atoms and the carbon atoms with three bonds to hetero atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
- C07D295/15—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with the ring nitrogen atoms and the carbon atoms with three bonds to hetero atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
-
- C—CHEMISTRY; METALLURGY
- C09—DYES; PAINTS; POLISHES; NATURAL RESINS; ADHESIVES; COMPOSITIONS NOT OTHERWISE PROVIDED FOR; APPLICATIONS OF MATERIALS NOT OTHERWISE PROVIDED FOR
- C09B—ORGANIC DYES OR CLOSELY-RELATED COMPOUNDS FOR PRODUCING DYES, e.g. PIGMENTS; MORDANTS; LAKES
- C09B67/00—Influencing the physical, e.g. the dyeing or printing properties of dyestuffs without chemical reactions, e.g. by treating with solvents grinding or grinding assistants, coating of pigments or dyes; Process features in the making of dyestuff preparations; Dyestuff preparations of a special physical nature, e.g. tablets, films
-
- D—TEXTILES; PAPER
- D06—TREATMENT OF TEXTILES OR THE LIKE; LAUNDERING; FLEXIBLE MATERIALS NOT OTHERWISE PROVIDED FOR
- D06P—DYEING OR PRINTING TEXTILES; DYEING LEATHER, FURS OR SOLID MACROMOLECULAR SUBSTANCES IN ANY FORM
- D06P1/00—General processes of dyeing or printing textiles, or general processes of dyeing leather, furs, or solid macromolecular substances in any form, classified according to the dyes, pigments, or auxiliary substances employed
- D06P1/44—General processes of dyeing or printing textiles, or general processes of dyeing leather, furs, or solid macromolecular substances in any form, classified according to the dyes, pigments, or auxiliary substances employed using insoluble pigments or auxiliary substances, e.g. binders
- D06P1/64—General processes of dyeing or printing textiles, or general processes of dyeing leather, furs, or solid macromolecular substances in any form, classified according to the dyes, pigments, or auxiliary substances employed using insoluble pigments or auxiliary substances, e.g. binders using compositions containing low-molecular-weight organic compounds without sulfate or sulfonate groups
- D06P1/642—Compounds containing nitrogen
- D06P1/6426—Heterocyclic compounds
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Pest Control & Pesticides (AREA)
- Plant Pathology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Wood Science & Technology (AREA)
- Public Health (AREA)
- Zoology (AREA)
- Dentistry (AREA)
- Agronomy & Crop Science (AREA)
- Environmental Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Textile Engineering (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Dermatology (AREA)
- Molecular Biology (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Treatments For Attaching Organic Compounds To Fibrous Goods (AREA)
- Hydrogenated Pyridines (AREA)
- Pyrrole Compounds (AREA)
- Cosmetics (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Lubricants (AREA)
- Detergent Compositions (AREA)
Abstract
(57)【要約】本公報は電子出願前の出願データであるため要約のデータは記録されません。 (57) [Summary] This bulletin contains application data before electronic filing, so abstract data is not recorded.
Description
【発明の詳細な説明】 1、艦五〇九」 本発明は、生理学的に活性な薬剤および、動物の体の皮膚または他の腹を通した 生理学的に活性な薬剤の透過を促進するのに有効な量の新規な経皮透過促進剤、 より成る組成物に関する。[Detailed description of the invention] 1. Ship 509.” The present invention provides a method for administering physiologically active agents and agents through the skin or other abdomen of an animal's body. a novel transdermal permeation enhancer in an amount effective to enhance the permeation of a physiologically active agent; A composition comprising:
その他のこのような組成物およびそれらの用法は、改良された繊維染色法、改良 された植物栄養素の配給、改良された植物有害生物制御、改良された植物成長調 整剤の配給、改良された反応体の反応生成物への酸触媒変換および改良された昆 虫駆除剤に関する。Other such compositions and their uses include improved textile dyeing methods, improved improved plant nutrient delivery, improved plant pest control, and improved plant growth regulation. distribution of stimulants, improved acid-catalyzed conversion of reactants to reaction products, and improved chemical compositions. Regarding insect repellents.
2.11改丘 本明細書で上に示したように、本発明には、それが利点を与える数多くの用途が 包含される。これらの用途はそれぞれ、体の皮Sまたは他の膜を通した生理学的 に活性な薬剤の透過の促進における本発明の組成物から始めてその詳説の順に本 明細書でこの後に説明されるであろう。2.11 Hill change As indicated herein above, the present invention has numerous applications to which it provides advantages. Included. Each of these applications is a physiological The present invention is presented in the order of its detailed description, beginning with the compositions of the present invention in promoting the permeation of agents active in It will be explained later in the specification.
多くの場合、生理学的に活性な薬剤は、希望する結果を得るためには局所的に適 用するのが最もよいことは周知である。全身適用に比べて、局所適用では、薬剤 の代謝による分解を避けることができ、薬剤の副作用が十分に避けられ、しかも 薬剤の高い局所濃度が得られる。Physiologically active drugs are often applied topically to achieve the desired results. It is well known that it is best to use Compared to systemic application, local application Decomposition due to metabolism can be avoided, side effects of drugs can be fully avoided, and High local concentrations of drug are obtained.
生理学的に活性な薬剤を局所適用する際の最も大きな問題は、皮膚が、透過に対 する非常に有効な障壁であることである。皮膚の表皮は、角質層と呼ばれる死ん だ細胞の外層を有しており、この角質層は堅く圧縮されていて油性であり、そし てこれは、気体状、固体または液体の化学薬剤に対して、単独で使用されても水 または油溶液で使用されても、有効な障壁となる。もしも生理学的に活性な薬剤 が角質層を透過するならば、それは容易に表皮の基底層を通過して真皮内に入る ことができる。The biggest problem with topical application of physiologically active agents is that the skin resists penetration. This is a very effective barrier. The epidermis of the skin has a dead layer called the stratum corneum. It has an outer layer of stratum corneum, which is tightly compressed and oily; This applies to chemical agents in gaseous, solid or liquid form, even when used alone. Or when used in oil solution, it also provides an effective barrier. If a physiologically active drug If it penetrates the stratum corneum, it easily passes through the basal layer of the epidermis and enters the dermis. be able to.
角質層の障壁としての有効性は大きな保護を与えるけれども、このことはまた、 体の局部に直接有益な薬剤を適用するための努力を失敗させることにもなる。生 理学的に活性な薬剤が角質層を透過することができないことにより、炎症、aR 1乾癖1単純庖疹、湿疹、真菌、ウィルスまたは他の細菌による感染、またはそ の他の病気のような状態、および、皮膚または粘膜のあるいは皮膚または粘膜の 外表面下の条件の状態を治療するためのそれらの有効な使用が妨げられる。角質 層はまた、皮膚がサンスクリーン、香水、蚊駆除剤およびこれに類するもののよ うな化粧料型の物質を吸収し保持することをも妨げる。Although the effectiveness of the stratum corneum as a barrier confers great protection, this also It also thwarts efforts to apply beneficial agents directly to localized areas of the body. Living The inability of physically active drugs to penetrate the stratum corneum causes inflammation, aR 1 Psoriasis 1 Herpes simplex, eczema, fungal, viral or other bacterial infection, or and other disease-like conditions of the skin or mucous membranes or of the skin or mucous membranes. Their effective use for treating subsurface conditions is hampered. horny The layer also protects the skin from products such as sunscreen, perfume, mosquito repellents and similar products. It also prevents the absorption and retention of cosmetic-type substances.
生理学的に活性な薬剤は、本明細書中に記載した賦形剤系を通じて、体の局部的 に冒された部分に適用することができる。Physiologically active agents are delivered locally to the body through the excipient systems described herein. It can be applied to the affected area.
米国薬局方コールドクリーム、エタノールおよび種々の軟膏、油、溶剤、および エマルジョンのような賦形剤が生理学的に活性な成分を局所的に適用するために これまで使用されてきた。USP cold cream, ethanol and various ointments, oils, solvents, and Vehicles such as emulsions for topical application of physiologically active ingredients has been used so far.
このような賦形剤のほとんどは、有意量の生理学的に活性な薬剤を皮膚を通して 運ぶのには有効でなかった。このような賦形剤の一つは、ジメチルスルホキシド である。Most such excipients deliver significant amounts of physiologically active agents through the skin. It was not useful for transport. One such excipient is dimethyl sulfoxide It is.
アルキル基中に1−4個の炭素原子を有する1−低級アルキル置換されたアザシ クロペンタン−2−オン類は、化学薬品、例えば医薬品の経皮吸収を適度に促進 することが公知である。1-lower alkyl-substituted azashi with 1-4 carbon atoms in the alkyl group Clopentan-2-ones moderately promote the percutaneous absorption of chemicals such as pharmaceuticals. It is known to do so.
実質的により低濃度の透過促進化合物を用いて同一かまたはより高い水準の経皮 吸収を得ることが望ましいであろうことは早くから認められていた。そのため、 所望の性質を有する種々のN−置換アザシク口アルカン−2−オン類が発明され た。これらの新規な透過促進剤は、米国特許第3,989,815号、3,98 9,816号、3.991.203号;4,122,170号;4,316,8 93号、4.405.616号、4,415゜563号、4,423,040号 ;4,424,210号:および4,444,762号;に記載されており、こ れらの米国特許は、本明細書で参照されている。the same or higher levels of transdermal treatment using substantially lower concentrations of permeation-enhancing compounds. It was recognized early on that it would be desirable to obtain absorption. Therefore, Various N-substituted azasic-alkan-2-ones with desired properties have been invented. Ta. These novel permeation enhancers are described in U.S. Pat. No. 3,989,815, 3,98 No. 9,816, No. 3.991.203; No. 4,122,170; No. 4,316,8 No. 93, No. 4.405.616, No. 4,415゜563, No. 4,423,040 ; No. 4,424,210: and No. 4,444,762; These US patents are referenced herein.
1−低級アルキル置換アザシクロペンタン−2−オン類よりも低い濃度で、生理 学的に活性な薬剤の経皮吸収を促進するという所望の性質を有する新規な透過促 進剤を提供することが、本発明の目的である。At lower concentrations than 1-lower alkyl-substituted azacyclopentan-2-ones, physiological Novel permeation enhancers with the desired properties of enhancing transdermal absorption of biologically active drugs It is an object of the present invention to provide a promoter.
上記の米国特許に記載された前述の新規な透過促進剤と同等の透過促進剤を提供 することも、本発明の目的である。Provides a permeation enhancer comparable to the novel permeation enhancers described in the above-mentioned US patents It is also an object of the invention to.
本発明のその他の目的および利点は、下記の明細書を注意深く読めば明らかであ ろう。Other objects and advantages of the present invention will become apparent from a careful reading of the following specification. Dew.
この明細書においては、“動物”という言葉には他の形の動物、特に飼慣らされ た動物およびベットと同様に、ヒトが含まれる。In this specification, the term "animal" refers to other forms of animals, in particular domestic animals. Humans are included, as are animals and beds.
発明の要約 本発明は、皮膚のような体の膜を通過して生理学的に活性な薬剤を運び、体の組 織中にこれらの薬剤を保持するための、化合物およびそれらの使用法に関する。Summary of the invention The present invention transports physiologically active agents across body membranes, such as the skin, and The present invention relates to compounds and their use for retaining these agents in tissues.
さらに詳細には、本発明はカルボン酸誘導体およびそれらの塩に関するもので、 これらの化合物は、薬剤および有効量の一般式:Zは、酸素、硫黄、または−C H,−を表わし;Rは、場合により工ないし3個の二重または三重結合で置換さ れているアルキル基、 S R1l 1.−OR”’、−NHR”°。More particularly, the present invention relates to carboxylic acid derivatives and salts thereof; These compounds have the general formula: Z is oxygen, sulfur, or -C H,-; R is optionally substituted with hydroxyl or 3 double or triple bonds; Alkyl group, S R1l 1. −OR”’, −NHR”°.
−CH,・またはCooRI(ここでR3は水素または低級アルキル基を表わし ; R′°′は、アルキル基、アルキルチオアルキル基、アルコキシアルキル基、場 合によりフェニル基、ベンゾイル基または複素環基で置換された置換アミノアル キル基を表わす)を表わし;Roは水素、アルキル基、アルコキシ基、アシルオ キシ基、アルキルチオ基、ヒドロキシ基、(CH2) y COORH(ココテ yは0ないし3である)を表わし; そしてR”は、水素または−(CH2) yCOOR+を表わすが、但し、R” が水素であるときWは2個の水素基であってRoは水素ではなく;そしてRoが 水素であるときR”は水素ではなく;そして、−は、1ないし5、好ましくは2 .3または4であり、一方nは1ないし24、好ましくはうないし12であり、 Xは0または1である。] によって表わされる化合物より成る組成物によって、生理学的に活性な薬剤をヒ トまたは動物に局所投与する際に有用である。-CH, or CooRI (where R3 represents hydrogen or a lower alkyl group) ; R'°' is an alkyl group, an alkylthioalkyl group, an alkoxyalkyl group, or Substituted aminoalkyls substituted with phenyl, benzoyl or heterocyclic groups by (represents a kyl group); Ro represents hydrogen, an alkyl group, an alkoxy group, an acyl group; xy group, alkylthio group, hydroxy group, (CH2)y COORH y is 0 to 3); And R" represents hydrogen or -(CH2)yCOOR+, provided that R" is hydrogen, W is two hydrogen groups and Ro is not hydrogen; and Ro is R'' is not hydrogen when it is hydrogen; and - is 1 to 5, preferably 2 .. 3 or 4, while n is 1 to 24, preferably 1 to 12; X is 0 or 1. ] A composition comprising a compound represented by Useful for topical administration to humans or animals.
これに代わる具体化においては、新規な透過促進剤には、一般式: [式中、Bは、酸素、硫黄、または2信の水素基を表わし;Aは、酸素、硫黄、 または−(CH2)−を表わし;R,R2およびR5は、別個に、場合により工 ないし3個の二重または三重結合で置換されたアルキル基、−SR’”°。In an alternative embodiment, the novel permeation enhancer has the general formula: [Wherein, B represents oxygen, sulfur, or a dihydrogen group; A represents oxygen, sulfur, or -(CH2)-; R, R2 and R5 are optionally optionally an alkyl group substituted with 3 to 3 double or triple bonds, -SR'"°;
OR” ’ 、N HR” ’ 、CH3、またはC0OR,を表わス;カここ でR゛′°は、水素、アルキル基、アルキルチオアルキル基。Represents OR”, NHR”, CH3, or C0OR. R゛′° is hydrogen, an alkyl group, or an alkylthioalkyl group.
アルコキシアルキル基、1合によりフェニル基、ベンゾイル基、または複素環基 で置換された置換アミノアルキル基を表わし;Roは水素、アルキル基、アルコ キシ基、アシルオキシ基、アルキルチオ基、ヒドロキシ基、または−(CH:) y COOR+を表わし: R”は、水素または−(CH2)yC○○R3を表わす:がここでR3は、水素 または低級アルキルを表わし、yは0ないし3であり; mは、0ないし5、好ましくは1または2であり;一方nは1ないし24、好ま しくは5ないし12である]によって表わされる化合物が包含される。Alkoxyalkyl group, phenyl group, benzoyl group, or heterocyclic group by one combination represents a substituted aminoalkyl group substituted with; Ro represents hydrogen, an alkyl group, an alkyl group; xy group, acyloxy group, alkylthio group, hydroxy group, or -(CH:) y represents COOR+: R'' represents hydrogen or -(CH2)yC○○R3: where R3 is hydrogen or lower alkyl, y is 0 to 3; m is 0 to 5, preferably 1 or 2; while n is 1 to 24, preferably or 5 to 12].
そしてさらに別の具体化においては、化合物は、式:二重または三重結合で置換 されたアルキル基であり;Roは水素基、アルキル基、アルコキシ基、アシルオ キシ基、アルキルチオ基、ヒドロキシ基、または−(CH2) y COOR+ であり; Boは酸素、硫黄、または2個の水素基を表わし;Boは酸素、硫黄、または2 個の水素基を表わすが、但しB”が水素ではなく、Boが2個の水素基であり、 モしてR2がアルキル基であるとき、R”は−(CH,)、Co○R+ (ここ でyは0であることはできない)であり: ここでyは、0ないし3であり、そしてR3は、低級アルキル基または水素基を 表わし; そして、mは3ないし6、好ましくは3.4または5であり、一方nは、1ない し24、好ましくは5ないし12であり;そして、yは0ないし3であり、R1 は低級アルキル基または水素基を表わすコ によって表わされる。And in yet another embodiment, the compound is substituted with the formula: is an alkyl group; Ro is a hydrogen group, an alkyl group, an alkoxy group, an acyl group; xy group, alkylthio group, hydroxy group, or -(CH2)y COOR+ And; Bo represents oxygen, sulfur, or 2 hydrogen groups; Bo represents oxygen, sulfur, or 2 hydrogen groups; represents two hydrogen groups, provided that B'' is not hydrogen and Bo is two hydrogen groups, When R2 is an alkyl group, R'' is -(CH,), Co○R+ (here and y cannot be 0) and: Here, y is 0 to 3, and R3 is a lower alkyl group or a hydrogen group. Representation; and m is 3 to 6, preferably 3.4 or 5, while n is 1 to 6. and 24, preferably 5 to 12; and y is 0 to 3, and R1 is a lower alkyl group or a hydrogen group. is expressed by
生理学的に活性な薬剤は、上記の透過促進剤によって体の膜を通って運ばれ、体 の組織中に保持されることがわかった。Physiologically active drugs are carried across the body's membranes by the permeation enhancers mentioned above and are transported through the body. was found to be retained in the tissues of
本発明はさらに、透過促進剤自体およびそうした透過促進剤の製造方法に間する 。The invention further relates to the permeation enhancers themselves and to methods of making such permeation enhancers. .
本明細書中で上述した1−置換アザシクロアルカン類は、また、染色工程で有効 量の1−f換アザシクロアルカンを利用することによって、繊維における染料の 透過の促進にも有用であることがわかった。本発明にはまた、有効量の染料およ び有効量の1=置換アザシクロアルカンより成る配合物も包含される。The 1-substituted azacycloalkanes mentioned herein above are also useful in dyeing processes. By utilizing a quantity of 1-f-substituted azacycloalkane, dye concentration in fibers can be improved. It was also found to be useful in promoting permeation. The invention also includes an effective amount of a dye and Also included are formulations comprising an effective amount of 1=substituted azacycloalkane.
植物栄養素と組み合わせるとき、1−置換アザシクロアルカンは、植物における 植物栄養素の吸収および同化を促進することによるこのような植物栄養素の改良 された配給法を提供する。When combined with phytonutrients, 1-substituted azacycloalkanes provide Improvement of such phytonutrients by promoting absorption and assimilation of phytonutrients Provides a distribution method.
本発明にはまた、有効量の植物栄養素および有効配給促進量の新規透過促進剤よ り成る配合物も包含される。The present invention also includes effective amounts of phytonutrients and effective distribution-enhancing amounts of novel permeation enhancers. Also included are formulations consisting of:
本明細書中で上記した新規な透過促進剤は、また、植物の有害生物への殺有害生 物剤の配給を促進することによる改良された植物有害生物制御法においても有用 であることが見出され、本発明には、有効量の殺植物有害生物剤および有効配給 促進量の新規透過促進剤より成る配合物が包含される。The novel permeation enhancers described hereinabove also have a pesticidal effect on plant pests. Also useful in improved plant pest control methods by facilitating distribution of agents It has been found that the present invention includes an effective amount of a phytotoxic agent and an effective distribution. Formulations comprising promoting amounts of the novel permeation enhancer are included.
配給促進化合物および殺有害生物剤を含有する配合物は、局所適用により直接植 物有害生物に、または局所適用により間接的に、保護されるべき植物に、適用す ることができる。この後者の間接適用法では、植物有害生物が処理された植物と 接触した後に、その最終的な作用部位、すなわち、植物有害生物に殺有害生物剤 が到達することができる。Formulations containing ration-promoting compounds and pesticides can be applied directly to the implant by topical application. applied to plant pests or indirectly by topical application to the plants to be protected. can be done. In this latter method of indirect application, the plant pest is removed from the treated plant. After contact, the pesticide is applied to its final site of action, i.e. to the plant pest. can be reached.
本明細書中で上記した新規な透過促進剤はまた、改良された植物成長調整剤配給 法においても有用であることが見出され、本発明には、有効量の植物成長調整剤 および有効配給促進量の新規透過促進剤より成る配合物が包含される0M物成長 調整剤および透過促進剤は、通常の方法で植物に適用することができる。The novel permeation enhancers described hereinabove also provide improved plant growth regulator distribution. The present invention also includes an effective amount of a plant growth regulator. and an effective distribution-enhancing amount of a novel permeation enhancer. Regulators and permeation enhancers can be applied to plants in the usual manner.
本明細書中で上記した新規な透過促進剤はまた、昆虫駆除剤としても有用である ことが見出されたが、このような用途のための透過促進剤の適用および/または 配給は、通常の手段による。The novel permeation enhancers described herein above are also useful as insect repellents. It has been found that the application of permeation enhancers and/or Distribution will be by normal means.
本発明はまた、反応体を本明細書中で上記した新規透過促進剤の塩より成る酸触 媒と接触させることより成る、酸触媒の存在における上記反応体の反応生成物へ の変換法をも提供する。The present invention also provides that the reactant is an acid catalyst comprising a salt of the novel permeation enhancer described hereinabove. to the reaction product of the above reactants in the presence of an acid catalyst, comprising contacting with a medium. It also provides a conversion method.
発明の詳細な説明 本発明の方法において有用な新規経皮透過促進剤には、カルボン酸誘導体および それらの塩類が包含され、これらは、一般式: [式中、Wは、酸素、硫黄、または2個の水素基を表わし;2は、酸素、硫黄、 または−CH,−を表わし;Rは、場合により工ないし3個の二重または三重結 合で置換さFした7 ルキル基、−SR”’、−OR”’、−NHR”’。Detailed description of the invention Novel transdermal penetration enhancers useful in the methods of the invention include carboxylic acid derivatives and Included are their salts, which have the general formula: [Wherein, W represents oxygen, sulfur, or two hydrogen groups; 2 represents oxygen, sulfur, or represents -CH,-; R is optionally hydroxyl to 3 double or triple bonds; -SR'', -OR'', -NHR''.
−CH3,またはC0OR,を表わすが、ここでR1は水素または低級アルキル 基を表わし; そしてR°゛°は、アルキル基、アルキルチオアルキル基、アルコキシアルキル 基、場合によりフェニル基、ベンゾイル基または複素環基で置換された置換アミ ノアルキル基を表わし;Roは水素、アルキル基、アルコキシ基、アシルオキシ 基、アルキルチオ基、ヒドロキシ基、(CH2)yCOOR+(yは0ないし3 である)を表わし; R”は、水素または−(CH2)アCOOR+を表わすが、但し、R”が水素で あるときWは2個の水素基であってRoは水素ではなく;Roが水素であるとき Roは水素ではなく;そして論は、工ないし5、好まし、くは2,3または4で あり、一方、nは工ないし24、好ましくはジないし12であり、Xは0または 1である。] によって表わされる化合物である。-CH3, or C0OR, where R1 is hydrogen or lower alkyl represents a group; and R°゛° is an alkyl group, an alkylthioalkyl group, an alkoxyalkyl group substituted amino groups, optionally substituted with phenyl, benzoyl or heterocyclic groups Represents a noalkyl group; Ro is hydrogen, alkyl group, alkoxy group, acyloxy group, alkylthio group, hydroxy group, (CH2)yCOOR+ (y is 0 to 3 ); R" represents hydrogen or -(CH2)aCOOR+, provided, however, that when R" is hydrogen When W is two hydrogen groups and Ro is not hydrogen; when Ro is hydrogen Ro is not hydrogen; , while n is from 0 to 24, preferably from 1 to 12, and X is 0 or It is 1. ] It is a compound represented by
これに代わる具体化においては、透過促進剤として有用な化合物には、一般式: [式中、Bは、酸素、硫黄、または2個の水素基を表わし;Aは、酸素、硫黄、 または−(CH2)−を表わし:R,R2およびR3は、別個に、場合により工 ないし3個の二重または三重結合で置換されたアルキル基、 S Rl l 1 ゜−OR”’、−NHR”’、−CH,,またはCOO,Rlを表わすが、ここ でR″°は、水素、アルキル基、アルキルチオアルキル基。In an alternative embodiment, compounds useful as permeation enhancers include the general formula: [Wherein, B represents oxygen, sulfur, or two hydrogen groups; A represents oxygen, sulfur, or -(CH2)-; R, R2 and R3 are optionally optionally or an alkyl group substituted with three double or triple bonds, S Rl l 1 ゜-OR"', -NHR"', -CH, or COO, Rl, but here where R″° is hydrogen, an alkyl group, or an alkylthioalkyl group.
アルコキシアルキル基、場合によりフェニル基、ベンゾイル基、または複素環基 で置換された置換アミノアルキル基を表わし;Roは水素、アルキル基、アルコ キシ基、アシルオキシ基、アルキルチオ基、ヒドロキシ基、または−(CH2) yCOOR+を表わし; R”は、水素または−(CH2)アCOOR+を表わし;−は、0ないし5、好 ましくは1または2であり;一方nは1ないし24、好ましくは5ないし12で あり;モしてRtは、水素または低級アルキル基を表わし、yは0ないし3であ る。コ によって表わされる化合物が包含される。Alkoxyalkyl group, optionally phenyl group, benzoyl group, or heterocyclic group represents a substituted aminoalkyl group substituted with; Ro represents hydrogen, an alkyl group, an alkyl group; xy group, acyloxy group, alkylthio group, hydroxy group, or -(CH2) represents yCOOR+; R" represents hydrogen or -(CH2)aCOOR+; - is 0 to 5, preferably preferably 1 or 2; while n is 1 to 24, preferably 5 to 12; Yes; Rt represents hydrogen or a lower alkyl group, and y is 0 to 3; Ru. Ko Compounds represented by are included.
そして、さらに別の具体化においては、化合物は、式:[式中、R2は、C0O R+または、場合により工ないし3個の二重または三重結合で置換されたアルキ ル基であり;Roは水素基、アルキル基、アルコキシ基、アシルオキシ基、アル キルチオ基、ヒドロキシ基、または−<CH2)、C0OR+であり; Boは酸素、硫黄、または2個の水素基を表わし;B”は酸素、硫黄、または2 個の水素基を表わすが、但しB”が水素でなく、Boが2個の水素基であり、モ してR2がアルキル基であるとき、Roは−(CH2) y COORI(コこ でyは0ではない)であり; ここでyは、0ないし3であり、モしてRoは、低級アルキル基または水素基を 表わし; そして、輸は3ないし6、好ましくは3.4または5であり、一方nは、1ない し24、野ましくは5ないし12である]によって表わされる。And, in yet another embodiment, the compound is of the formula: [wherein R2 is COO R+ or alkyl optionally substituted with 1 to 3 double or triple bonds Ro is a hydrogen group, an alkyl group, an alkoxy group, an acyloxy group, an alkyl group; a kylthio group, a hydroxy group, or -<CH2), C0OR+; Bo represents oxygen, sulfur, or 2 hydrogen groups; B'' represents oxygen, sulfur, or 2 hydrogen groups; represents two hydrogen groups, provided that B'' is not hydrogen, Bo is two hydrogen groups, and and when R2 is an alkyl group, Ro is -(CH2)y COORI and y is not 0); Here, y is 0 to 3, and Ro represents a lower alkyl group or a hydrogen group. Representation; and n is 3 to 6, preferably 3.4 or 5, while n is 1 to 6. 24, preferably 5 to 12].
これらの新規な経皮透過促進添加剤は、下記の実施例に具体的に示される方法に より製造することができる。上記の一般式によって表わされる化合物の典型的な 例としては、次のものがある: 1−N−ドデシル−2−ピロリドン−5−カルボン酸1−N−ブチル−2−ピロ リドン−5−カルボン酸1−N−ベンチルー2−ピロリドン−5−カルボン酸1 −N−へキシル−2−ピロリドン−5−カルボン酸1−N−オクチル−2−ピロ リドン−5−カルボン酸1−N−ノニル−2−ピロリドン−5−カルボン酸1− N−デシル−2−ピロリドン−5−カルボン酸1−N−テトラデシル−2−ピロ リドン−5−カルボン酸1−N−ヘキサデシル−2−ピロリドン−5−カルボン 酸1−N−へブチル−2−ピロリドン−5−カルボン酸1−N−ドデシル−2− ピペリドン−6−カルボン酸1−N−ブチル−2−ピペリドン−6−カルボン酸 1−N−ペンチルー2−ピペリドン−6−カルボン酸1−N−へキシル−2−ピ ペリドン−6−加しボン酸1−N−オクチルー2−ピペリドン−6−カルボン酸 1−N−ノニル−2−ピペリドン−6−カルボン酸1−N−デシル−2−ピペリ ドン−6−カルボン酸1−N−テトラデシル−2−ピペリドン−6−カルボン酸 1−N−ヘキサデシル−2−ピペリドン−6−カルボン酸1−N−へブチル−2 −ピペリドン−6−カルボン酸1−(2−(n−ドデシルチオ)エチル)−2− ピロリドン−5−カルボン酸 1−(2−(n−ブチルチオ)エチル)−2−ピロリドン−5−カルボン酸 1−(2−(n−ペンチルチオ)エチル)−2−ピロリドン−5−カルボン酸 1−(2−(n−へキシルチオ)エチル)−2−ピロリドン−5−カルボン酸 1−(2−(n−オクチルチオ)エチル)−2−ピロリドン−5−カルボン酸 1−(2−(n−ノニルチオ)エチル)−2−ピロリドン−5−カルボン酸 1−(2−(n−デシルチオ)エチル)−2−ピロリドン−5−カルボン酸 1−(2−(n−テトラデシルチオ)エチル)−2−ピロリドン−5−カルボン 酸 1−(2−(n−ヘキサデシルチオ)エチル)−2−ピロリドン−5−カルボン 酸 1−(2−(n−へブチルチオ)エチル)−2−ピロリドン−5−カルボン酸 1−(2−(n−ドデシルチオ)エチル)−ピペリジン−3−カルボン酸 1−(2−(n−ブチルチオ)エチル)−ピペリジン−3−カルボン酸 1−(2−(n−ペンチルチオ)エチル)−ピペリジン−3−カルボン酸 1−(2−(r+−へキシルチオ)エチル)−ピペリジン−3−カルボン酸 1−(2−(n−オクチルチオ)エチル)−ピペリジン−3−カルボン酸 1−(2−(n−ノニルチオ)エチル)−ピペリジン−3−力ルボン酸 1−(2−(n−デシルチオ)エチル)−ピペリジン−3−カルボン酸 1−(2−(n−テトラデシルチオ)エチル)−ピペリジン−3−カルボン酸 1−(2−(n−ヘキサデシルチオ)エチル)−ピペリジン−3−カルボン酸 1 (2−(n−へブチルチオ)エチル)−ピペリジン−3−カルボン酸 2−ドデシル、2−N−(2−ピロリドン)−酢酸2−ブチル、2−N−(2− ピロリドン)−酢酸2−ペンチル、2−N−(2−ピロリドン)−酢酸2−ヘキ シル、2−N−(2−ピロリドン)−酢酸2−オクチル、2−N−(2−ピロリ ドン)−酢酸2−ノニル、2−N−(2−ピロリドン)−酢酸2−デシル、2− N−(2−ピロリドン)−酢酸2−テトラデシル、2−N−(2−ピロリドン) −酢酸2−ヘキサデシル、2−N−(2−ピロリドン)−酢酸2−ヘプチル、2 −N−(2−ピロリドン)−酢酸2−ドデシル、2−N−(2−ピペリドン)− 酢酸2−ドデシル、2−N−(アザシクロへブタン−2−オン)−酢酸 2−ブチル、2−N−(アザシクロへブタン−2−オン)酢酸 2−ペンチル、2−N−(アザシクロへブタン−2−オン)酢酸 2−ヘキシル、2−N−(アザシクロへブタン−2−オン)酢酸 2−オクチル、2−N−(アザシクロへブタン−2−オン)酢酸 2−ノニル、2−N−(アザシクロへブタン−2−オン)酢酸 2−デシル、2−N−(アザシクロへブタン−2−オン)酢酸 2−テトラデシル、2−N−、、(アザシクロへブタン−2−オン)酢酸 2−ヘキサデシル、2−N−(アザシクロへブタン−2−オン)酢酸 2−へブチル、2−N−(アザシクロへブタン−2−オン)酢酸 6−(N−ピロリジン)−ヘキサン酸 8−(N−ピロリジン)−オクタン酸 1O−(N−ピロリジン)−デカン酸 12−(N−ピロリジン)−ドデカン酸12−ジエチルアミノドデカン酸 10−ジエチルアミノデカン酸 6−ジエチルアミノデカン酸 8−ジエチルアミノオクタン酸 2−(N−モルホリン)−2−ドデシル酢酸2−(N−モルホリン)−2−デシ ル酢酸2−(N−モルホリン)−2−オクチル酢酸2−(N−モルホリン)−2 −ヘキシル酢酸2−(N−モルホリン)−2−ブチル酢酸。These novel transdermal permeation-enhancing additives can be prepared by the methods illustrated in the Examples below. It can be manufactured more easily. Typical compounds represented by the above general formula Examples include: 1-N-Butyl-2-pyro 1-N-dodecyl-2-pyrrolidone-5-carboxylate Lydone-5-carboxylic acid 1-N-benzene-2-pyrrolidone-5-carboxylic acid 1 -N-hexyl-2-pyrrolidone-5-carboxylic acid 1-N-octyl-2-pyro Lydone-5-carboxylic acid 1-N-nonyl-2-pyrrolidone-5-carboxylic acid 1- N-decyl-2-pyrrolidone-5-carboxylic acid 1-N-tetradecyl-2-pyro Lydone-5-carboxylic acid 1-N-hexadecyl-2-pyrrolidone-5-carvone acid 1-N-hebutyl-2-pyrrolidone-5-carboxylic acid 1-N-dodecyl-2- piperidone-6-carboxylic acid 1-N-butyl-2-piperidone-6-carboxylic acid 1-N-pentyl-2-piperidone-6-carboxylic acid 1-N-hexyl-2-pi Peridone-6-carboxylic acid 1-N-octyl-2-piperidone-6-carboxylic acid 1-N-Nonyl-2-piperidone-6-carboxylic acid 1-N-decyl-2-piperi Don-6-carboxylic acid 1-N-tetradecyl-2-piperidone-6-carboxylic acid 1-N-Hexadecyl-2-piperidone-6-carboxylic acid 1-N-hebutyl-2 -piperidone-6-carboxylic acid 1-(2-(n-dodecylthio)ethyl)-2- pyrrolidone-5-carboxylic acid 1-(2-(n-butylthio)ethyl)-2-pyrrolidone-5-carboxylic acid 1-(2-(n-pentylthio)ethyl)-2-pyrrolidone-5-carboxylic acid 1-(2-(n-hexylthio)ethyl)-2-pyrrolidone-5-carboxylic acid 1-(2-(n-octylthio)ethyl)-2-pyrrolidone-5-carboxylic acid 1-(2-(n-nonylthio)ethyl)-2-pyrrolidone-5-carboxylic acid 1-(2-(n-decylthio)ethyl)-2-pyrrolidone-5-carboxylic acid 1-(2-(n-tetradecylthio)ethyl)-2-pyrrolidone-5-carvone acid 1-(2-(n-hexadecylthio)ethyl)-2-pyrrolidone-5-carvone acid 1-(2-(n-hebutylthio)ethyl)-2-pyrrolidone-5-carboxylic acid 1-(2-(n-dodecylthio)ethyl)-piperidine-3-carboxylic acid 1-(2-(n-butylthio)ethyl)-piperidine-3-carboxylic acid 1-(2-(n-pentylthio)ethyl)-piperidine-3-carboxylic acid 1-(2-(r+-hexylthio)ethyl)-piperidine-3-carboxylic acid 1-(2-(n-octylthio)ethyl)-piperidine-3-carboxylic acid 1-(2-(n-nonylthio)ethyl)-piperidine-3-carboxylic acid 1-(2-(n-decylthio)ethyl)-piperidine-3-carboxylic acid 1-(2-(n-tetradecylthio)ethyl)-piperidine-3-carboxylic acid 1-(2-(n-hexadecylthio)ethyl)-piperidine-3-carboxylic acid 1 (2-(n-hebutylthio)ethyl)-piperidine-3-carboxylic acid 2-dodecyl, 2-N-(2-pyrrolidone)-2-butyl acetate, 2-N-(2- pyrrolidone)-2-pentyl acetate, 2-N-(2-pyrrolidone)-2-hexyl acetate sil, 2-N-(2-pyrrolidone)-2-octyl acetate, 2-N-(2-pyrrolidone) Don)-2-nonyl acetate, 2-N-(2-pyrrolidone)-2-decyl acetate, 2- N-(2-pyrrolidone)-2-tetradecyl acetate, 2-N-(2-pyrrolidone) -2-hexadecyl acetate, 2-N-(2-pyrrolidone)-2-heptyl acetate, 2 -N-(2-pyrrolidone)-2-dodecyl acetate, 2-N-(2-piperidone)- 2-dodecyl acetate, 2-N-(azacyclohebutan-2-one)-acetic acid 2-Butyl, 2-N-(azacyclohebutan-2-one)acetic acid 2-pentyl, 2-N-(azacyclohebutan-2-one)acetic acid 2-hexyl, 2-N-(azacyclohebutan-2-one)acetic acid 2-octyl, 2-N-(azacyclohebutan-2-one)acetic acid 2-nonyl, 2-N-(azacyclohebutan-2-one)acetic acid 2-decyl, 2-N-(azacyclohebutan-2-one)acetic acid 2-tetradecyl, 2-N-, (azacyclohebutan-2-one)acetic acid 2-hexadecyl, 2-N-(azacyclohebutan-2-one)acetic acid 2-Hebutyl, 2-N-(azacyclohebutan-2-one)acetic acid 6-(N-pyrrolidine)-hexanoic acid 8-(N-pyrrolidine)-octanoic acid 1O-(N-pyrrolidine)-decanoic acid 12-(N-pyrrolidine)-dodecanoic acid 12-diethylaminododecanoic acid 10-diethylaminodecanoic acid 6-diethylaminodecanoic acid 8-diethylaminooctanoic acid 2-(N-morpholine)-2-dodecyl acetate 2-(N-morpholine)-2-decylacetate 2-(N-morpholine)-2-octylacetic acid 2-(N-morpholine)-2 -Hexylacetic acid 2-(N-morpholine)-2-butylacetic acid.
本明細書中の透過促進剤はまた、それ自体が抗ウィルス活性を有していて、単独 でウィルス感染と戦うために使用することができることも見出された。The permeation enhancers herein also have antiviral activity themselves and It was also found that it can be used to fight viral infections.
第二の生理学的に活性な薬剤を含む組成物中に使用するとき、本発明で使用する 新規な経皮透過促進剤の量は、経皮吸収を促進するための有効量である。一般に 、この量は組成物の約0.01ないし約5、好ましくは約0.1ないし2重量パ ーセントの範囲にある。Use in the invention when used in a composition comprising a second physiologically active agent The amount of the novel transdermal penetration enhancer is an effective amount to promote transdermal absorption. in general , this amount accounts for about 0.01 to about 5, preferably about 0.1 to 2 parts by weight of the composition. – in the range of cents.
主題の組成物は、開示された賦形剤に可溶性である多くの生理学的に活性な薬剤 について用途を見出し得る。透過促進剤は、生理学的に活性な薬剤の前に、後に 、またはこれと組み合わせて、適用することができる。適用の順序は重要ではな い。The subject compositions contain a number of physiologically active agents that are soluble in the disclosed excipients. You can find uses for it. Permeation enhancers are used before and after physiologically active agents. , or in combination with this. The order of application is not important. stomach.
例工ば、チアベンダゾール、クロロキシン、アンボテリシンB、カンジシジン、 フンギマイシン、ナイスクチン、クロルダントイン、クロトリマゾール、硝酸ミ コナゾール、ピロルニドリン、サリチル酸、フェザチオン、トルナフテート、ト リアセチンおよび、亜鉛およびナトリウムピリチオン、のような靜真菌および殺 真菌剤は、本明細書中に記載された透過促進剤に溶解させて、皮膚の患部に局所 的に適用することができる0例えば、このようにして適用された靜真菌または殺 真菌剤は、角質層を通りぬけて運ばれ、それによってうまく真菌に起因する皮膚 の問題を治デする。このように適用されたこれらの薬剤は、先行技術の賦形剤中 で適用されたときよりも迅速に透過するばかりでなく、さらに、高い濃度で動物 のffi織に入って、事実上より長時間保持され、これによってはるかに有効な 治療が行なペンダゾールまたは類似の抗真菌剤を溶解させて、これを患部に適用 することにより、運動家兄または口癖をひき起こすカンジダ属および皮膚糸状菌 によって起こる皮膚上の真菌感染の治療にも使用することができる。For example, thiabendazole, chloroxin, embotericin B, candicidin, fungimycin, nyscutin, chlordantoin, clotrimazole, minitrate Conazole, pyrrolnidrine, salicylic acid, featherthion, tolnaftate, tol fungicides and fungicides such as lyacetin and zinc and sodium pyrithione. The fungal agent is dissolved in a permeation enhancer described herein and applied topically to the affected area of the skin. For example, a fungicidal or fungicidal agent applied in this way Fungal agents are transported through the stratum corneum, thereby successfully removing fungal infections from the skin. cure the problem. Applied in this way, these agents are in prior art excipients. Not only does it permeate more quickly than when applied in animals, but also at higher concentrations. into the FFI fabric, effectively holding it for a longer period of time, which makes it much more effective. Treatment involves dissolving pendazole or a similar antifungal agent and applying this to the affected area. Candida and dermatophytes that cause candida and dermatophytes It can also be used to treat fungal infections on the skin caused by.
主題組成物はまた、皮膚の問題5例えば単純庖疹(これは透過促進剤の一つに溶 解させたヨードデオキシウリジンの溶液によって治療することができる八または いぼ(透過促進剤の一つに溶解させたボドフィリンのような薬剤で治療すること ができる)のような問題、を治療する際にも有用である。1廖のような皮膚の問 題は、透過促進剤の一つ中の通常の局所用ステロイドの溶液の局所適用、または 透過促進剤の一つ中の、テオフィリンまたは、イソプロテレノールのようなβ− アドレナリン作動性遮断剤の拮抗剤を用いた療法によって治療することができる 0円形脱毛症のような頭皮の状態は、本発明の透過促進剤の一つに溶解させたト リアムシノロンアセトニドのようなステロイド顕を直接頭皮に適用することによ り、より効果的に治療することができる。The subject compositions may also be used to treat skin problems such as herpes simplex, which is dissolved in one of the penetration enhancers. 8 or which can be treated with a solution of dissolved iododeoxyuridine Warts (treated with a drug such as bodophilin dissolved in one of the permeation enhancers) It is also useful in treating problems such as: 1 Liao skin problem The topic is topical application of a solution of a regular topical steroid in one of the permeation enhancers, or β- such as theophylline or isoproterenol in one of the permeation enhancers. Can be treated by therapy with adrenergic blocker antagonists 0 Scalp conditions such as alopecia areata can be treated with a toxin dissolved in one of the permeation enhancers of the present invention. By applying steroids such as liamcinolone acetonide directly to the scalp. can be treated more effectively.
主題組成物はまた、例えば、透過促進剤の一つに溶解させたフルオシノロンアセ トニドまたはその誘導体;ヒドロコルチゾン、トリアムシノロンアセトニド、イ ンドメタシン、またはフェニルブタシンの溶液を患部に適用することにより、軽 い湿疹を治療するのにも有用である。The subject compositions also include, for example, fluocinolone acetate dissolved in one of the permeation enhancers. tonide or its derivatives; hydrocortisone, triamcinolone acetonide, Applying a solution of domethacin or phenylbutacin to the affected area can provide relief. It is also useful in treating eczema.
賦形剤とともに使用することができるその他の生理学的に活性なステロイドの例 としては、例えば、コルチゾン、コルトドキソン、フルセトニド、フルオロコル チゾン、ジフルルゾンジアセテート、フルランドレノロン、アセトニド、メトリ シン、アムシナフェル、アムシナフィド、ベタメタシンおよびそのエステル顕、 クロロプレドニゾン、クロコルテロン、デスジノロン、デソニド、デキサメタシ ン、ジクロリシン、デフルプレドネート、フルクロロニド、フルメタシン、フル ニジリド、フルオシノニド、フルコルトロン、フルオロメタロン、フルベロロン 、フルプレドニゾロン、メブレドニゾン、メチルメプレドニゾロン、パラメタシ ン、プレドニゾロンおよびプレドニゾン、のようなコルチコステロイド類がある 。Examples of other physiologically active steroids that can be used with excipients For example, cortisone, cortodoxone, flucetonide, fluorocor Tizone, diflurzone diacetate, flulandrenolone, acetonide, metri cin, amcinafel, amcinafide, betamethacin and its esters, Chlorprednisone, clocorterone, desdinolone, desonide, dexamethacyl dichloricin, defluprednate, fluchloride, flumethacin, flu Nigilide, fluocinonide, flucortolon, fluorometalone, fluverolon , fluprednisolone, mebrednisone, methylmeprednisolone, parametasci corticosteroids, such as prednisone, prednisolone, and prednisone. .
主題組成物はまた、抗菌化学療法、例えば病原菌を伴う皮膚状態の治療、にも有 用である0本発明で使用することができる典型的な抗菌剤には、スルホンアミド 類、ペニシリン類、セファロスポリン類、ベニシリナーゼ、エリスロマイシン類 、リンコマイシン類、バンコマイシン類、テトラサイクリン類、クロラムフェニ コール類、ストレプトマイシン類、などがある、前記のものの典型的な例は、エ リスロマイシン、エチル炭酸エリスロマイシン、エリスロマイシンエストレート 、グルコヘプトン酸エリスロマイシン、エチルコハク酸エリスロマイシン、ラク トビオン酸エリスロマイシン、リンコマイシン、クリンダマイシン、テトラサイ クリン、クロルテトラサイクリン、デスクロサイクリン、ドキシサイクリン、メ タサイクリン、オキシテトラサイクリン、ミノサイクリン、などである。The subject compositions are also useful in antibacterial chemotherapy, such as the treatment of skin conditions involving pathogenic bacteria. Typical antimicrobial agents that can be used in the present invention include sulfonamides. penicillins, cephalosporins, benicillinase, erythromycins , lincomycins, vancomycins, tetracyclines, chlorampheni Typical examples of the above include choles, streptomycins, etc. Rithromycin, erythromycin ethyl carbonate, erythromycin estrate , erythromycin glucoheptonate, erythromycin ethylsuccinate, lac Erythromycin tobionate, lincomycin, clindamycin, tetracyc Clin, chlortetracycline, descrocycline, doxycycline, medicinal Tacycline, oxytetracycline, minocycline, etc.
主題組成物はまた、過敏性皮膚または通常の敏感な皮膚を日焼けによる損傷また は不快感から保護するのにも有用である。The subject compositions also protect sensitive or normally sensitive skin from sun damage or is also useful for protecting against discomfort.
すなわち、上述の透過促進剤の一つと組み合わせたパラ−アミノ安息香酸または その周知の誘導体のようなサンスクリーンを性皮膚炎を避けることができる。保 護剤バラ−アミノ安息香酸またはその誘導体は、それによって角質層内により有 効に運ばれるであろうし、そのために、通常の賦形剤中で皮膚に適用されたとき よりも事実上長時間、水または洗液にさらされたときでさえ、保持されるであろ う、先行技術のキャリヤー中の紫外線遮蔽成分は水に浸漬されたとき皮膚から洗 い流されるので、本発明は、水泳を含む活動に使用される通常のサンタン(su njan)ローション用に特に有用である。i.e. para-aminobenzoic acid or Dermatitis can be avoided with sunscreens such as its well-known derivatives. Protection The protective agent para-aminobenzoic acid or its derivatives thereby increases the concentration within the stratum corneum. and therefore when applied to the skin in the usual excipients will be retained even when exposed to water or cleaning fluids for virtually longer periods of time than The UV-screening ingredients in prior art carriers are washable from the skin when immersed in water. Because the water is flushed away, the present invention can be applied to normal suntans used for activities including swimming. njan) is particularly useful for lotions.
主題組成物はまた、本発明の透過促進剤の一つに溶解させたアミノプロピオニト リルまたはペニシラミンのような、コラーゲンを柔軟化する薬剤を癲痕組織に局 所適用することにより、癲痕組織の治療に用途を見出すこともできる。The subject composition also includes aminopropionite dissolved in one of the permeation enhancers of the invention. A collagen-softening agent, such as Ril or penicillamine, is applied to the scar tissue. Applied locally, it may also find use in the treatment of scar tissue.
普通に点眼剤、点耳剤、または点鼻剤として適用される薬剤は、本発明の透過促 進剤に溶解させたとき、より効果的である。Drugs commonly applied as eye drops, ear drops, or nasal drops can be treated with the penetration enhancer of the present invention. It is more effective when dissolved in a promoter.
診断に用いられる薬剤は、本発明の透過促進剤の一つに溶解させて適用するとき 、より効果的に使用することができる。アレルギーを診断するための貼付試験は 、アレルゲンを本発明の透過促進剤の一つ中で適用するときは、皮膚を引っかく ことまたはアレルゲンにさらされる部分を覆うことなしにすばやく行なうことが できる。When a drug used for diagnosis is dissolved in one of the permeation enhancers of the present invention and applied. , can be used more effectively. Patch test for diagnosing allergies , scratch the skin when applying the allergen in one of the permeation enhancers of the invention. This can be done quickly without covering the areas exposed to the allergen or the allergen. can.
主題組成物はまた、化粧または美容料の局所適用のためにも有用である0例えば 、メラニン刺激ホルモン(MSH>またはジヒドロキシアセトンおよびこれに類 するもののような化合物は、本発明の透過促進剤の一つに溶解させたとき、日焼 けを刺激すとき、薬剤は、より迅速に、そしてより多量に、皮膚内に運ばれる。The subject compositions are also useful for topical cosmetic or cosmetic applications, e.g. , melanin-stimulating hormone (MSH) or dihydroxyacetone and similar When dissolved in one of the permeation enhancers of the present invention, compounds such as those that When stimulating an injury, the drug is delivered into the skin more quickly and in greater quantities.
染髪料もまた、本発明の透過促進剤の一つに溶解させたとき、より完全かつ効果 的に透過する。Hair dyes also become more complete and effective when dissolved in one of the penetration enhancers of the present invention. transparent.
昆虫駆除剤または、香水およびオーデコロンのような芳香剤のような局所適用さ れた物質の有効性は、このような薬剤を本発明の透過促進剤の一つと組み合わせ て適用したとき、延長させることができる。Topically applied insecticides or fragrances such as perfumes and colognes The effectiveness of such agents is demonstrated by the combination of such agents with one of the permeation enhancers of the present invention. When applied, it can be extended.
前記したものは、本発明に従えばその公知の性質についてより効果的に使用する ことができる、公知の状態に対して公知の効果を有する治療および化粧剤を含む 生理学的に活性な薬剤の、単なる例であることは、強調されねばならない。The above-mentioned ones are used more effectively according to the invention due to their known properties. including therapeutic and cosmetic agents with known effects on known conditions It must be emphasized that these are only examples of physiologically active agents.
さらに、本発明の透過促進剤は、また、これまで知られていなかった治療効果を 生ずるために使用することもできる。すなわち、本明細書中に記載された透過促 進剤の使用により、これまで知られていなかった治療効果を達成することができ る。Furthermore, the permeation enhancers of the present invention also exhibit hitherto unknown therapeutic effects. It can also be used to produce That is, the permeation promotion described herein Through the use of stimulants, previously unknown therapeutic effects can be achieved. Ru.
前述したものの例として、グリセオフルビンは、皮膚または爪の真菌感染に対す る選りすぐりの療法として公知である。これまでは、グリセオフルビンの配給の 方法は、経口によるものであった。しかしながら、全身をグリセオフルビンにさ らすことからおこる副作用および、冒された皮膚の外層のみが治療を必要とする という事実のため、経口的治療は好ましくないことは長い間知られていた。その ため、真菌感染は一般に、皮膚および爪の感染であるので、グリセオフルビンを 局所的は利用することが有利であろう、しかしながら、長い間感じられていた局 所用グリセオフルビンの必要性にもかかわらず、治療上有用であるべき十分な皮 膚内のグリセオフルビンの保持をひきおこすと考えられる、局所的に配給され得 る処方は、これまで全く知られていなかったので、グリセオフルビンは、局所的 な真菌状態を治療するために、経口的に使用されてきた。As an example of those mentioned above, griseofulvin is effective against fungal infections of the skin or nails. It is known as the therapy of choice. Until now, the distribution of griseofulvin The method was oral. However, the whole body is exposed to griseofulvin. side effects from dry skin and that only the outer layer of skin affected requires treatment It has long been known that oral treatment is undesirable due to the fact that the Because fungal infections are commonly infections of the skin and nails, griseofulvin Local use would be advantageous, however, the long-felt local Despite the need for topical griseofulvin, there is enough skin to be therapeutically useful. Can be delivered topically, which is thought to cause retention of griseofulvin in the skin. Until now, there was no known formulation for griseofulvin. It has been used orally to treat many fungal conditions.
しかしながら、今回、もし本明細書中に開示された透過促進剤の一つと組み合わ せるならば、約0.1$ないし約1ozの治療濃度の範囲のグリセオフルビンは 、局所的に有効に使用することができることが発見された。However, this time, if combined with one of the permeation enhancers disclosed herein, griseofulvin in the therapeutic concentration range of about $0.1 to about 1 oz. It has been discovered that it can be used effectively topically.
さらに別の例として、ff−Ifは、すべての脂腺の炎症性疾患に共通して適用 される名称であり;またの名を尋常性If癒ともいう、痒癒感染に対する典型的 な原因となっている細菌は、コリネバクテリウム・アクネス(Coryneba cteriu+m 5cenes)である・局所用抗菌剤、例えばヘキサクロロ フェン、およびテトラサイクリンのような全身用抗生物質を含んで、疫療を治療 するための種々の治療法が試みられてきた。全身的抗生物質療法は一部有効であ ることが知られているが、局所的療法は、−iに効果がない。As yet another example, ff-If applies commonly to all sebaceous gland inflammatory diseases. It is a typical name for a pruritic infection; also known as Ifitis vulgaris. The bacteria that causes this is Corynebacterium acnes. topical antibacterial agents, such as hexachloro Treating epidemics, including systemic antibiotics such as phenyl, and tetracycline Various treatments have been attempted for this purpose. Systemic antibiotic therapy is partially effective. Although it is known that topical therapy has no effect on -i.
しかしながら、痒疹の全身的治療は、抗生物質に全身をさらすことの結果起こる 副作用および、冒された皮膚だけが治療される必要があるという事実のため、好 ましくない、これまでは、fffiFの局所的療法の必要性が長い間感じられて いたにもかかわらず、fffの治療において有効な療法として局所的に使用する ことができる抗菌処方は知られていなかったので、抗生物質は一般に、lf[を 治療するために全身的にのみ使用されてきた。However, systemic treatment of prurigo results from whole-body exposure to antibiotics. Due to side effects and the fact that only the affected skin needs to be treated, it is not preferred. Until now, the need for topical therapy of fffiF has long been felt. used topically as an effective therapy in the treatment of fff. Since there were no known antibacterial formulations that could It has only been used systemically to treat.
しかしながら、今回もし本明細書中に記載された透過促進剤の一つと組み合わせ るならば、抗生物質、特にリンコマイシンおよびエリスロマイシン系の抗生物質 は、fftFの治療において局所的に使用することができることが発見された。However, if this combination with one of the permeation enhancers described herein antibiotics, especially lincomycin and erythromycin, if It has been discovered that can be used topically in the treatment of fftF.
このようにして適用された抗生物質組成物は治療上有効量が小胞、[コリネバク テリウム・アクネス(C,Acnes)を含んでいる層内、と同様に皮膚の表皮 ならびにさらに深い層内にそしてこれらを通りぬけて運ばれ、それによって1l ffの徴候および症状を一時的に除去するためにうまく使用されることができる 。Antibiotic compositions applied in this manner may be administered in therapeutically effective amounts to vesicles, [Corynebacterium In the layer containing C. acnes, as well as the epidermis of the skin. as well as into and through deeper layers, whereby 1l Can be successfully used to temporarily eliminate signs and symptoms of ff .
“生理学的に活性な薬剤”という言葉は、生理学的に活性なステロイド、抗生物 質、抗真菌剤、抗菌剤、抗腫瘍剤、アレルゲン、抗ヒスタミン剤、抗炎症剤、紫 外線遮蔽剤、診断剤、香水、昆虫駆除剤、染j!料などを包含する広い範囲の有 用な化学薬剤および治療剤を指すために、本明細書中では使用されている。The term “physiologically active drugs” refers to physiologically active steroids, antibiotics, quality, antifungal, antibacterial, antitumor, allergen, antihistamine, antiinflammatory, purple External radiation shielding agent, diagnostic agent, perfume, insect repellent, dye j! A wide range of materials including is used herein to refer to chemical agents and therapeutic agents that are used.
局所適用用の剤層としては、溶液鼻用スプレー剤、ローション、軟膏、クリーム 、ゲル、生薬、スプレー剤、エーロゾル剤、およびこれに類するものがある。前 記の剤層を製造する典型的な不活性キャリヤーとしては、水、アセトン、イソプ ロピルアルコール、フレオン、エチルアルコール、ポリビニルピロリドン、プロ ピレングリコール、芳香剤、ゲル生成物質、鉱油、ステアリルアルコール、ステ アリン酸、鯨ろう、ソルビタンモノオレエート、′ポリソルベート類(P ol ysorbates)”、“ツイーン@(Tweens>”、ソルビタール、メ チルセルロース、などがある。For topical application, liquid nasal sprays, lotions, ointments, creams , gels, herbal medicines, sprays, aerosols, and the like. Before Typical inert carriers for preparing the agent layers described above include water, acetone, and isopropylene. Lopyl alcohol, Freon, Ethyl alcohol, Polyvinylpyrrolidone, Pro Pyrene glycol, fragrances, gel formers, mineral oil, stearyl alcohol, stearyl alcohol, Aric acid, spermaceti, sorbitan monooleate, polysorbates (Pol) ysorbates)”, “Tweens>”, sorbital, Chill cellulose, etc.
投与されるべき組成物および/または生理学的に活性な薬剤の量は、明らかに、 それから期待される所望の結果のための有効量であろう、これはもちろん、開業 医の普通の技術によって確かめられるであろう、達成される増大された活性のた め、生理学的に活性な薬剤の用量は、しばしば一般にあてはまる量より減少させ られることができる0通常の細心な処方実務に従って、その特定の生理学的に活 性な薬剤の有用範囲の下限に近い用量を最初に使用し、医師の常用手順における ようにして観察される反応から指示される通りに用量を増加させることができる 。The amount of composition and/or physiologically active agent to be administered will obviously be This, of course, will be the effective amount for the desired result expected from it. Due to the increased activity achieved, which will be ascertained by the ordinary skill of a physician. Therefore, doses of physiologically active drugs are often reduced from what is generally applicable. 0 Following normal careful prescribing practices, its specific physiological activity can be determined. Dosages near the lower end of the useful range of the drug should be used initially and The dose can then be increased as indicated by the observed response. .
本発明を、下記の実施例によってさらに詳しく説明するが、これらの実施例は、 本発明の種々の側面を具体的に説明するものであり、添付された請求の範囲によ って定義される本発明の範囲を制限するものではない。The present invention will be explained in more detail by the following examples, which include: It specifically describes various aspects of the invention, and is defined by the appended claims. It is not intended to limit the scope of the invention as defined by the above.
実施例1 −N−ドーシルー2−ピロ1トンー5− ルボン の製造A、乾燥THF中に1 .9hのN1H(60%、蒸留エーテルで洗ったもの)を含む溶液を、室温、窒 素雰囲気下で撹拌しているところへ、20w1lのTHF中に7.069のエチ ル2−ピロリドン−5−カルボキシレートを含む溶液を1滴ずつ加えた。この混 合物を1時間還流し、室温まで放冷し、続けて1.3当量の1−ブロモドデカン を1滴ずつ加えた。さらに1晩還流し、ワークアップし、粗油状物をフラッシュ クロマトグラフィー(シリカ、蒸留ニーナル:酢酸エチル=8:2)にかけ、3 .14.のエチル1−N−ドデシル−2−ピロリドン−5−カルボキシレートを きれいな油状物として得た。Example 1 -N-Doshiru 2-pyro 1 ton-5-rubon preparation A, 1 in dry THF .. A solution containing 9 h of N1H (60%, washed with distilled ether) was heated with nitrogen at room temperature. While stirring under an elementary atmosphere, 7.069 ethyl alcohol was added in 20w1L of THF. A solution containing 2-pyrrolidone-5-carboxylate was added dropwise. This mixture The mixture was refluxed for 1 hour, allowed to cool to room temperature, and subsequently treated with 1.3 equivalents of 1-bromododecane. was added drop by drop. Reflux for another night to work up and flush the crude oil. Chromatography (silica, distilled ninal: ethyl acetate = 8:2) .. 14. of ethyl 1-N-dodecyl-2-pyrrolidone-5-carboxylate Obtained as a clear oil.
NMR(CDC1,)δ4.2(m) 、3.68(m) 、2.9(+s) 、2.6−2.2(m) 、2.1(m)、1.6−1.0(蒙)、0.9(t )。NMR (CDC1,) δ4.2 (m), 3.68 (m), 2.9 (+s) , 2.6-2.2 (m), 2.1 (m), 1.6-1.0 (Mongolia), 0.9 (t ).
室温にて、実施例IAの生成物のアルカリ加水分解を行い、続いて酸処理するこ とによって、1.73.の1−ドテシル−2−ピロリドン−5−カルボン酸が白 色固体として生じた・NM R(CDCIコ)δ4.29(m)、3.75(+ *)、3.00(vs)、2.7−2.3(m)。Alkaline hydrolysis of the product of Example IA at room temperature followed by acid treatment. By 1.73. 1-dotecyl-2-pyrrolidone-5-carboxylic acid is white NM R (CDCI) δ 4.29 (m), 3.75 (+ *), 3.00 (vs), 2.7-2.3 (m).
2.2(輸)、1.5(m)、1.3(s)、0.9(t)−B、実施例IAを エチル12−プロモドデカノアートを用いて行い、ついで加水分解することで1 2−(N−ピロリジン−2−オン−5−カルボキシ)ドデカン酸を得た。2.2 (import), 1.5 (m), 1.3 (s), 0.9 (t)-B, Example IA By using ethyl 12-promododecanoate and then hydrolyzing, 1 2-(N-pyrrolidin-2-one-5-carboxy)dodecanoic acid was obtained.
C1実施例IAをエチル2−プロモドデカノアートを用いて行い、ついで加水分 解することで、2−(N−ピロリジン−2−オン−5−カルボキシ)−2−ドデ シル酢酸を得た。C1 Example IA was carried out using ethyl 2-promododecanoate, followed by hydrolysis. By understanding, 2-(N-pyrrolidin-2-one-5-carboxy)-2-dode Silacetic acid was obtained.
D、実施例IAをエチル2−ピロリドン−5−カルボン酸をプロリンエチルエス テルに変えて行い、ついで加水分解することで、N−ドデシルプロリンを得な。D, Example IA to ethyl 2-pyrrolidone-5-carboxylic acid to proline ethyl ester N-dodecylproline can be obtained by converting the compound into ester and then hydrolyzing it.
E、実施例IAのエチル−2−ピロリドン−5−カルボン酸をN−アセチルアラ ニンエチルエステルとがえて行い、ついで加水分解することで、N−アセチル− N−ドデシルアラニンを得た。E. Ethyl-2-pyrrolidone-5-carboxylic acid of Example IA was converted to N-acetylara By separating N-ethyl ester and then hydrolyzing it, N-acetyl- N-dodecylalanine was obtained.
F、実施例IAの出発物質を、N−エチルアラニンエチルエステルとドデカノイ ルクロライドに変えて行い、ついで加水分解することで、N−エチル−N−(1 −オキソドデシル)アラニンを得た。F. The starting material of Example IA was combined with N-ethylalanine ethyl ester and dodecanoyl N-ethyl-N-(1 -oxododecyl)alanine was obtained.
実施例2 9−ベン ルー −−−ピロlジン の製造A、2.0gの2−ピロリドンのア ルキル化を、実施例IAで述べた方法と同様の条件下、7.23gのエチル−2 −ブロモへ1タノアートを用いて行い、1.6gの2−ペンチルー2−オキソ− 1−ピロリジン酢酸エチルエステルを明るい黄色の油状物として得た。Example 2 9-ben-ru---Production A of pyrrolidine, 2.0g of 2-pyrrolidone The alkylation was carried out under conditions similar to those described in Example IA with 7.23 g of ethyl-2 - to bromo using 1-tanoate and 1.6 g of 2-pentyl-2-oxo- 1-pyrrolidine acetic acid ethyl ester was obtained as a light yellow oil.
NMR(CDCら)δ4.75(dd) 、4.15(q) 、3.55(o+ ) 、3.35(m) 。NMR (CDC et al.) δ4.75 (dd), 4.15 (q), 3.55 (o+ ), 3.35 (m).
2.45(t) 、2.2−1.6(a+) 、1.4−1.2(+e) 、0 .9(m) 。2.45 (t), 2.2-1.6 (a+), 1.4-1.2 (+e), 0 .. 9 (m).
実施例2Aの生成物を室温でアルカリ加水分解し、続いて酸処理し、0.89. の2−ペンチル−2−オキソ−1−ピロリジン酢酸を白色固体として得た。The product of Example 2A was subjected to alkaline hydrolysis at room temperature followed by acid treatment to yield 0.89. 2-pentyl-2-oxo-1-pyrrolidineacetic acid was obtained as a white solid.
N M R(CD Cfs)δ4.8(dd) 、3.6(m) 、3.4(m ) 、2.5(t> 、2.2−2.05(m) 、1.75(a+) 、1. 4−1.2(s) 、0.9(t) 。N M R (CD Cfs) δ4.8 (dd), 3.6 (m), 3.4 (m ), 2.5 (t>, 2.2-2.05 (m), 1.75 (a+), 1. 4-1.2 (s), 0.9 (t).
B、実施例2Aを2−オキサゾリジンを用いて行い、ついで、加水分解により2 −ドデシル−2−オキサ−3−オキサゾリジン#酸を得た。B. Example 2A was carried out using 2-oxazolidine and then hydrolyzed to give 2 -dodecyl-2-oxa-3-oxazolidine #acid was obtained.
C1実施例2Aをε−カプロラクタムとエチル2−ブロモテトラゾカッアートを 用いて行い、ついで加水分解により2−(1−アザシクロへブタン−2−オン) −2−ドデシル酢酸を得た。C1 Example 2A with ε-caprolactam and ethyl 2-bromotetrazocaate 2-(1-azacyclohebutan-2-one) by hydrolysis -2-dodecyl acetic acid was obtained.
D、実施例2人をモルホリンを用いて行い、ついで加水分解により、2−ドデシ ル−4−モルホリン酢酸を得た。D. Example 2 was carried out using morpholine and then by hydrolysis, 2-dodecyl Le-4-morpholine acetic acid was obtained.
E、実施例2Aをピロリジンを用いて行い、ついで加水分解により2−ドデシル −1−ピロリジン酢酸を得た。E. Example 2A was carried out using pyrrolidine, followed by hydrolysis to 2-dodecyl -1-pyrrolidine acetic acid was obtained.
F、実施例2Aをプロリンエチルエステルを用いて行い、ついで加水分解により 2−(N−ピロリジノ−2−カルボキシン−2−ドデシル酢酸を得た。F. Example 2A was carried out using proline ethyl ester and then by hydrolysis. 2-(N-pyrrolidino-2-carboxine-2-dodecyl acetic acid was obtained.
G、実施例2AをN−エチルアセトアミドを用いて行い、ついで加水分解により 2−(N−エチルアセトアミド)−2−ドデシル酢酸を得た。G. Example 2A was carried out using N-ethylacetamide and then by hydrolysis. 2-(N-ethylacetamido)-2-dodecyl acetic acid was obtained.
H11実施2人をジエチルアミンを用いて行い、ついで加水分解により2−(N 、N−ジエチルアミノ)−2−ドデシル酢酸を得た。Two H11 runs were carried out using diethylamine, followed by hydrolysis to prepare 2-(N , N-diethylamino)-2-dodecyl acetic acid was obtained.
■、実施例2Aをエチル2−ブロモテトラゾカッアートを用いて行い、ついで加 水分解により2−ドデシル−2−オキソ−1−ピロリジン酢酸を得た。■, Example 2A was carried out using ethyl 2-bromotetrazocaate, and then 2-dodecyl-2-oxo-1-pyrrolidine acetic acid was obtained by water decomposition.
実施例3 11−(ジエ ル ミノ−ラン−ン の製造A、冥実施IBのアルカリ加水分解 の方法に従って、0.47.のエチル11−(ジエチルアミノ)−ウンデカノア ートを加水分解し、目的物を白色固体として得た。Example 3 11-(Production A of diele minolane, alkaline hydrolysis of Meijin IB) According to the method of 0.47. Ethyl 11-(diethylamino)-undecanoa The target product was obtained as a white solid.
N M R(CD Cjs’)δ3.1(q) 、2.95(e) 、2.25 (t) 、1.7−1.6(m) 。N M R (CD Cjs’) δ3.1 (q), 2.95 (e), 2.25 (t), 1.7-1.6 (m).
B、実施例3Aをピロリジンを用いて行い、ついで加水分解し、1l−(1−ピ ロリジノ)ウンデカン酸を得な。B. Example 3A is carried out using pyrrolidine and then hydrolyzed to produce 1l-(1-pyrrolidine). Loridino) Obtain undecanoic acid.
C0実施例3Aをモルホリンを用いて行い、ついで加水分解し、1l−(4−モ ルホリノ)ウンデカン酸を得た。C0 Example 3A was carried out using morpholine and then hydrolyzed to produce 1l-(4-mol). luphorino)undecanoic acid was obtained.
D、実施例3Aをピペラジンを用いて行い、ついで加水分解し、1l−(1−ピ ペラジノ)ウンデカン酸を得た。D. Example 3A was carried out using piperazine and then hydrolyzed to give 1l-(1-piperazine). Pelagino) undecanoic acid was obtained.
E、実施例3Aを2−ピロリジノンを用いて行い、ついで加水分解し、1l−( N−ピロリジノ−2−オン)ウンデカン酸を得た。E. Example 3A was carried out using 2-pyrrolidinone, which was then hydrolyzed to give 1l-( N-pyrrolidino-2-one) undecanoic acid was obtained.
F、実施例3Aを2−オキサゾリドンを用いて行い、ついで加水分解し、1l− (3−オキサゾリン−2−オン)ウンデカン酸を得た。F. Example 3A was followed using 2-oxazolidone, then hydrolyzed and 1l- (3-oxazolin-2-one)undecanoic acid was obtained.
G、実施例3Aをε−カプロラクタムを用いて行い、ついで加水分解し、1l− (1−へキサメチレンイミン−2−オン)ウンデカン酸を得た。G. Example 3A was carried out using ε-caprolactam, then hydrolyzed and 1l- (1-hexamethyleneimin-2-one)undecanoic acid was obtained.
H0莫実例3Aをプロリンエチルエステルを用いて行い、ついンデカン酸を得た 。H0Mo Example 3A was carried out using proline ethyl ester, which then yielded indecanoic acid. .
■、莫実例3AをN−エチルアセトアミドを用いて行い、ついで加水分解し、1 l−(N−二チルアセトアミド)−ウンデカン酸を得た。■, Example 3A was carried out using N-ethylacetamide, then hydrolyzed, and 1 l-(N-ditylacetamido)-undecanoic acid was obtained.
J、実施例3AをN−アセチルアラニンエチルエステルを用いて行い、ついで加 水分解し、N−アセチル−N−(10−カルボキシ−1−デシル)−アラニンを 得た。J, Example 3A was carried out using N-acetylalanine ethyl ester, followed by addition of Water splits to produce N-acetyl-N-(10-carboxy-1-decyl)-alanine. Obtained.
実施例4 生理的活性剤の皮フや粘膜への透明性を高めるための、1位がアザシクロアルカ ン頚に置換されたカルボン酸誘導体の能力を表わすために、対照としてCl4− エタノールもしくはc I4−ブタノールを用いた一連の実験を行った。浸透量 は対照物の浸透量に対するパーセントで計算した。それぞれの対照と比較するた めに、既知の浸透増加剤である1−n−ドデシルアザシクロへブタン−2−オン を用いて平行試験を行った。Example 4 Azacycloalkaline ranks first in order to increase the transparency of physiologically active agents to the skin and mucous membranes. As a control, Cl4- A series of experiments using ethanol or cI4-butanol was performed. Penetration amount was calculated as a percentage of the permeation amount of the control substance. To compare with each control 1-n-dodecyl azacyclohebutan-2-one, a known penetration enhancer, A parallel test was conducted using
エタノールとブタノールについては、拡散セルを経たヌードマウスの皮フへの浸 透の透過係数が既に分っている。透過係数は次式で表わされる: 式中りは拡散度(拡散係数)、K はM(、)と媒質(v+媒媒介m/ 物)、そしてhは腹の厚さを表わす、Kurihara−Bergstrom、 T、ら“ジメチルスルホキシドによる浸透吸収増加現象の生理化学的研究ニジメ チルスルホキシドによるアルカノール類の物質移動の動力学的、熱力学的決定因 子″(J ournal of P harmaeeuticalScienc es Vat、 75.No、 5.May、1986.pp、479−86を 参照されたい、充分な厚さの腹部および背部の部分のマウスの皮膚膜は、ヌード マウス系より得られた。 (SkinCancer Ho5pital、Tev aple University、Ph1ladelphia。For ethanol and butanol, immersion into the skin of nude mice via a diffusion cell was performed. The transparent transmission coefficient is already known. The transmission coefficient is expressed by the following formula: In the formula, K is the diffusivity (diffusion coefficient), and K is M (, ) and medium (v + medium medium m/ ), and h represents the thickness of the belly, Kurihara-Bergstrom, T., et al. “Physicochemical study of the phenomenon of increased osmotic absorption due to dimethyl sulfoxide” Kinetic and thermodynamic determinants of mass transfer of alkanols by tylsulfoxide Child'' (J internal of PharmaeuticalScience es Vat, 75. No, 5. May, 1986. pp, 479-86 For reference, the skin membrane of the mouse in the abdominal and dorsal areas of sufficient thickness is nude. Obtained from mouse strain. (Skin Cancer Ho5pital, Tev aple University, Ph1ladelphia.
PA) 試験に用いた処方は、浸透増加剤の1もしくは5重量パーセント、3重量パーセ ントのTween 20 、そして対応する蒸留水を含む、放射性ラベルしたC 14エタノールの量を追跡した。PA) The formulations used in the tests contained 1 or 5 percent by weight, 3 percent by weight of penetration enhancer. radioactively labeled C containing Tween 20 and the corresponding distilled water. 14 The amount of ethanol was tracked.
分析の前にそれぞれの処方に加え、それから10FNの標識物質を液体シンチレ ーションカウンターで計測し、1分間あたりの崩壊数(D P M)を決めた。10FN labeled material was added to each formulation prior to analysis and then added to the liquid scintillator. The number of disintegrations per minute (DPM) was determined by measuring with a motion counter.
フランツ拡散セルを限定量投与した9つの受容細胞を等張な食塩水に浸たし、恒 温調節できる水浴にしずめ、37℃に保った9食塩水は磁性撹拌子で30分間撹 拌し、平衡にした。Nine recipient cells injected with a limited amount of Franz diffusion cells were immersed in isotonic saline solution and kept constant. The saline solution kept at 37℃ was placed in a temperature-controlled water bath and stirred for 30 minutes using a magnetic stirrer. Stir and equilibrate.
新たに充分な厚さのマウスの皮フの切片を切りとり、ついで供与細胞と受容細胞 のあいだに0環を入れて固定した、平衡後1時間のちに受容体細胞から食塩水を とりのぞき、37℃の新しい食塩水4−5m1’と交換した。Cut a new section of mouse skin of sufficient thickness and then separate the donor and recipient cells. One hour after equilibration, saline was removed from the receptor cells. It was removed and replaced with 4-5 ml of fresh saline solution at 37°C.
9つの供与細胞のうち3つの細胞はコントロールとして、浸透増加剤を含まない 放射性標識した食塩水100μlを加えた。Three of the nine donor cells contained no penetration enhancer as controls. 100 μl of radiolabeled saline was added.
他の3つの細胞群には、1重量%の浸透増加剤成分を含む標識食塩水100μp を加えた。残りの3つの細胞には5重量%の浸透増加剤成分を含む像識食塩水を 同量加えた。45分の間かくをおいて、それぞれの受容体細胞の孔からマイクロ ピペッタ−で50A1fの試料を取り出した。減少した容積骨は50μlの新た な37℃の食塩水を加えて置換した。それぞれの試料は4.0μlのシンチレー ションカクテルにそって液体シンチレーションカウンターのバイアル中に置いた 。(アクアゾル、ニュー イングランド ヌークリア(New England Nuclear)、ボストン、MA)。For the other three cell groups, 10 μp of labeled saline containing 1% by weight of the permeation enhancer component was added. added. The remaining three cells were treated with imaging saline containing 5% by weight of a penetration enhancer component. Added the same amount. Wait for 45 minutes, then remove the microorganism from the pore of each receptor cell. A 50A1f sample was taken out with a pipettor. Reduced volume bone is replaced with 50 μl of new The solution was replaced by adding 37°C saline solution. Each sample contains 4.0 μl of scintillator placed in a vial on a liquid scintillation counter along with a scintillation cocktail. . (Aquasol, New England Nuclear (Nuclear), Boston, MA).
それぞれの系のあらかじめ決めたdpmにより、それぞれの系においてマウスの 皮フを透過したアルカノールの量を既知の方法で計算した0表■と■の、浸透性 増加剤の添加による放射性標識したアルカノールの透過度の増加のまとめを以下 に示す。The predetermined dpm of each system allows the mouse to The amount of alkanol that permeated through the skin was calculated using a known method.Table 0 ■ and ■, permeability The following is a summary of the increase in permeability of radiolabeled alkanols due to the addition of enhancers. Shown below.
すべての試験において、本発明における浸透性増加剤の、助力がない時より、エ タノールの透過度が少なくとも76%以上増大することは注目に値いするだろう 。In all tests, the permeability enhancer of the present invention was found to be more effective than unaided. It is worth noting that the permeability of tanol increases by at least 76%. .
これらの試験のうちで最も良い結果は1重量%の濃度のN−0917浸透性増加 剤を用いたときで、その結果、ヌードマウスの皮フに対するエタノールの透過度 は、浸透性増加剤がないときの616%を示した。The best results among these tests showed that N-0917 permeability increased at a concentration of 1% by weight. As a result, the permeability of ethanol to the skin of nude mice showed 616% in the absence of permeability enhancer.
表■に示したとうり、本発明におけるすべての浸透性増加剤は、ブタノールの透 過性を対照実験で達する値の少なくとも119%を示した。As shown in Table ■, all the permeability enhancers in the present invention The sensitivity was at least 119% of the value reached in the control experiment.
宍」− CI4−エタノール 浸透物として 透過係数 対照(1001)ム、 ’ N XIO弓CMNR4 : ル$2^ 51 25.62 484 1: 11.28 341 2I 5% 6.89 208 11 2.38 76 2C514,S2 155 アゝン 51 18.58 466 1^ 5g 40.74 324 1$ 14.69 135 2^ 51 22.23 204 冥施例5 以下の処方を製造した: ! % グリセオフルビン I N−ドデシル−2−ピロリジン−5−カルボン酸 1ミリスチン酸イソプロピル 5 芳香剤 0.1 エタノール 92.9 この処方は真面感染症の治療に有効である。meat CI4-ethanol Permeability coefficient control (1001) as permeate, N XIO bow CMNR4 : Le$2^ 51 25.62 484 1: 11.28 341 2I 5% 6.89 208 11 2.38 76 2C514, S2 155 Anne 51 18.58 466 1^ 5g 40.74 324 1$ 14.69 135 2^ 51 22.23 204 Mystery example 5 The following formulations were manufactured: ! % Griseofulvin I N-dodecyl-2-pyrrolidine-5-carboxylic acid 1 isopropyl myristate 5 Air freshener 0.1 Ethanol 92.9 This regimen is effective in treating serious infections.
実施例6 実施例7の処方成分のエアロゾル型で、以下の混合物により製造 れる: 処方 25g フレオン+ 75g 1フレオンはフレオン114:フレオン12=75:25実施例7 以下のクリーム剤を製造した: タリンダマイシン塩 1.0 ステアリルアルコールU、 S、 P、 12.0エトキシレートコレステロー ル 0.4合成鯨ろう −7,5 ソルビタンモノオレエート 1.0 ポリツルバツト80 U、S、P、 3.ON−ドデシル−2−ピロリドン−5 −カルボン¥10.5ソルビトール液 U、S、P、 5.5クエン酸ナトリウ ム 0.5 ケモダーム#844芳香剤 0.2 C68,4 この製剤はにきびの治療に有効である。Example 6 An aerosol form of the formulation of Example 7, prepared by the following mixture: Prescription 25g Freon + 75g 1 freon is freon 114: freon 12 = 75:25 Example 7 The following creams were manufactured: Talindamycin salt 1.0 Stearyl alcohol U, S, P, 12.0 ethoxylate cholesterol Le 0.4 Synthetic whale wax -7,5 Sorbitan monooleate 1.0 Polytruss Bat 80 U, S, P, 3. ON-dodecyl-2-pyrrolidone-5 -Carvone ¥10.5 Sorbitol liquid U, S, P, 5.5 Sodium citrate Mu 0.5 Chemoderm #844 fragrance 0.2 C68,4 This formulation is effective in treating acne.
実施例8 以下の液剤を製造した: クリンダマイシン塩 1.0 クリンダマイシンリン酸物 1・3 −水酸化ナトリウム 0.077 − 1.0M塩酸 2・27 エデト酸二ナトリウム・2水和物 0.003 0.003芳香剤 0.5 0 .5 N−ドデシル−2−ピロリドン−5− カルボン酸 、0 1.0 精製水 20.0 17.73 イソプロパ −ル 77.21 77.497この製剤はヒトのにきびの治療に 有用である。Example 8 The following solutions were manufactured: Clindamycin salt 1.0 Clindamycin phosphate 1.3 - Sodium hydroxide 0.077 - 1.0M hydrochloric acid 2.27 Edetate disodium dihydrate 0.003 0.003 Fragrance 0.5 0 .. 5 N-dodecyl-2-pyrrolidone-5- Carboxylic acid, 0 1.0 Purified water 20.0 17.73 Isopropal 77.21 77.497 This preparation is used to treat acne in humans. Useful.
実施例9 以下の液剤を製造した: % 硫酸ネオマイシン 0.5 リドカイン 0.5 ヒドロコルチゾン 0.25 N−ドデシル−2−ピロリドン−5−0,5カルボン酸 プロピレン 暮コール 98.25 この液剤は家畜の耳炎の治療に有効である。Example 9 The following solutions were prepared: % Neomycin sulfate 0.5 Lidocaine 0.5 Hydrocortisone 0.25 N-dodecyl-2-pyrrolidone-5-0,5carboxylic acid Propylene Kurekor 98.25 This solution is effective in treating otitis in livestock.
実施例10 以下の日焼は止め乳剤を製造した: ρ−アミン安息香i!! 2.0 ベンジルアルコール O,S N−ドデシル−2−ピロリドン−5−1,0カルボン酸 ポリエチレングリコール500−M5 10.0イソプロビルラル−ト 3.0 ラントロール 1.0 アセチル化ラノリン 0.5 ミリスチン酸イソプロピル 5.0 軽鉱質油 8,0 セチルアルコール 1.0 ビーガム 1.0 プロピレングリコール 3.O C64,0 実施例11 以下の抗悪性腫瘍溶液を製造した: % 5−フルオロフラシル 5.O N−ドデシル−2−ピロリドン−5−0,1カルボン酸 ポリエチレングリコール 5.0 制、 89.9 実施例12 以下の噴霧型昆虫駆除剤を製造したニ ジエチルトルアミド 0・I N−ドデシル−2−ピロリドン−5−0,1カルボン酸 エタノール 99.8 実施例13 以下のローション剤で、フルオシノロンアセトアミドを0.001から11、好 ましくは0.1z含む製剤を製造した:フルオシノロンアセトニド 0.001 〜1セチルアルコール 15.0 プロピレングリコール 10.0 硫酸ラウリルナトリウム 15.O N−ドデシル−2−ピロリドン−5−1,0カルボン酸 ’ ioog 7 ステロイドを媒介物に溶解し、撹拌し、他の成分を冷やしながらとかした。この 製造品は影響のある皮フ領域への局所使用によって炎症部位の治療に生理学的に 有用である。適用の量と頻度はこのステロイドの典型的な適用に従う、ステロイ ドの炎症組織への透過性は、増加し、治療レベルへよりすばやく到達し、そして 普通に適用゛したときよりも作用の長い持続を維持した。Example 10 The following sunscreen emulsions were prepared: ρ-Amine benzoic i! ! 2.0 Benzyl alcohol O, S N-dodecyl-2-pyrrolidone-5-1,0 carboxylic acid Polyethylene glycol 500-M5 10.0 Isoprobilralt 3.0 Runtroll 1.0 Acetylated lanolin 0.5 Isopropyl myristate 5.0 Light mineral oil 8,0 Cetyl alcohol 1.0 Begum 1.0 Propylene glycol 3. O C64,0 Example 11 The following antineoplastic solutions were prepared: % 5-Fluorofuracil 5. O N-dodecyl-2-pyrrolidone-5-0,1carboxylic acid Polyethylene glycol 5.0 system, 89.9 Example 12 The company that manufactured the following spray insecticides Diethyltoluamide 0/I N-dodecyl-2-pyrrolidone-5-0,1carboxylic acid Ethanol 99.8 Example 13 The following lotions contain fluocinolone acetamide from 0.001 to 11, preferably Preferably, a formulation containing 0.1z was manufactured: fluocinolone acetonide 0.001 ~1 cetyl alcohol 15.0 Propylene glycol 10.0 Sodium lauryl sulfate 15. O N-dodecyl-2-pyrrolidone-5-1,0 carboxylic acid ’ ioog 7 The steroid was dissolved in the vehicle, stirred, and the other ingredients dissolved while cooling. this The manufactured product is physiologically effective for treating inflamed areas by topical application to the affected skin area. Useful. The amount and frequency of application follows the typical application of this steroid, The permeability of the drug into inflamed tissue increases, reaching therapeutic levels more quickly, and It maintained a longer duration of action than when applied normally.
本発明の浸透性増加側は、m維の染色、添加もしくは補助的な織物などの織物の 染色にも組み合わせでっかうことができ、この増加剤を用いないときにくらべ繊 維を染色を、より低温で、より短時間に行うことを可能にすることで染色の過程 を改良もしくは増強させるのに有用である。染色可能なamは天然繊維と人造m uの両方を含む0本発明の方法で用いる適当な天然繊維は、綿、リネン、木、絹 、そしてパンヤ、麻、インド麻、ラミー麻のようなその他の物を含む0人造繊維 はレーヨン(繊維は再生セルロースから成る)、アセテート(繊維はほとんど、 セルロースのジーもしくはトリーアセテートである。)、そして、ポリアミド、 アクリル、ポリエステルやポリオレフィンのような、化学的方法によって工業的 にできる、天然にはない1aiIt構造より成る合成#a維を含む。The permeability-enhancing side of the present invention can be applied to fabrics such as m-fiber dyeing, addition or supplementary fabrics. It can also be used in combination for dyeing, and the fibers are reduced compared to when this increaser is not used. The dyeing process is improved by allowing fibers to be dyed at lower temperatures and in a shorter time. It is useful for improving or enhancing. Dyeable am is natural fiber and artificial m Suitable natural fibers for use in the process of the invention include cotton, linen, wood, silk , and 0 man-made fibers including panya, hemp, Indian hemp, ramie hemp, etc. are rayon (the fibers are made of regenerated cellulose), acetate (the fibers are mostly made of regenerated cellulose), It is di- or tri-acetate of cellulose. ), and polyamide, Industrially manufactured by chemical methods, such as acrylic, polyester and polyolefin Contains synthetic #a fibers consisting of a non-natural 1aiIt structure that can be
代表的なポリアミドwitは、ポリ(ヘキサメチレン−アジパミド)、ポリ(飴 −キシリレン−アジパミド)、ポリ(キシリレンセバカミド)、ポリカプロラク タム、その他同様なもの、といったナイロンを含む0代表的なアクリル繊維は完 全にポリアクリロリトルから成るかもしくはアクリロニトリルと他のオルロン( Orion)、ダイエル(D ynel)、ベレル(Verel)、クレステン (C1eslin)、アクリラン(、Aerilan)、コツテレ(Court elle)、そしてビンオン(Vinyon)といったビニル化合物との混合物 から成る合成物である0代表的なポリエステル繊維はテリレン、ダクロンおよび コデールを含む0代表的なポリオレフィン繊維はポリエチレン、ポリプロピレン 、ビニロン、ローイル(Rhouyl)、ゼフラン(Zefran)としてダー バン(Dirvan)を含む。Typical polyamides are poly(hexamethylene-adipamide), poly(candy) -xylylene-adipamide), poly(xylylene sebacamide), polycaprolac Typical acrylic fibers, including nylon, such as toms and similar materials, are completely Consisting entirely of polyacrylotriole or acrylonitrile and other orlon ( Orion), Dynel, Verel, Cresten (C1eslin), Acrylan (, Aerilan), Kottere (Court) elle), and mixtures with vinyl compounds such as Vinyon. Typical polyester fibers are terylene, dacron and Typical polyolefin fibers including codele are polyethylene and polypropylene. , Vinylon, Rhouyl, Zefran. Including Dirvan.
種々の染色剤が利用でき、直接染料、アゾ染料もしくはナフトール染色、大おけ 染色、硫酸染色、酸染色、そして媒染剤もしくは金属染色、塩基もしくは陽イオ ン染色、分散染色あるいは繊維反応染色と分類している。Various dyes are available, including direct dyes, azo dyes or naphthol dyes, staining, sulfuric acid staining, acid staining, and mordant or metal staining, base or cationic staining It is classified as dyeing, dispersion dyeing, or fiber reaction dyeing.
直接染色は水にとけ、ふつう、セルロース繊維に用い、時々、タンパク質繊維や ポリアミドをも用いる。アゾ色素とナフトール染色はときどき直接染色と同様に 用い、同じ繊維種に対して使用した。酸染色と媒染剤もしくは金属染色はタンパ ク繊維、アクリル繊維、ナイロン(nylon)mtiを使用し、いくらかの改 良法でポリエステル11維を用いることができる。陽イオンもしくは塩基性染色 は特に、アクリル繊維の着色に用いられ、そしてmayはナイロン(nylon )やポリエステル繊維に有用である0分散染色はアセテート繊維に用いたのがは じまりで、現在はアセテート、ポリエステル、アクリル、ポリアミド繊維に用い ている0反応染色は、綿、セルロース、木、絹、アクリルに用いたのがはじまり である。はとんどの天然W!維を染色する間は染液は100℃に加熱される。こ の条件は一般的に合成繊維の深い色調を保ってゆくのには不充分である。さらに 、毛などの天然1!維は水性染液中で煮ることにより満足に染色することができ る。これはふつう、1.5から2時間かかり、この間に染料は充分に吸収され深 い色味を出す0毛の染色は綿やビスコースレーヨンよりゆっくりである。このた め、一般的に実際の毛織物の染色は通常の連続染色法では行わない、しかしなが ら、100℃以上の温度では、毛や合成m維でもすばやく染料が吸収するので、 毛の連続染色法は可能である。但し、このような高温の染色条件は繊維に悪影響 を与える。Direct dyeing is soluble in water and is usually used on cellulose fibers, sometimes on protein fibers and Polyamide is also used. Azo dyes and naphthol stains are sometimes used as well as direct stains. and used for the same fiber type. Acid stains and mordants or metal stains are protein-based. acrylic fiber, nylon mti, and some modifications. Polyester 11 fibers can be used in a good manner. Cation or basic staining is especially used for coloring acrylic fibers, and may be used for coloring nylon. ) and 0-dispersion dyeing, which is useful for polyester fibers, is used for acetate fibers. Initially used for acetate, polyester, acrylic, and polyamide fibers. 0-reactive dyeing was first used on cotton, cellulose, wood, silk, and acrylic. It is. The most natural W! During the dyeing of the fibers, the dye liquor is heated to 100°C. child These conditions are generally insufficient to maintain the deep color tone of synthetic fibers. moreover , natural hair etc. 1! fibers can be dyed satisfactorily by boiling them in an aqueous dye solution. Ru. This usually takes 1.5 to 2 hours, during which time the dye is fully absorbed and deep. The dyeing of zero wool to produce dark colors is slower than that of cotton or viscose rayon. others Therefore, the actual dyeing of woolen fabrics is generally not done using the normal continuous dyeing method, but However, at temperatures above 100°C, dyes are quickly absorbed by hair and synthetic fibers. Continuous dyeing of hair is possible. However, such high-temperature dyeing conditions have a negative effect on the fibers. give.
ここに述べた化合物を使うことにより、染色過程はしばしばそのような化合物を 使わないときよりも低温、短時間で行われた。さらに、ここに述べた化合物をつ かうことにより、染料の繊維内への浸透性はあがり、速さも迅速に改良された。By using the compounds mentioned here, the dyeing process often involves the use of such compounds. The process was performed at a lower temperature and in a shorter time than when not in use. In addition, the compounds mentioned here This increased the permeability of the dye into the fibers and rapidly improved the speed.
ここに述べた化合物はカーペットの合成繊維の染色についてもとくに有効である 。The compounds described here are also particularly effective for dyeing synthetic carpet fibers. .
本発明において使われる前述の化合物の量は染色にさいしてさまざまなwit、 染料、時間、温度がめられ、その条件で染色される。一般的にここに述べた化合 物は重量の0.1から約50%好ましくは1から10%で染液とまぜた0本発明 の化合物と織物原料はいかなるタイプのものにも使え、制限がなく、いかなる既 知の織物のタイプの編み糸や生地で織る、編む、もしくはそのままというすべて のタイプを含む、特に適当な織物は編んだカーペットもしくはループ状に繊維を 並べたカーペットである。The amount of the above-mentioned compounds used in the present invention may vary depending on the dyeing process. The dye, time, and temperature are determined and dyed under those conditions. Compounds generally mentioned here The product is mixed with the dye liquor at 0.1 to about 50% by weight, preferably 1 to 10%. Compounds and textile raw materials can be of any type, without restrictions and without any existing Everything that is woven, knitted, or as is with knitting yarns and fabrics of the knowledge textile type. Particularly suitable textiles include types of woven carpets or loops of fibers. They are carpets lined up.
ここで用いたように「作用量の限界」とは、織物の助剤に間しての説明において 、染色すべき繊維を膨潤させるか染料をより小さい微小片として染色の耐性を改 良するか、染色過程を、低温で短時間に容易になるような充分な化合物の量を官 味する。As used here, the term "limit of working amount" refers to textile auxiliaries. , improve the resistance of dyeing by swelling the fibers to be dyed or turning the dye into smaller particles. Add sufficient amount of the compound to facilitate the dyeing process at low temperatures and in a short time. Taste.
本物質成分は個々の植物栄養素の伝達方法の改良によって、植物の治療に有効で ある。化学物質の供給と吸収は成長と・代謝に必要であり、これを栄養と定義し 、そして化学物質は栄養素とり込み時に有機物を要求する。この機構によって栄 養素は細胞物質にかえられるか、代謝系でエネルギーにかえられる。This material component is effective for plant treatment by improving the delivery method of individual phytonutrients. be. The supply and absorption of chemicals is necessary for growth and metabolism, and is defined as nutrition. , and chemicals require organic matter during nutrient uptake. Prosperity through this mechanism Nutrients can be converted into cellular substances or converted into energy by the metabolic system.
′代謝゛の期間は数々の反応が生きている細胞をとりまくように行われ、これは 生命維持と生長のために行われている。栄養と代謝は非常に近い相互関係にある 。緑色植物によって要求される必須栄養素はもっばら天然無機物質である。この 点で緑色植物は基本的にヒト、動物および数種の微生物といった、さらに食物と して有機物質を必要とするものとはことなっている。必須元素は生物の通常のラ イフサイクルによって要求されるものとして決められている。加えてそのような 元素は必須酵素システムの構成要素であるなどのように、直接に栄養中に含まれ ているにちがいない、この定義に基ずき、現在知られている高等植物の必須化学 元素を以下に示す。During the period of 'metabolism', a number of reactions take place surrounding living cells; This is done for life support and growth. Nutrition and metabolism are closely interrelated . The essential nutrients required by green plants are mostly natural inorganic substances. this In this respect, green plants are basically used for food and food, such as humans, animals and some microorganisms. This is different from those that require organic substances. Essential elements are the normal molecules of living things. It is determined as required by the life cycle. In addition such Elements are found directly in nutrients, such as being components of essential enzyme systems. Based on this definition, the currently known essential chemistry of higher plants must be The elements are shown below.
炭素 Cカリウム K 亜鉛 Zn 水素 Hカルシウム C& モリブデン MO酸素 0 マグネシウム Mg ホウ素 B窒素 N 鉄 Fe 塩素 C1 リン P マンガン Nn ナトリウム Ha硫黄 S tRCu ケイ素 S i コバルト C。Carbon C Potassium K Zinc Zn Hydrogen H Calcium C & Molybdenum MO Oxygen 0 Magnesium Mg Boron B Nitrogen N Iron Fe Chlorine C1 Phosphorus P Manganese Nn Sodium Ha Sulfur S tRCu Silicon S i Cobalt C.
上記の必須元素のリストは完全ではないであろう、他の元素も非常に低い濃度で あって高等植物でまだ必須物質として見つかつ・ていないのかもしれない、たと えば、ある種の微生物ではバナジウム(V)が必須元素として確かめられている 。植物栄養素はマクロ栄養素とミクロ栄養素に分離される。マクロ栄養素は見つ かっており、植物体内でミクロ栄養素よりも犀が多いという関係がある。たとえ ば、植物繊維に、マクロ栄養素Nはミクロ栄養素Znよりi 、ooo倍以上多 く含まれている。植物物質内にある元素の含量をもとに分類すると、以下の元素 はマクロ栄養素と定義されるだろう:C、H、○、N、P、S、に、Ca、Mg 、Naと、Si。ミクロ栄養素は: F e 、 M n 、 Cu 、 Z n 、 M o 、 BとC1,この、植物栄養素のマクロとミクロ栄養素への 分配は、任意のものであり、多くの場合にマクロとミクロ栄養素の間の量がちが ってくるが、これは上に引用した例よりは考慮しなくてよい、植物による栄養素 の取り込みおよび同化作用の過程は充分にはわかっていない。しかしながら鉄の 取り込みと移送についての多くの理論が知られており、たとえば、Mengel ら、植j〔もヌlIL則−1第3章、“栄養素のとり込みと同化作用”、I n ternationalPotash In5titute、Bern(197 8)、を参照されたい。The list of essential elements above may not be complete; other elements are also present in very low concentrations. It may be that it has not yet been discovered as an essential substance in higher plants. For example, vanadium (V) has been confirmed as an essential element in certain microorganisms. . Plant nutrients are separated into macronutrients and micronutrients. Find macronutrients There is a relationship between rhinoceros and micronutrients in the plant body. parable For example, in plant fibers, macronutrient N is more than i, ooo times higher than micronutrient Zn. Contains a lot. Classifying based on the content of elements in plant materials, the following elements would be defined as macronutrients: C, H, O, N, P, S, Ca, Mg. , Na, and Si. Micronutrients are: F e, M n, Cu, Z n, M o, B and C1, this conversion of plant nutrients to macro and micro nutrients. Partitioning is arbitrary and there is often a difference in amounts between macro and micro nutrients. However, this does not need to be considered as much as the example cited above. The processes of uptake and anabolism are not fully understood. However, iron Many theories of uptake and transport are known, for example Mengel's et. internationalPotash In5titude, Bern(197 Please refer to 8).
本発明において使用される物質成分の量は、植物栄養素が植物に伝達される量の 増大をおこす有効量でみる。一般的に有効作用量は成分重量の0.01から約9 9.9のあいだで、好ましくは0.1から10%がよい。The amounts of material components used in the present invention are such that the amounts of phytonutrients delivered to the plants are Look at the effective amount that causes an increase. Generally, the effective amount ranges from 0.01 to about 9 of the weight of the ingredient. 9.9, preferably 0.1 to 10%.
本発明において使われる植物栄養素はマクロ−とミクロ−両方の栄養素を含み、 前述の非必須な植物栄養素を含む、たとえば栄養素が増加したとき、限度がない なら、これは第1次植物フードであり:アンモニアと硝酸イオンに含まれる窒素 、リン(リン酸)、カリウム(灰);第2次植物フードは:カルシウム、マグネ シウムと硫黄;そしてこん跡元素は:マンガン、ホウ素、銅、亜鉛、銀、モリブ デンと塩素である。前述の栄養素の型は通常の形体でたとえば、McVicka rら、(’) f) 、TheInterstate Publishers、 Danville、イリノイ(1978)。The phytonutrients used in the present invention include both macro- and micro-nutrients, Contains the aforementioned non-essential phytonutrients, e.g. when nutrients are increased, there is no limit If so, this is a primary plant food: nitrogen contained in ammonia and nitrate ions. , phosphorus (phosphoric acid), potassium (ash); secondary plant foods include: calcium, magne Si and sulfur; and the trace elements are: manganese, boron, copper, zinc, silver, molyb. They are den and chlorine. The types of nutrients mentioned above are in conventional form, for example, McVicka r et al., (') f), TheInterstate Publishers, Danville, Ill. (1978).
を参照されたい。Please refer to
ここでのべた物質の植物栄養素への適用方法は単純である。The application of the substances described here to phytonutrients is simple.
たとえば、MeViekarら、m肥困ヱ旧吏囲−9第14章、“肥料の適用方 法”を参照されたい、植物栄養素成分が植物へと伝達されるべきその正確な量は 結果を期待する要求のための有効作用量であることは明らかである。もちろん、 これは従来の方法でたしかめられる。活性の増加にしたがい、植物栄養素の量は 一般的適用によりしばしば減少した0通常の慎重さに従って処方するには、個々 の薬剤の最低有効量が最初に用いられ、応答がみられるにしたがい投薬量は増え てゆくだろう。先にのべた殺虫剤との組み合せのように、この物質は方法と対照 植物害虫の成分を供給する。殺虫剤は農業的、園芸的作物のいろいろな害虫を攻 撃するように化学的に設計された。それらは主に3つの分類に分けられる:すな わち殺虫剤、殺真菌剤、除草剤(もしくは殺雑草剤)、それらはまた、殺鼠剤( 有害せきつい動物の駆除)、殺線虫剤(ま微鏡的な線虫類の殺除)殺軟体動物剤 (ナメクジとカタツムリの駆除)、そして殺ダニ剤(チーズダニの駆除)。For example, MeViekar et al., Chapter 14, “How to Apply Fertilizers” The exact amount of phytonutrient components that should be delivered to the plant is It is clear that this is an effective dose for desired results. of course, This can be verified using conventional methods. As the activity increases, the amount of phytonutrients Often reduced by general application, individual The lowest effective dose of the drug is used initially and the dosage is increased as a response is observed. I'm sure it will go on. Like the combination with insecticides mentioned earlier, this substance can be Supply ingredients for plant pests. Pesticides attack various pests of agricultural and horticultural crops. chemically engineered to attack. They are mainly divided into three categories: Insecticides, fungicides, herbicides (or weed killers), they also contain rodenticides ( (extermination of harmful pests), nematocide (extermination of microscopic nematodes), molluscicide (to kill slugs and snails), and acaricides (to kill cheese mites).
にわけられる。It is divided into two.
殺虫剤は主に2つに分類される、すなわち接触もしくは非全身性殺虫剤と全身性 殺虫剤にわけられる。接触もしくは表面殺虫剤はすこしもM物組織へ浸透しない ので、植物の導管系での輸送、局部移動がおこらない。初期の殺虫剤、殺真菌剤 、除草剤はこのタイプだった。それらの不利な点は、天f@(風、雨1日光)に より影響をうけやすく、長期間ののちおよび新芽は無防びであり、それゆえ昆虫 や真菌などの害虫に対して防御がなにもなかったことであった。それゆえ初期の 農業用殺真菌剤は殺真菌剤の保護剤であった。いいかえると、それらは昔は真菌 の胞子の発達を妨げるよう設計されていたが、ひとたび真菌が(胞子から)!生 ずると植物組織に感染を開始し、そのような非全身性殺真菌剤では真菌を殺す能 力はほとんどなく、常に感染を止めることができなかった。Pesticides are mainly classified into two categories: contact or non-systemic pesticides and systemic It is classified as an insecticide. Contact or surface insecticides do not penetrate at all into the tissue of the material. Therefore, transportation through the plant's ductal system and local movement do not occur. Early insecticides and fungicides , the herbicide was of this type. Their disadvantages are: wind, rain 1 sunlight more susceptible, after a long period of time and shoots are unprotected and therefore susceptible to insects. There was no protection against pests such as bacteria and fungi. Therefore the early Agricultural fungicides were fungicide protectants. In other words, they used to be fungi. Was designed to prevent the development of spores, but once the fungus (from spores)! Living Infection of plant tissue can begin, and such non-systemic fungicides have no ability to kill the fungus. They had little power and were always unable to stop the infection.
一方それに比べて、最近の殺虫剤の多くは全身性であることが特徴であるつまり 、それらは植物の表皮(クチクラ)を透過することができ、植物の導管系におい て植物内を動くことができる。たとえば、フェノキシ酢酸は除草剤として選択性 があり、確かな有機リン系殺虫剤であり、さらに最近、ベノミル(benomy l)のような全身性殺真菌剤であることが発見された。On the other hand, compared to that, many recent insecticides are characterized by being systemic. , they can penetrate the epidermis (cuticle) of plants and are odorless in the plant's ductal system. can move within the plant. For example, phenoxyacetic acid is selective as a herbicide. is a reliable organophosphorus insecticide, and more recently, benomyl (benomyl) has been developed. l) was discovered to be a systemic fungicide.
全身性殺真菌剤もまた、ときどき植物化学療法剤と称され、植物を真菌の攻撃か ら守るだけではなく、完全に感染した部位の治療もしくは阻害作用をも行う、そ れらは天候にはほとんど影響をうけず、植物の新芽にも免疫性を与えるだろう、 害虫はいろいろな群にわけることができる。植物界は空気と水より、葉緑素、ク ロロフィルの助けをへて、光合成により炭化水素をつくることのできる生物とい う特徴をもち、ヒトが、生えてほしくない所に育ついわゆる雑草と称される高等 植物と重要な害虫がいる。下等植物の藻類には一般に重要な害虫はいない、しか し、ある種の環境−一一たとえば湖とか他の、ゆっくりしか水が流れないところ では藻が大過剰に繁殖し、“花”を形成することは、無視できない損害と化学的 処理の要求がある、(殺藻剤)、真菌もしくは非光合成植物はクロロフィルをも っていないので空気や水から栄養素を得ることができない。Systemic fungicides, also sometimes referred to as phytochemotherapy agents, protect plants from fungal attack. It not only protects against infection, but also treats or inhibits completely infected areas. They are largely unaffected by the weather and will provide immunity to plant shoots. Pests can be divided into various groups. The plant world produces more than air and water, including chlorophyll and minerals. An organism that can produce hydrocarbons through photosynthesis with the help of rolophils. Weeds that have the characteristic of growing in places where humans do not want them to grow. There are plants and important pests. Algae of lower plants generally have no important pests, but and certain environments - for example lakes or other places where water flows only slowly. However, the overgrowth of algae and the formation of “flowers” can cause considerable damage and chemical damage. Treatment is required (algaecides), fungi or non-photosynthetic plants also contain chlorophyll. They cannot obtain nutrients from air or water because they are not exposed to water.
したがってそれらは腐った植物や動物性物質がら直接栄養をとっている。(死物 寄生真菌)。もしくは、生きている植物や動物から栄養をとっている(寄生真菌 )。それらは子種ものちがった種類の真菌がいて、おもに土壌より発見された。They therefore feed directly on rotting plant and animal matter. (Dead thing parasitic fungi). Or they get their nutrition from living plants and animals (parasitic fungi) ). They have different types of fungi and are mainly found in soil.
−一一いくらかは、酵母に似て他の細胞と分校フィラメントのネットワークをつ くる単細胞もいる。(菌糸)、真菌の多くは生きた食物と貯蔵中の食物の両方を 攻撃する重大な害虫である。いくつかの細菌は植物疾患の原因となっているが、 しかしながらそれらは光病原性の真菌はどの深刻さは全くない。m菌は顕微鏡で 観察でき、その形態から分類できる;それゆえ球状のm菌はコツカスと称するの に対し、桿状のものはバチルスと称する。ウィルスは細菌や真菌と似ており、植 物や動物やいくつかの種に攻撃し、植物疾患をおこさせる。ウィルスは真の細胞 ではないので、ウィルスの形は寄生する生物の種類によってかわる。細菌とのち がいはとても小さい(直径100−300^)ことで、普通の顕微鏡ではタンパ クの保護膜につつまれた1本鎖のDNAもしくはRNAから成っている。−11 Some cells, similar to yeast, connect other cells with networks of branch filaments. There are also unicellular cells. (hyphae), many fungi consume both live and stored food. It is a serious pest that attacks. Although some bacteria cause plant diseases, However they are photopathogenic fungi which are not at all serious. m bacteria under a microscope It can be observed and classified based on its morphology; therefore, spherical m bacteria are called coccus. On the other hand, the rod-shaped one is called bacillus. Viruses are similar to bacteria and fungi and can be Attacks objects, animals and some species, causing plant diseases. Viruses are real cells Therefore, the shape of the virus changes depending on the type of organism it parasitizes. Bacteria and life The membrane is so small (100-300mm in diameter) that it cannot be seen with a normal microscope. It consists of a single strand of DNA or RNA surrounded by a protective membrane.
いくつかの高等動物(を椎動物)はマウスやラットやウサギのように重要な害獣 であり;昆虫(節足動物)に代表される無を椎動物の群も害虫である。後者は3 つの足のベアをもち、成虫の体は3つの部分から成る一節足動物(チーズダニと ダニ)は体に、はっきりした3つの部分をもたないところが昆虫とちがっている 。そしてまた、ふつう4つの足のベアをもつ。下等動物、線虫類や寄生虫はしば しば非部分分裂を行い重大な食物害虫である。もし、殺虫剤を活性にするには、 標的生物の根本の活性部位内に到達しなくてはならない。それゆえ、ボルドーミ ックスチャ−のように、殺真菌剤の表面は真菌の胞子へ浸透できなくてはならな い;同様に素剤が標的に接触したら、接触性殺虫剤は昆虫の外皮を浸透しなくて はならず、接触性除草剤は植物の表皮を浸透しなくてはならない。もし殺虫剤が 活性において全身性であるとより有力になる。加えてそれらが根や葉や種子から 吸収される能力をもち、それから植物の他の部分へと伝達できればとても有力な ものとなる。この方法においては新芽を含むすべての植物体は真菌の攻撃から保 護され、その植物を食べたり吸ったすべての昆虫に有害物質を与えることとなる 0本発明においてつかわれるであろう物質成分の量は殺虫剤の植物害虫への伝達 の増加がおこる量である。植物活性物質の間接使用の場合、独自に改良したもの を含む1−置換アザシクロアルカンの使用と殺虫剤の全身性作用で活性物質の伝 達が増加した。Some higher animals (vertebrates) are important pests, such as mice, rats, and rabbits. Also, groups of vertebrates represented by insects (arthropods) are also pests. The latter is 3 The adult body is a monoarthropod (cheese tick and ticks) differ from insects in that they do not have three distinct parts on their bodies. . They also usually have four-legged bears. Lower animals, nematodes and parasites are often It often undergoes non-partial fission and is a serious food pest. If you want to make the insecticide active, It must reach the active site in the root of the target organism. Therefore, Bordomi The surface of the fungicide, like the texture, must be able to penetrate the fungal spores. Yes; similarly, contact insecticides must penetrate the insect's outer skin once the agent comes into contact with the target. contact herbicides must penetrate the epidermis of the plant. If pesticides The more systemic it is in its activity, the more potent it is. In addition, they are extracted from roots, leaves, and seeds. It would be very powerful if it had the ability to be absorbed and then transmitted to other parts of the plant. Become something. In this method, all plants, including shoots, are protected from fungal attack. protected plants, which would then pass on harmful substances to all insects that eat or breathe the plants. 0 The amount of material components that may be used in the present invention will be is the amount at which an increase in In the case of indirect use of plant active substances, original improvements The use of 1-substituted azacycloalkanes containing has increased.
一般に、作用量は殺虫剤成分の重量の0.01から約99.9%のあいだにあり 、このましくは約0.1から1ozのあいだにあるのがよい。Generally, the active amount is between 0.01 and about 99.9% by weight of the insecticide ingredient. , preferably between about 0.1 and 1 oz.
適当な殺虫剤は、ニコチン、デリス(derrig) (ロチノン((rote none))、ビレスラム(pyrethrum)のような植物の殺虫剤を含む もの;合成殺虫剤でDNOCのようなジニトロフェノール類を含むもの;有機チ オシアン系でレタン(lethane)やタニー) (thanite)のよう なもの、有機塩素系殺虫剤でDDTや関連化合物を含むもの;アルドリンやディ ルドリン、のようなシクロジエン基を含むもの、有機リン系殺虫剤:ヘキサクロ 口シクロヘキサン;マラチオンを含むもの、メビンホス(+evinphos) 、ローガー(rogar)、ジメチトアート(di鋤ethtoate)、ネノ ザン(nenozan)、ミラル(m i ra I )、ジアジノン(dia zinon)、ダルスボン(dursbon)、ベイールシル(bay−rus il);有機カルボネート殺虫剤でビリミカルブ(pirimicarb)、カ ルバリル、ベイボン(baygon)、プロポキサ−(propoxur)、ゼ クトロン(zectron)、カルボフラン、アルジカルブ(aldicarb )(テミック((Temik)))、メソムル(w+ethomul)(ロンア ート((L onnate) ))を含むもの;殺真菌剤でフェニル水銀化合物 、ナバン(naban)、フラン(metham)、ナトリウム、チロン(th iron)を含むもの;n−トリクロロメチルチオ基を含む、カプタン、ネルベ ット(folpet)やオイホラタン(offolajan)のような化合物; ジニトロフェノール顕、ジノカップ(dinocap)(カラサン((K ar athane) ))を含むもの;りクロベンジン類と関連化合物、キノン票で 、トラン(dodine)、ローラル(roural)のようなもの、スルホン アミド類、ベンズイミダゾール類;チオホナート類(th 1ophonate s) ;オキサチン類;ビリマシン頚;ビベロジン、モルホリンとアゼピン誘導 体;有機リン化合物でウェブシン(wepsyn)、キタジン(K 1tazi n)とコネン(conen)を含むもの、除草剤でカルボン酸除草剤を含む2, 4−D、MCPA、2,3.6−TEA、IAA、ビクロラム(piclora +m)やジクロベニル(dichlobenil)のようなもの;りoロアリフ ァティック酸で(chloroaliphatic acid)ダラファン(d alapan)やTCAのようなもの、そしてヘテロサイクリック化合物でアト ロジン(atrozine)(ゲサプリン((Gesaprim)))のような もの;トリアザレス(triazales)でアミトロール(amitrole )、ピラゾン、ブロマシル(bro+++ac i I )、エンドサール(e ndotha I )のようなもの;ビピリジナム(bipyridinuw+ )除草剤でパラコートとジノアット(diquat)を含むもの;ベンゾニトリ ル類;ジフェニルエーテル類;有機リン化合物類で、ベンスリド(bensul lide)のようなホスホロチオレート票のもの;ホスホールアミデート類でD M P A (Zyr。n)のようなもの;ホスホネート類でグリホスアート (glyphosate)のようなもの;植物成長調節剤;くん蒸剤;殺そ剤で ワルファリン、ビドン(pidone)とノルポルミド(Raticote)の ような抗凝血剤を含むもの;すいみん導入麻酔薬でフロラローゼ(chlora lose)のようなもの;ボッアシド[gophaeide]、シラトラン(s ilatrane)とクリミジン(crimidine)、殺線虫剤でダゾメッ ト(dazomet)、およびネルライト(nellite)のようなもの;殺 軟体動物剤でメトアルデヒド、メチオカスブ(+*ethiocasb)および フレスコン(freseon)のようなもの;駆虫薬、抗飼料化合物でZIPの ようなもの;化学不妊剤、ホルモンおよび成長阻害剤。さらに、本発明で使用す る適当な殺虫剤は技術的に知られている。(たとえば、R,Cremyln。Suitable insecticides include nicotine, derrig (rotinone), (none)), including insecticides for plants such as pyrethrum. Synthetic insecticides containing dinitrophenols such as DNOC; Organic pesticides Ossian type, like lethane or thanite Organochlorine insecticides containing DDT and related compounds; those containing a cyclodiene group such as rudolin, organophosphorus insecticides: hexaclo Oral cyclohexane; containing malathion, mevinphos (+evinphos) , rogar, dimethoate, neno nenozan, miral (mira I), diazinon (dia zinon), dursbon, bay-rus il); Organic carbonate insecticides such as pirimicarb Lubaryl, Baygon, Propoxur, Ze zectron, carbofuran, aldicarb ) (Temik)), mesomul (w+ethomul) (rona containing ((Lonnate))); a fungicide containing phenylmercury compounds. , naban, metham, sodium, th containing n-trichloromethylthio group, captan, nerve Compounds such as folpet and offolajan; Dinitrophenol, Dinocap (Karsan) athane))); riclobenzines and related compounds, quinones , dodine, roural, sulfone Amides, benzimidazoles; thiophonates s); Oxatins; biriminin; viberozin, morpholine and azepine induction body; organic phosphorus compounds such as wepsyn and kitazine n) and those containing conen, herbicides containing carboxylic acid herbicides 2, 4-D, MCPA, 2,3.6-TEA, IAA, picloram +m) and dichlobenil; chloroaliphatic acid dalafane (d) alapan), TCA, and heterocyclic compounds. Rosin (atrozine) (such as Gesaprim) things; triazales and amitrole ), Pyrazone, Bromacil (bro+++ac I I ), Endosal (e ndotha I); bipyridinum (bipyridinuw+ ) Herbicides containing paraquat and diquat; benzonitri diphenyl ethers; organic phosphorus compounds; phosphorothiolate substances such as phosphoramidates; Things like MPA (Zyr.n); phosphonates such as glyphosate (glyphosate); plant growth regulator; fumigant; rodenticide Warfarin, Pidone and Norporamide (Raticote) Those containing anticoagulants such as; gophaeide, silatran (s ilatrane) and crimidine, and dazometh with nematocide. such as dazomet, and nellite; Molluscan drugs mettaldehyde, methiocasb and Something like freseon; anthelmintic, anti-feed compound for ZIP. such as; chemical sterilization agents, hormones and growth inhibitors. Furthermore, the present invention uses Suitable insecticides are known in the art. (For example, R, Cremylin.
″ のモール、John Wiley and 5ons。″ mall, John Wiley and 5ons.
1979 ;−F 、 McEwan、ら、、環 にお番る の 義。1979;-F, McEwan, et al., Definition of the term "ring".
John Wiley and 5ons、1979;D、 Rober’ts 、[コントロールの E、 H,Frees+an and Co論pany。John Wiley and 5ons, 1979; D, Roberts , [Control E, H, Frees+and and Co theory pany.
1978、を参照されたい。)ここに述べた殺虫剤成分の適用方法は通例通りで ある。たとえば、G、 Hartleyら、化3J引4査−(Q’:17’l− 0−tk、第15章、“殺虫剤の適用” P ergamonPress、 1 969 、を参照されたい。殺虫剤成分が植物もしくは害虫に伝わる正確な量は 、望む結果を得たときの作用量から明らかになるだろう。最も新しい殺虫剤は農 業用に使用され、1ニーカー当り1ボンド以下の当薬量であった。もちろん、こ れは従来の方法でたしかめられるだろう。活性の増加にしたがって、試薬の投与 量はしばしば一般に用いられた量にくらべて少なくてすむようになるだろう。通 常の慎重な使用条件によれば、投薬量は個々の試薬について最初は低く、観察で きる応答反応からの結果を見て、投薬量を増加する。See 1978. ) The method of application of the insecticide ingredients described here is as usual. be. For example, G. Hartley et al. 0-tk, Chapter 15, “Application of Pesticides” P ergamon Press, 1 Please refer to 969. The exact amount of insecticide ingredients transmitted to plants or pests is , it will become clear from the amount of action needed to achieve the desired result. The newest pesticides are It was used commercially, and the dosage was less than 1 bond per knee car. Of course, this This will be verified using conventional methods. Dosing reagents according to increasing activity The amounts will often be smaller than those commonly used. General Under normal and prudent conditions of use, dosages for individual reagents should be initially low and observable. Increase the dosage based on the results from the possible response response.
ここに記載した組成物は植物成長剤とともに、植物の成長の方法および組成物と して用いられる。The compositions described herein, along with plant growth agents, include plant growth methods and compositions. It is used as
植物成長調節剤は、低濃度で植物の生g構造および/または生理過程に影響する 栄養素以外の有機化合物である。植物ホルモン(P 1ant horeeon eまたはphytohormone)は、天然に存在する成長調節因子で、低濃 度で植物の生理過程を制御する0合成数長調節剤は、人工的に果実の生育、果実 の間引き、落葉、成長の促進および遅延、挿し木の根付け、および他の多くの過 程を調節するために使用される。過去30年にわたり、植物成長調節剤の調査お よび開発は、基礎および応用植物研究のもっとも活発な分野であった。 The P A N S P 1int GroowthRegulator Ind ex(P、 J、 Kempt、2j−0)、211および213)は、一般名 、商標、およびコード番号で492の調節剤を掲載している(雑草の殺滅以外の 目的の成長調節のために特に用ちれるものを除いて除草剤は含まれていない)。Plant growth regulators affect plant g structure and/or physiological processes at low concentrations It is an organic compound other than nutrients. Plant hormone (P1ant horeeon) E or phytohormone) is a naturally occurring growth regulator that is present at low concentrations. 0-synthetic number length regulators, which control physiological processes in plants, can be used to artificially control fruit growth and fruit production. thinning, defoliation, promoting and retarding growth, rooting cuttings, and many other Used to adjust the temperature. Over the past 30 years, we have been researching plant growth regulators. Plant life and development have been the most active areas of basic and applied botanical research. The P A N S P 1int GrowthRegulator Ind ex(P, J, Kempt, 2j-0), 211 and 213) are common names Lists 492 regulators by , trademark, and code number (for purposes other than killing weeds). Contains no herbicides except those specifically used for desired growth control).
現在用いられている植物成長調節剤は、次に示すものを含めて非常に広範な植物 の成長過程に影響する(一般に用られる成長調節剤のあるものはカッコ内に示さ れている〉:挿し木の根付け(インドール酪酸)、パイナツプルの開花の促進( 1−ナフタレン酢酸;β−ヒドロキシエチル−ヒドラジン;エテホン);リンゴ の収穫前の落下防止(NAA;ダミノジド);芝生の成長の抑制(マレイン酸ヒ ドラジド;メフルイジデジエタルールアミン);ジャガイモの発芽の防止(マレ イン酸ヒドラジド);リンゴ、ナシ、モモの開花誘発(コハク酸−2,2−ジメ チルヒドラジン;2.3.5−)リョード安息香酸);例えばレタス、大根、芥 子、イノンドのような長日植物の開花の早期化(ジベレリン);通常開花に低温 を要求する2年生植物の開花(ジベレリン);砂糖黍の収穫向上および開花の防 止(ディウロン;ディファツト);悪天候を避けるためのアーモンドおよびモモ の開花の遅延(ジアミノシト):成熟柑橘類の離層形成の誘発(シクロベキシム ;5−クロロ−3−メチル−4−ニトロ−1−H−ピラゾール);綿花の莢の収 穫をたすけるための落葉(エテホン);例えば、ブドウ、モモのような果実の間 引き(ジベレリン酸;エテホン;3−クロロフェノキシ−α−プロピオンアミド );柑橘類の収穫前の落下防止(2,4−ジクロロフェノキシ酢酸);例えばト マト、カポチャ、ナス、イチジクの果実の着生の誘発(4−クロロ−フェノキシ 酢酸;2−ナフチルオキシ酢酸);ブドウのサイズおよび品質の向上(ジベレリ ン);麦芽用大麦のアミラーゼの誘発(ジベレリン);砂糖黍の成長促進(ジベ レリン);穀物の茎の長さの短!(2−クロロエチルトリメチル−アンモニウム クロリド);例えばカポチャにおける雌花の発達(NAA;エテホン;ダミノジ ド);例えばホップにおける雄花の促進(ジベレリン);植物の組成のバイオレ ギュレーション、例えば柑橘類の色、砂I!黍の糖、野菜のビタミン含量、乾燥 重量の増加、穀物の発達時期の一定化、ゴムの木のラテックス量の向上(種々の 成長調節剤)。Currently used plant growth regulators cover a wide range of plants, including: (some commonly used growth regulators are listed in parentheses). : Rooting of cuttings (indole butyric acid), promotion of flowering of pineapple ( 1-naphthaleneacetic acid; β-hydroxyethyl-hydrazine; ethephon); apple Pre-harvest fall prevention (NAA; daminozide); suppression of lawn growth (maleic acid arsenide); drazide; mefluidide dietaluramine); prevention of potato germination (male Induction of flowering in apples, pears, and peaches (succinic acid hydrazide); tylhydrazine; 2.3.5-) ryodobenzoic acid); e.g. lettuce, radish, mustard early flowering of long-day plants such as digonium (gibberellin); usually low temperature for flowering Flowering of biennial plants that require Almonds and peaches to protect against bad weather. Delayed flowering (diaminocyto): Induction of abscission formation in mature citrus (cyclobexime) ;5-chloro-3-methyl-4-nitro-1-H-pyrazole);Collection of cotton pods Fallen leaves (ethephon) to aid the harvest; e.g. between fruits such as grapes and peaches (gibberellic acid; ethephon; 3-chlorophenoxy-α-propionamide ); Preventing citrus fruit from falling before harvest (2,4-dichlorophenoxyacetic acid); e.g. Induction of fruit set in tomato, capocha, eggplant, and fig (4-chlorophenoxy Acetic acid; 2-naphthyloxyacetic acid); Improving grape size and quality (Giberelli ); induction of amylase in malting barley (gibberellin); promotion of sugar cane growth (gibberellin); Relin); short grain stalk length! (2-chloroethyltrimethyl-ammonium chloride); for example, female flower development in Kapocha (NAA; ethephon; daminoji); e.g. promotion of male flowers in hops (gibberellins); Regulation, for example citrus color, sand I! Sugar in millet, vitamin content in vegetables, drying Increasing weight, stabilizing the grain development period, increasing the amount of latex in the rubber tree (various growth regulators).
本発明で使用できる本発明の化合物の量は、植物に対する植物成長調節剤の配給 を増大させるために有効な量である。一般に有効量の範囲は、組成物の重量を基 準にして、約0.01ないし約99.9gであり好ましくは約0.1ないし1o zである。The amount of the compound of the invention that can be used in the invention is determined by the amount of the compound of the invention that can be used in the delivery of the plant growth regulator to the plant. This is an effective amount to increase. Effective amount ranges are generally based on the weight of the composition. from about 0.01 to about 99.9 g, preferably from about 0.1 to 1 oz. It is z.
適するM物成長調節剤には、天然および合成のオーキシン、例えばIAA(イン ドリル−3−酢酸)、IBA(4−(インドール−3−イル)酪酸)、NAO( アルファナフチル酢酸)、N0A(2−ナフチルオキシ−酢酸)およびNAD( l−ナフチルア七タミド);フェノキシアルカン酸、ジベレリン、サイトキニン 、アブシジン酸、マレイン酸ヒドラジド、プロファムおよびクロロプロファム、 S、S、S−トリブチル ボスポロトリチオエート、S、S、S−)リブチル ホスホロトリチオアイト、クロロメクアット、ダミノジド、グリホシン、アンシ ミドール、塩化クロルホニウム、ジクグラックナトリウム(dikegulac sodium)、塩化モルホリニウム、ホサミン、メフリダイド、4−メトキ シベンゾフェノン、PP528(エチル−5−(4−クロロフェニル)−2H− テトラゾール−2−イル アセテート)、ピアロクタニル プロミド、2−(3 −アリール−5−ビラジイル)安息香酸、BTS34723(1−(N−2−フ ェノキシエチル)−N−プロピルカルバモイル)−N−イミダゾール)、BTS 34442(1−(N−2,4−ジクロロベンジル)−N−イソプロとルーカル バモイル)−1−N−イミダゾール)、UBIP293(2,3−ジヒドロ−5 ,6−ジフェニル−1,4−オキサチイン)、M&B25,105(70ビル 3−t−ブチル7 エ/キシ酢酸)、チダイズロン(N−フェニル−N“−(1 ,2,3−チアジアゾール−5−イル)尿素)、メピクアット(1,1−ジメチ ルピペリジニウム クロリド)、BASO9800W(メビクアット クロリド とエテファン)、IZAA(5−クロロインダゾール−8−酢Mzチルzスフル )、N0N8000.DOWCO2428(テトライソペンチル−アンモニウム プロミド)、第4アミンモニムヨージド;クロロフルレコールーメチル、フル レコールーブチル、TI BA(2,3,5−)リーヨード安息香酸を含むモル フアクチン;PLH531(1−(4−クロロフェニル)−1,2−ジヒドロ− 4,6−シメチルー2−オキソニコチン酸ナトリウム)、DPX−3778(3 −(4−クロロフェニル)−6−メドキシー1,3.5−トリアジン−2,4− ジオントリエタノールアミン)およびアレロバチン頚を含むガメトシドがある。Suitable growth regulators include natural and synthetic auxins, such as IAA (in (dolyl-3-acetic acid), IBA (4-(indol-3-yl)butyric acid), NAO ( alpha naphthyl acetic acid), N0A (2-naphthyloxy-acetic acid) and NAD ( l-naphthyla heptamide); phenoxyalkanoic acid, gibberellin, cytokinin , abscisic acid, maleic hydrazide, propham and chloropropham, S, S, S-tributyl bosporotritthioate, S, S, S-) butyl Phosphorotrichioite, Chloromequat, Daminozide, Glyfosine, Anthi Midol, chlorphonium chloride, dikegulac sodium sodium), morpholinium chloride, fosamine, mephridide, 4-methoxy Cybenzophenone, PP528 (ethyl-5-(4-chlorophenyl)-2H- tetrazol-2-yl acetate), piaroctanil bromide, 2-(3 -Aryl-5-biradiyl)benzoic acid, BTS34723 (1-(N-2-ph) enoxyethyl)-N-propylcarbamoyl)-N-imidazole), BTS 34442 (1-(N-2,4-dichlorobenzyl)-N-isopro and Lucal bamoyl)-1-N-imidazole), UBIP293 (2,3-dihydro-5 , 6-diphenyl-1,4-oxathiine), M&B 25,105 (70 Bill 3-t-butyl 7eth/oxyacetic acid), tidaiduron (N-phenyl-N"-(1 , 2,3-thiadiazol-5-yl)urea), mepicuquat (1,1-dimethy Lupiperidinium chloride), BASO9800W (Mebiquat chloride) and ethephane), IZAA (5-chloroindazole-8-acetic acid Mztilzsufur ), N0N8000. DOWCO2428 (Tetraisopentyl-ammonium (promide), quaternary amine monoimiodide; chloroflurecol-methyl, flu Lecor-butyl, TI BA (2,3,5-)moles containing lyodobenzoic acid Factin; PLH531 (1-(4-chlorophenyl)-1,2-dihydro- Sodium 4,6-dimethyl-2-oxonicotinate), DPX-3778 (3 -(4-chlorophenyl)-6-medoxy1,3.5-triazine-2,4- There are gametosides, including dionetriethanolamine) and allelobatin neck.
さらなる植物成長調節剤は文献で知られており、例えばF 1eteherら、 Herbicides and P Iant GrowthRegulaor s、第2章を参照。Further plant growth regulators are known in the literature, for example F1eteher et al. Herbicides and P Iant Growth Regulation s, see Chapter 2.
植物成長調節剤の使用の機会は、迅速な成長および根の発達を促すための、種子 または苗の処理:穀物の品質(通常は蛋白質レベルおよびアミノ酸バランス)の 向上物質;葉の収穫および量を向上させる物質;森林の育成の機会例えば苗の生 存および成長;迅速な種子生成および成長率の加速;栽培、肥料(即ち吸収、移 動等)および濯深水に対する反応を最大にしてエネルギーコストを低下させる系 ;エチレンの作用または生産を抑制して果実の発達が不確実な作物の若い果実の 離脱を減少させる化合物;種もしくは機能特異的作用を有する新規ジベレリン類 ;公知のホルモン相互作用に基づく既知物質の新規応用および貯蔵/不活性化系 (徐放性化合物)および自然の接合反応を操作する物質;植物病害および昆虫の 影響を消失もしくは最小化させる物質または総合的有害生物管理システムを可能 にする物質;明所呼吸、暗所呼吸を減少させもしくは窒素代謝/固定、光合成、 流転を促進して生産性を変化させる物質;特異的に非常に好ましい最終生成物( 油、蛋白質、セロルース)の合成を強化する物質;発達パターンを変化させて、 例えば開花への分化または種子への発達の期間を長期化して、生産性を向上させ る物質を含む。Opportunities for the use of plant growth regulators exist in seeds to promote rapid growth and root development. or seedling processing: to improve grain quality (usually protein levels and amino acid balance). Enhancing substances; substances that improve leaf yield and quantity; forest cultivation opportunities e.g. seedling growth; survival and growth; rapid seed production and accelerated growth rate; cultivation, fertilization (i.e. absorption, transfer) A system that reduces energy costs by maximizing the response to ; of young fruits of crops with uncertain fruit development by suppressing the action or production of ethylene; Compounds that reduce withdrawal; novel gibberellins with species- or function-specific actions ; New applications and storage/inactivation systems for known substances based on known hormone interactions (sustained release compounds) and substances that manipulate natural conjugation reactions; Enable substances or integrated pest management systems to eliminate or minimize impacts Substances that reduce photorespiration, scotopic respiration, nitrogen metabolism/fixation, photosynthesis, Substances that promote flux and change productivity; specifically very favorable end products ( A substance that enhances the synthesis of oil, protein, cellulose); changes the developmental pattern, For example, by prolonging the period of differentiation into flowering or development into seeds, productivity can be improved. Contains substances that
上記説明は農芸化学者が利用しうる種々の機会を説明する。The above discussion illustrates the various opportunities available to agricultural chemists.
White、 S teward、 S koogおよびその他の研究者により 開拓された植物組織培養は殆ど植物学てきな興味から始まったのであるが、成長 調節化合物の助けを借りて、植物育成者の強力な手段となった。現在では殆どい かなる植物も組織培養可能である。By White, S. Teward, S. Koog and other researchers. Most of the pioneering plant tissue cultures started out of an interest in botany, but With the help of regulatory compounds, it has become a powerful tool for plant breeders. Nowadays there are almost no Any plant can be tissue cultured.
花粉粒でさえも用いて、生じたハブロイド植物を適当な化学薬剤でポリプロイド に変えることができる。頂部分裂組織培養とともに、無限の材料の供給がある。Even pollen grains are used to make the resulting haploid plants polyploid with appropriate chemical agents. can be changed to With apical meristem culture, there is an endless supply of material.
本明細書に記載された植物成長調節剤組成物を応用する方法は慣用的である0例 えば、W、 W、 FletcherおよびR,C。The method of applying the plant growth regulator composition described herein is a conventional method. For example, W, W, Fletcher and R,C.
K’irkwoodのHerbicides and P Iant Grow tbRegu 1ators 、グラナダ出版社、ニューヨーク、1982を参 照。K’irkwood’s Herbicides and P Iant Grow See tbRegu 1ators, Granada Publishing, New York, 1982. Light.
植物に配給すべき植物成長調節剤組成物のN、密な量は、該組成物に期待する所 望の結果を得るに有効な量であることは明らかである。これはもちろん、当業者 の通常の技術で確認することが可能である。達成される増強効果のため、植物成 長調節剤の使用量は一般の使用量より少なくてすむであろう0通常の用心深い処 方技術に従えば、特定の薬剤の最小有用範囲を最初に採用し、そして観察された 反応に応じて使用量を増量する。The N-density amount of the plant growth regulator composition to be delivered to the plants depends on what is expected of the composition. It is clear that the amount is effective to obtain the desired results. This is, of course, understood by those skilled in the art. This can be confirmed using standard techniques. Due to the enhanced effect achieved, plant growth The amount of length regulator used may be less than the amount normally used. According to the technique, one first employs the minimum useful range for a particular drug and then Increase the amount used depending on the reaction.
本発明の特定の態様を記載したが、勿論多くの明らかな改変が可能であり、本発 明の範囲は特定の態様に限定されるものではなく、そのような改変は請求の範囲 に記載された発明の範囲で本発明に包含される。Although particular embodiments of the invention have been described, it is understood that many obvious modifications and variations of the invention are possible. The scope of the invention is not limited to particular embodiments, and such modifications are not limited to the scope of the claims. It is included in the present invention within the scope of the invention described in .
手続補正書(方式) 平成 2年11月乙日Procedural amendment (formality) November 1st, 1990
Claims (39)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US17914488A | 1988-04-08 | 1988-04-08 | |
| US179,144 | 1988-04-08 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP10263059A Division JPH11171795A (en) | 1988-04-08 | 1998-09-17 | New permeation accelerator |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPH03500543A true JPH03500543A (en) | 1991-02-07 |
| JP2965303B2 JP2965303B2 (en) | 1999-10-18 |
Family
ID=22655402
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP1505213A Expired - Fee Related JP2965303B2 (en) | 1988-04-08 | 1989-04-05 | New transdermal penetration enhancer |
| JP10263059A Pending JPH11171795A (en) | 1988-04-08 | 1998-09-17 | New permeation accelerator |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP10263059A Pending JPH11171795A (en) | 1988-04-08 | 1998-09-17 | New permeation accelerator |
Country Status (6)
| Country | Link |
|---|---|
| EP (1) | EP0374218A4 (en) |
| JP (2) | JP2965303B2 (en) |
| KR (1) | KR900700112A (en) |
| AU (1) | AU628344B2 (en) |
| CA (1) | CA1334646C (en) |
| WO (1) | WO1989009800A1 (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2009514897A (en) * | 2005-11-07 | 2009-04-09 | ロス アラモス ナショナル セキュリティー,エルエルシー | Use of proline to improve growth and / or production |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0491076A1 (en) * | 1990-12-19 | 1992-06-24 | Theratech, Inc. | Penetration enhancement with multi-component system of N-aliphatic pyrrolidones with lower alcohols |
| ATE165597T1 (en) * | 1992-01-20 | 1998-05-15 | Sanol Arznei Schwarz Gmbh | DRUGS CONTAINING 1-OLEOYLAZACYCLOHEPTANONE(2) TO ENHANCE TRANSPORT THROUGH BIOLOGICAL MEMBRANES |
| RU2311409C2 (en) | 2003-01-10 | 2007-11-27 | Ф.Хоффманн-Ля Рош Аг | Derivatives of 2-piperidone as prostaglandin agonists |
| US7179820B2 (en) | 2003-06-06 | 2007-02-20 | Allergan, Inc. | Piperidinyl prostaglandin E analogs |
| JP5700915B2 (en) * | 2008-04-18 | 2015-04-15 | 栄研化学株式会社 | S. aureus detection medium |
| CN118021639A (en) * | 2024-03-05 | 2024-05-14 | 广州丽彦妆生物科技有限公司 | Composition capable of enhancing transdermal absorption and preparation method and application thereof |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS58157706A (en) * | 1982-03-12 | 1983-09-19 | Norin Suisansyo Kajiyu Shikenjo | Fruit thinning agent of fruit tree |
| CA1225594A (en) * | 1983-05-20 | 1987-08-18 | Jourge Heller | Method for percutaneously administering physiologically active agents |
| US4743588A (en) * | 1984-06-13 | 1988-05-10 | Allergan Pharmaceuticals, Inc. | Compositions and methods of enhancing transdermal and transmembrane penetration systemic agents |
| JPS61103840A (en) * | 1984-10-26 | 1986-05-22 | Nitto Electric Ind Co Ltd | Dermatologic administration composition |
| US4743597A (en) * | 1986-01-27 | 1988-05-10 | Javitt Norman B | Composition comprising an oxygenated cholesterol and use thereof for topical treatment of diseases |
| WO1987004706A1 (en) * | 1986-01-31 | 1987-08-13 | Nelson Research And Development Company | Compositions comprising 1-substituted azacycloalkanes and their uses |
| JPH0717521B2 (en) * | 1986-03-27 | 1995-03-01 | 日東電工株式会社 | Composition for outer skin administration |
| JPH0643390B2 (en) * | 1986-04-08 | 1994-06-08 | 久光製薬株式会社 | Azacycloalkane derivative |
| CH666621A5 (en) * | 1986-06-27 | 1988-08-15 | Ciba Geigy Ag | TOPICALLY APPLICABLE PHARMACEUTICAL COMPOSITIONS WITH SYSTEMIC EFFECT. |
| CA1319613C (en) * | 1986-10-07 | 1993-06-29 | Gevork Minaskanian | Penetration enhancers for transdermal delivery of systemic agents |
| US4920101A (en) * | 1987-09-30 | 1990-04-24 | Nelson Research & Development Co. | Compositions comprising 1-oxo- or thiohydrocarbyl substituted azacycloaklkanes |
-
1989
- 1989-04-04 CA CA000595603A patent/CA1334646C/en not_active Expired - Fee Related
- 1989-04-05 JP JP1505213A patent/JP2965303B2/en not_active Expired - Fee Related
- 1989-04-05 KR KR1019890702292A patent/KR900700112A/en not_active Ceased
- 1989-04-05 WO PCT/US1989/001381 patent/WO1989009800A1/en not_active Ceased
- 1989-04-05 EP EP19890905539 patent/EP0374218A4/en not_active Withdrawn
- 1989-04-05 AU AU35616/89A patent/AU628344B2/en not_active Ceased
-
1998
- 1998-09-17 JP JP10263059A patent/JPH11171795A/en active Pending
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2009514897A (en) * | 2005-11-07 | 2009-04-09 | ロス アラモス ナショナル セキュリティー,エルエルシー | Use of proline to improve growth and / or production |
Also Published As
| Publication number | Publication date |
|---|---|
| JPH11171795A (en) | 1999-06-29 |
| JP2965303B2 (en) | 1999-10-18 |
| EP0374218A1 (en) | 1990-06-27 |
| CA1334646C (en) | 1995-03-07 |
| AU628344B2 (en) | 1992-09-17 |
| AU3561689A (en) | 1989-11-03 |
| WO1989009800A1 (en) | 1989-10-19 |
| KR900700112A (en) | 1990-08-11 |
| EP0374218A4 (en) | 1991-09-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US5472946A (en) | Transdermal penetration enhancers | |
| US4886545A (en) | Compositions comprising 1-substituted azacycloalkanes and their uses | |
| AU599433B2 (en) | Compositions comprising n,n-dialkylalkanamides and their uses | |
| JP2683578B2 (en) | Composition comprising 1-substituted lactams | |
| JP2954247B2 (en) | Penetration enhancer for transdermal delivery of systemic drugs | |
| AU602164B2 (en) | Compositions comprising 1-oxohydrocarbyl-substituted azacyclohexanes | |
| CA1334647C (en) | Penetration enhancers for transdermal delivery of systemic agents | |
| JP2965303B2 (en) | New transdermal penetration enhancer | |
| AU599964B2 (en) | Topical pharmaceuticals dye compositions, and plant nutrient compositions comprising 1-substituted azacycloalkanes as penetration enhancers | |
| JPS63502590A (en) | Compositions comprising 1-substituted azacycloalkanes and their uses | |
| CN102293218A (en) | Insecticidal composition containing spirotetramat and bifenthrin | |
| EP0582065A1 (en) | 1-Oxohydrocarbyl-substituted azacyclohexanes compositions used as acid catalyst | |
| CN108424245A (en) | A kind of preparation method of Rice Cropping ecological fertilizer | |
| UA44509A (en) | METHOD OF TREATMENT OF SUGAR BEET SEEDS WITH PROTECTIVE-STIMULANT SUBSTANCES |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| LAPS | Cancellation because of no payment of annual fees |